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A bstr a c t
A bstract
A novel toxicological tool, which consisted of a differentiated, 3-D, in vitro 
model of human respiratory epithelia, i.e. EpiAirway-100 cells (MatTek Corp., 
USA), was utilised to identify intelligent biomarkers in human respiratory 
epithelia following exposure to selected particle and vapour phase tobacco 
smoke components (TSC); thus providing a holistic approach towards the 
identification of biomarkers in the pulmonary epithelium. A range of TSC 
doses were used to elicit a classic dose response which was characterised by 
conventional toxicology techniques (transepithelial electrical resistance 
[TEER], cell viability [MTT] and protein assay). All four TSC appeared to 
induce similar stress responses (e.g. protective mechanisms) within the 
model. Histological (LM level) examination was utilised to investigate the 
morphological changes in cellular-tissue organisation in the ETM, following 
exposure challenges with the TSC. In conjunction with this, targeted immuno- 
histochemistry assays were performed in order to better characterise the 
tissue response at the cellular level, i.e. basal, ciliated, intermediate and 
Goblet cells. Three discrete zones of tissue injury and repair were delineated: 
(1) the apical region, (2) the suprabasal region and (3) the basal zone (i.e. 
where basal cells acted as progenitors or stem cells).
Toxicogenomics was carried out to identify early molecular markers for events 
in pulmonary injury. This study identified nine genes, with the potential of 
being genomic biomarkers, for specific disease mechanisms known to be 
associated with tobacco smoke. Another potential genomic biomarker was 
identified which was not previously related to tobacco smoke, PTGS1. Its 
induction could result in a disruption of tissue homeostasis that may lead to 
the onset of a number of human inflammatory diseases (e.g. chronic 
obstructive pulmonary disorder). The proteomic analysis identified two 
proteins (cystatin-A and ubiquitin) that were significantly induced for all TSC 
exposures and could be described as ‘defence proteins’. Consequently, they 
represented potential biomarkers of general lung injury. This study also 
identified three proteins (complement C3, calmodulin and CD9) that could be 
used as biomarkers for specific disease mechanisms (e.g. atherosclerosis).
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1.1 S tu d y  In tr o d u c tio n
The respiratory tract is the primary site of exposure to airborne compounds, 
resulting in a growing need for high throughput in vitro models. This project 
utilised a differentiated, 3-D, in vitro model of human respiratory epithelia to 
identify intelligent biomarkers in human respiratory epithelia following 
exposure to selected particle and vapour phase tobacco smoke components 
(TSC); thus providing a holistic approach towards the identification of 
biomarkers in the pulmonary epithelium.
1.2 Th e  R espir a to ry  S ystem
The mammalian respiratory system (RS) is a structurally complex 
arrangement of tissues designed primarily for the intake of oxygen and the 
removal of carbon dioxide, but also performs a variety of other functions (i.e. 
clearance of inhaled foreign materials, hormonal regulation and metabolism of 
xenobiotics). The RS is separated into 4 major regions: (1) the extrathoracic 
(ET) region or upper respiratory tract comprises of the nasal and oral cavities, 
pharynx, larynx, and trachea; (2) the tracheo-bronchial region (TB) consists of 
the trachea, bronchi and bronchioles; (3) the parenchyma region (P) 
incorporates the alveoli, pulmonary vasculature, mesothelium and connective 
tissue and; (4) pleura, which is a thin layer (one cell in diameter) of 
mesothelial tissue (Figure 1.1). Each region has a specific function in gaseous 
exchange and protection from inhaled xenobiotics.
1.3 The  Extr a th o r a c ic  R eg io n
The ET region has the role of conditioning the temperature and humidity of 
inhaled air, which takes place in the air passages in the head and neck. Air 
enters via the nasal cavity and/or oral cavities and passes in to the pharynx, 
and then enters into the first structure in the respiratory tract, i.e. the larynx.
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Upper
respiratory
system
Nasal Cavity 
Sphenoidal sinus -
Internal nares 
Pharynx
Lower
respiratory
system
Esophagus
Frontal Sinus
Nasal conchae
Nose
Tongue
Hyoid bone
Larynx
Trachea
Bronchus
Bronchioles
Diaphragm
Figure 1.1 Depiction of the anatomy of the respiratory system. (Adapted 
from Germann, 2004)
1.4 Th e  Tr ac h eo -B r o n c h ia l  R e g io n
The TB region is responsible for adjusting flow dynamics to ensure optimal 
oxygen and carbon dioxide exchange at the P region. Excluding the 
oropharynx and laryngopharynx, the lower two thirds of the nasal cavity down 
to the terminal bronchioles are lined with pseudo-stratified, ciliated, columnar 
epithelia. The TB region changes slightly as it progresses through the 
respiratory tract, although the main cellular components remain the same 
(e.g. ciliated and columnar cell populations). With further progression towards 
the respiratory bronchioles, the numbers of Goblet cells diminishes and are 
replaced by Clara cells.
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There are at least eight principal types of epithelial cells identified in the 
linings of the TB airways (Spencer, 1985). The key types of cells include the 
ciliated cells, basal cells, mucus Goblet cells and Clara cells (Figure 1.2).
Goblet cell
Nucleus of 
columnar -  
epithelial cell
Lamina propria -
Basal lamina
Sectional view
Figure 1.2 Depiction of the anatomy of the linings of the tracheo­
bronchial airways depicting the principal cell components. (Adapted from 
Germann, 2004)
1.4.1 C il ia ted  Cells
The ciliated cell is attached to the basal lamina and extends towards the 
luminal surface (Figure 1.3). Ciliated epithelial cells have many finger-like 
projections of the plasma membrane (cilia) on their apical surfaces. Epithelial 
cells are commonly arranged in layers that are one cell thick. The "sides" of 
the cells join together to form a sheet, while the remaining two surfaces are 
exposed to either the environment on the top (or apical surface) and the 
bottom (or basolateral surface). Cells can coordinate the motions of the cilia to 
create a wave-like motion which moves the overlying mucus and trapped 
foreign bodies for removal from the RS towards the upper respiratory tract 
(Sleigh et a/., 1988).
1.4.2 Basal  Cells
Basal cells are flattened in appearance and have a small cytoplasm to 
nucleus ratio (Figure 1.3). They are closely attached to the basal lamina but
4
Lamina
propria
Movement of 
mucus towards 
pharynx
Goblet cell
Ciliated
columnar
epithelial
cell
In t r o d u c t io n
do not extend into the airway lumen. It is the existence of these cells that 
accounts for the pseudo-stratified classification of the airway epithelium. 
Studies have demonstrated the primary role of basal cells is to attach 
columnar cells to the basal lamina (Evans et a/., 1989). In addition, they are 
also thought to act as progenitor cells for the epithelial cells (Hong et al., 
2004).
1.4.3 Mucus G o b l e t  C e l l s
Goblet cells are considered to be secretory due to their cytoplasm containing 
spherical, membrane bound secretory granules (Figure 1.3). When secreted 
onto the apical surface, along with the secretion from the muscosal gland cell, 
the organelles products becomes classed as mucus; a viscoelastic fluid 
composed primarily of highly glycosylated proteins. The mucus serves many 
functions that include protection against chemical damage, moistens inspired 
air, prevents drying of the respiratory epithelia, and traps particulate matter. 
The number of secretory products that extend into the bronchial lumen 
increase in number dramatically (mucus hypersecretion) following acute 
bronchial exposure to a xenobiotic (e.g. tobacco smoke [Coles et al., 1979] 
and chemical irritants [Clark et al., 1980]). The mucus blanket, along with the 
ciliated cells, constitutes the muco-ciliary escalator (see Section 1.5).
1.4.4 Cla r a  Cells
Clara cells are unique to the bronchioles. The respiratory bronchioles 
represent the transition from the conducting portion to the respiratory portion 
of the RS. These narrow channels are usually less than 2 mm in diameter and 
they are lined by a simple cuboidal epithelium, consisting of ciliated and non- 
ciliated Clara cells. This region is denoted by the absence of Goblet cells. In 
addition to being structurally diverse, Clara cells are also functionally variable. 
One major function they carry out is the synthesis and secretion of the 
material lining the bronchiolar lumen. This material includes some of the 
protein components of surfactant, antibodies and lysozymes and play an 
important defensive role.
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C iliated
Epithelium
■ Constitute ~50% of cell population
- Roughly 20-60|im tall
- Main function is the propulsion of 
mucous
B asal cell
• Jy
• Reside near the basement 
membrane interspersed between 
ciliated and secretory cells 
■ Flattened or spindle shaped w ith 
scant cytoplasmic regions
G o blet Cell - Characterised by an electron dense 
cytoplasmic region due to the 
secretory cyanules
■ Mucous produced is designed to trap 
inhaled particles
C lara  Cell
> •
•
■ •• •
■ Actively dr/ide and differentiate to 
form ciliated cells
- Produce glycoaminoglycans
■ Metabolise airborne toxins
S erous Cell • They have microvilli and contain 
mucin granules that produce mucous 
to trap inhaled particles
Brush Cell
P
■ Small mucous granule cells
■ Known as brush cells due to their 
microvilli
- Also secrete mucous to trap inhaled 
particles
A lveo lar Type  
I C e ll
•
« Thin and spread over a relatively 
large area
■ Make up approximately 95% of the 
alveoli
■ Form a thin blood-gas barrier 
through which gas exchange occurs
A lv e o la rT y p e  
II C e ll i f e r
- Large and cuboidal in shape 
■ Secrete a pulmonary surfactant 
which decreases the surface tension 
o f the alveolar s irface
M acro ph age
.
•  -. .. e>
• Specialised defence cells that move 
freely over the surface of the alveolus 
- Macrophages ingest foreign particles 
by a process known as phagocytosis
Figure 1.3 Overview of the cell types through the RS. For continuity but the research will focus on the TB region (e.g. basal, ciliated and 
Goblet cells; adapted f rom GgrmaTm, 2004)
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The heterogeneous nature of the dense granules within the Clara cell's 
cytoplasm suggests that they may not all have a secretory function. Some of 
them may contain lysosomal enzymes, which carry out a digestive role, either 
in defense: Clara cells engulf airborne toxins and degrade them down via 
cytochrome P-450 enzymes present in their smooth endoplasmic reticulum 
(Baron et al., 1988 and Serabjit-Singh et al., 1988); or in the recycling of 
secretory products (Widdicombe and Park, 1982). Clara cells are continuously 
dividing and differentiating to form both ciliated and non-ciliated epithelial cells 
(Evans etal., 1976).
1.5 D e f e n c e  M e c h a n is m s  in  t h e  L u n g
Defence mechanisms are essential to prevent damage and infection (Figure 
1.4). The lung utilises a vast array of biological responses which includes 
coughs and sneezes to clear debris/excess secretions in the ET region, to 
specific cell responses in the P region. Defence mechanisms of the lung can 
be categorised as cellular, immunological and non-cellular responses.
1.5.1 N a s a l  Ca v it y
The initial defence mechanism of the RS is the nasal vibrissae (prominent 
intranasal hairs). If a foreign body (FB) by-passes these protrubances it will 
gain access into the nasal cavity. The nasal cavity consists of a transitional 
epithelium and an olfactory epithelium. The transitional epithelium is 
characterised by microvilli and the olfactory by the capacity to biotransform 
xenobiotics. The stimulation of nerves or nerve endings by an inhaled 
xenobiotic can produce a cough or sneeze reflex (non-cellular response) to 
propel the FB from the ET region. Moreover, a FB could be swallowed down 
the gastro-intestinal tract (Hlastala and Berger, 2001).
1.5.2 B u c c a l  Ca v it y
Moving further into the RS, the buccal (oral) cavity and pharynx have mucus 
and saliva lined walls, which act by trapping particles and allowing toxic gases 
to dissolve.
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cavity and 
pharynx
•  Saliva and mucus line the walls and act to 
warm the air, trap particles and dissolve toxic 
gases
Trachea
• Absorption of ions and liquids across the 
epithelium is needed to maintain the correct level 
of periciliary liquid (POL) necessary for the active 
movement of the cilia
•  'Mucociliary escalator' -  the cilia beat in a 
coordinated manner to transport the mucus layer 
above the cilia and PCL to be removed by 
swallowing, spitting, sneezing or lymphatic 
circulation
• Stimulation of receptors in the trachea by 
certain xenobiotics may result in a cough to expel 
these materials
Bronchi and 
Bronchioles
• Migratory macrophages roam the epithelial and 
act to engulf and digest xenobitoic particles
•  Cellular secretions contain enzymes which act 
to modify and detoxify toxic materials
• Recruitment of PMN or polymorphonuclear cells 
-w h ite  blood cells which include neutrophils and 
eisinophils. These act like macrophages to break 
down invaders. The PMN also release cytokines 
(e.g. IL-6) which act to induce inflammation
A lveo li •  Alveolar macrophages act to engulf and digest 
xenobiotics
• Type II cells secrete GSH, surfactant
•  Type II cells are able to transform into type I 
cells in the event of damage
Figure 1.4 Overview of the different mechanisms involved in lung defence. (Adapted from Germann, 2004)
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1.5.3 Tr a c h e o -B r o n h c ia l  R e g io n
Increased branching of the tracheo-bronchial region continues to filter out 
FB’s which is enhanced by the mucociliary escalator. The cilia are extensions 
of plasma membrane from specialised epithelial cells (ciliated cells) and beat 
unilaterally towards upper respiratory tract by utilising energy in the form of 
ATP (Wanner et a/., 1996). In order to minimise energy use and increase 
efficiency, cilia flex so the motility is in the serous peri-epithelial layer. Once 
fully re-coiled the cilia extend into the mucus layer thus propelling it forward. 
This cycle, repeated by countless cilia, is responsible for transport of 
xenobiotics up the mucociliary escalator (Satir and Sleigh, 1990).
1.5.4 Im m u n o lo g ic a l  R e s p o n s e
The recruitment of polymorphonuclear cells (PMN) further increases the 
defences, these white cells, which include neutrophils and eosinophils, 
circulate in the blood and are attracted to a site of injury. The cells are 
associated with a more persistent inflammation (Lam et al., 2002), and have 
the ability to release cytokines (e.g. IL-6). The net effect of an inflammatory 
response is determined by the balance between pro-inflammatory cytokine 
and anti-inflammatory cytokines. Cytokines such as IL-4, IL-10 (inhibit pro- 
inflammatory cytokine release) and transforming growth factor (TGF)-B 
(growth inhibitor) play a role in anti-inflammatory responses (Fiorentino et al., 
1991). It is clear that protective responses are necessary in combating 
damage caused by xenobiotics. As a result, in many in vivo studies, it is often 
indeterminate whether cellular injury is due to either initial toxicologic insult or 
the subsequent immunologic responses (Bhalla etal., 2009).
1.6 Tobacco
1.6.1 To b a c c o  H is t o r y
The western hemisphere has used the common tobacco plant for millennia. 
The plants were cultivated often for religious uses, as depicted in the Mayan
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temple carvings dating back to 650-800 A.D. (Slade, 1997). It was in 1492, 
when Christopher Columbus was offered a dried tobacco leaf at the house of 
the Arawaks that initiated the spread of tobacco to Europe (IARC 1986a). It is 
thought the tobacco plant was named ‘nicotiana’ after the French ambassador 
to Portugal, Jean Nicot, who presented it to the French court in 1556.
There were two main varieties of tobacco grown in Europe. France and Spain 
used the Nicotiana tobacum that originated from Brazil and Mexico, whilst 
England and Portugal used the Nicotiana rustica that originated from Florida 
and Virginia (IARC 1986a). The trade of tobacco since 1492 to present day 
has remained an important source of commercial income.
The late nineteenth century witnessed a dramatic change in the history of 
tobacco with the design and patent of the cigarette machine by James 
Bonsack (Bonsack, 1881). The spread of Tuberculosis increased concern 
over spitting with the use of smokeless tobacco and moved users towards 
cigarette smoking (Glover & Glover, 1992). Post-1920’s tobacco use has been 
dominated by smoking cigarettes, cigars and pipes, although there are small 
numbers of chewing tobacco users globally. The trends over the last two 
decades in the 2 0 th century have changed with fashion and health concerns 
but were heavily influenced by marketing drives by the cigarette industry 
(Glover & Glover, 1992; Gerlach eta l., 1998).
1.6 .2  C ig a r e t t e  To b a c c o
Currently, the most common use of tobacco in the developed countries is the 
manufactured cigarette. A cigarette is defined as ‘any role of tobacco wrapped 
in paper or any other non-tobacco material, which when lit the burning 
process produces smoke that is inhaled through the unlit end’ (IARC, 2004). 
Cigarettes vary in length (70-120mm) and are usually 8 mm in diameter 
(Borgerding et al., 1998). When they are lit they produce three categories of 
smoke; mainstream, sidestream and second hand smoke.
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1.6.2.1 Ma in s t r e a m  C ig a r e t t e  S m o k e
Mainstream smoke (MS) is defined as cigarette (tobacco) smoke which is 
emerging from the mouth end of the cigarette during puffing (Borgerding and 
Klus, 2005; Figure 1.5). It is produced at a high temperature from the 
cigarette's burning tip. The composition of MS is affected by how the smoker 
inhales and exhales, and thus, it varies from person-to-person. The frequency 
of puffs, duration and volume all contribute to the composition of exhaled MS 
(Dunn-Rankin, 2006). The four main components of MS are tar, carbon 
monoxide, nicotine and acetaldehyde. The data from the Massachusetts 
benchmark study (1999) suggests the median yields per cigarette are 25.8mg 
(tar), 22.5mg (CO), 1.7mg (nicotine) and 1.6mg (acetaldehyde; Brown and 
Williamson, 2000). This dynamic aerosol also contains particles with an 
aerodynamic diameter range of 0.3-0.5pm at a concentration of 5 x 109 
particles per cm3 (Anderson et al., 1989).
1.6.2 .2  SlDESTREAM CIGARETTE SMOKE
Sidestream smoke (SS) is primarily the smoke emerging into the environment 
created from the emissions of a smoldering cigarette (Figure 1.5). The same 
substances present in MS are also found in SS; however, the relative yields 
per cigarette are totally dependant on the temperature of the glowing cone. An 
example of this is nicotine, with 50-80% existing in the gaseous form 
(Johnson e ta i,  1973; Brown eta!., 1980); in MS it is in the particle form. This 
type of smoke will suspend in the air longer because its aerosolised particles 
are smaller than those in MS (0.1-0.2pm; Schick and Glantz, 2005). The 
combination of smaller size of the particles with the toxic chemical properties 
of this smoke makes it more of a respiratory hazard to breathe in than its MS 
counterpart (Schick and Glantz, 2005).
1.6.2 .3  Se c o n d  h a n d  c ig a r e t t e  s m o k e
Second hand smoke (SHS) is also known as environmental tobacco smoke 
(ETS). A toxic cocktail is produced when a cigarette is smoked, approximately
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half of the smoke is inhaled/exhaled (MS) by the smoker and the other half is 
suspended in the ambient air (SS).
Air
Mainstream 
Smoke 
(0.3 - 0.5^m)
Sidestream 
Smoke 
(0.1 -0.2nm)
Figure 1.5 Cigarette smoke productions. Diagrammatic overview of the production 
of mainstream, sidestream smoke and relevant particle sizes from a lit tobacco cigarette
Once released into the environment of the smoker, components are diluted by 
the ambient air, diffusing in and being transported through it. These smoke 
constituents may also aggregate with other components in the air, and further 
age and change its physico-chemical character. SHS is classified as a known 
human carcinogen by the National Institutes of Health (NIH, 2000) and the 
International Agency for Research on Cancer (IARC, 2004).
1.6.3 To b a c co  Sm o k e  a n d  H u m a n  H e a lth
Exposure to ETS is prevalent worldwide despite the growing awareness of the 
adverse health effects on the users and non-smokers. Traditionally, studies 
have concentrated on the effects of ETS within the respiratory system. 
However, studies have demonstrated associations with cancers such as 
cervical, bladder, nasal-sinus and the brain (Table 1.1).
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A rea  of Ca n c e r Reference
C e r v ic a l Hellberg & Stendahl, 2005
B l a d d e r Zeegers eta!., 2004
N a s a l - s in u s Benninger M, 1999
B r a in Norman etal., 1996
O e s o p h a g u s Pera et al., 2005
s t o m a c h Yamamoto, 2004
L iv e r Yu MC & Yuan JM, 2004
Table 1.1 Other risks of ETS exposure. Examples of studies which suggest 
exposure to ETS may increase the risk of cancer to areas of the human body other than the 
respiratory system
Cancer is not the only adverse health effect associated with tobacco smoke. 
Studies have shown associations between smoking and heart disease, with 
increased risk of myocardinal infarction (Rastogi et al., 2005) and ischemic 
heart disease (inadequate blood supply to the heart; Tonstad & Svendsen, 
2005). These conditions can be further exaggerated with components of ETS 
having damaging effects on blood platelets (Section 1.6.6.3; Benowitz et al., 
1993; Folts and Bonebrake, 1982).
A limited number of studies have shown the effects on the fetus when the 
mother is exposed to cigarette smoke. Cigarette smoking and ETS exposure 
of non-smokers during pregnancy appeared to be the main cause of lower 
birth weight of newborns (Adamek et al., 2005). Young children are 
particularly vunerable to ETS due to their higher ventilation rates. Their 
exposure to ETS mainly arises from adults smoking in their local vicinity, with 
maternal smoking being the largest source of children’s exposure in utero and 
in early life (Chan-Yeung & Dimich-Ward, 2003).
1.6.4 Tobacco Smoke and R e s p ira to ry  H e a lth
There are other effects of ETS exposure such as the non-cancer respiratory 
effects which are predominantly observed in sensitive groups (e.g. asthmatics
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the elderly and young children; Reed, 1999; Olivieri et al., 2006; Raherison et 
al., 2007). These respiratory effects include reduced lung function, lower 
respiratory tract illness, asthma and non-allergic bronchial hyper­
responsiveness (Wang and Pinkerton, 2008).
1.6.4.1 L u n g  F u n c tio n
Most of the studies investigating lung function of children are based on health 
effects and air pollution. The Boston cohort (March 1986 to October 1992) 
study found reductions in lung functions with exposure to ETS. The projected 
reductions in lung function growth were 28, 51 and 101ml for children of 1, 2 
and 5 years of age, respectively (Chan-Yeung & Dimich-Ward, 2003; Wang 
and Pinkerton, 2008). Another study by Cook et al., (1998), carried out meta­
analysis and documented a decrease in lung function of 1.4% when 
compared to children with no exposure.
1.6.4 .2  Lo w e r  R e s p ir a t o r y  Tr a c t  Il ln e s s
Epidemiology studies in the 1980’s (Fergusson and Horwood, 1985; Chen et 
al., 1986 and Taylor and Wadsworth, 1987), demonstrated links with maternal 
smoking and the increased chance of contracting lower respiratory tract 
illness, e.g. bronchitis and pneumonia. Taylor and Wadsworth (1987) also 
showed an increase in respiratory syncytial virus (RSV) bronchiolitis with 
maternal smoking, which is a common cause of hospitalisations in children. 
There is increasing evidence that RSV has been identified as a risk factor in 
the development of asthma (Bradley et al., 2005; Puthothu et al., 2008).
1.6.4 .3  A sth m a  a n d  N o n -Al le r g ic  B r o n c h ia l  H y p e r -R e s p o n s iv e n e s s
Smoking or ETS exposure is considered as a risk factor for asthma and it is 
suggested that smoking or ETS-exposed asthmatics exhibit a different 
phenotype when compared to non-smoking asthmatics (Gusbin et al., 2006). 
Clinically, the asthma of smokers has an increased severity than in a non- 
smoker, both at the symptomatic and the functional level. The asthma severity
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in smokers is partly linked to a resistance to inhaled corticoids; the 
cornerstone of maintenance treatment in asthma (Gusbin et al., 2006).
Cook and Strachen (1997) investigated the prevalence of asthma, wheezing 
and chronic cough with parental smoking. They found an increase of 21% in 
childhood asthma, a 24% increase in children with a wheeze and an increase 
of 40% in children with a chronic cough whose parents smoke. This study also 
found that maternal smoking had a greater effect than paternal smoking. A 
year later Cook and Strachen (1998) used meta-analysis and found an 
increase in bronchial hyper-responsiveness in children with smoking mothers.
1.6 .5  To b a c c o  S m o k e  C o m p o n e n t s
Tobacco and tobacco smoke are complex chemical matrices consisting of 
thousands of compounds. A total of 3044 constituents (vapour phase [95% by 
weight] and particle phase [5% by weight]) have been identified/isolated from 
tobacco, and in excess of 4000 from the MS (exhaled) of cigarettes (Green 
and Rodgman 1996; Roberts, 1998; Jenkins etal., 2000).
Qualitatively, there are minimal compositional (by weight) differences between 
MS, SS and SHS. However, quantitatively their compositions can differ 
considerably. For example, approximately 1.5mg of formaldehyde can be 
found in the total smoke from one cigarette, and this was distributed 
between the MS and SS smoke in the ratio of 1:50, (i.e., 30pg in the MS and 
1526pg in the SS) [Jermini etal., 1976; IARC, 2004].
The vapour phase components dominate the constituents of tobacco and 
tobacco smoke, and being soluble, will likely be reactive metabolites 
(formaldehyde; de Serres and Brockman, (1999) and urethane; Gupta and 
Dani (1989)). The solid or particle phase of tobacco and tobacco smoke 
constitutes only a small fraction (5%) of the bi-products but these can be 
cytotoxic (e.g. cadmium; Zalups and Ahmad, 2003) or thrombogenic (nicotine; 
Pfueller etal., 1988).
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1.6 .6  N ic o t in e
Nicotine is a naturally occurring alkaloid found in members of the 
Solanoceous plant family that includes potatoes, green peppers and tobacco; 
within these plants nicotine acts as a botanical insecticide (Soloway, 1976; 
Tomizawa and Casida, 2003). The structure of nicotine is [1-methyl-2-(3- 
pyridyl-pyrrolidine), C10H14N2] (Figure 1.6).
Nicotine was first isolated from the leaves of Nicotiana tobacum (the tobacco 
plant), in 1828 by Possett and Reiman (Schevelbein, 1982). This extraction 
instigated the interest of nicotine and its actions on the body. Experiments 
carried out by Orfila in 1843, initiated the first pharmacological studies 
involving nicotine. Following these primary experiments work continued with 
Lanley and Dickinson (1889) identifying the prime site of interaction between 
nicotine and the nervous system of animals. This work demonstrated the 
ability of nicotine to interact with the body and possible involvement in the 
etiology of a number of disease processes (e.g. inhibition of cell proliferation; 
Wonnacott, 1999).
Nicotine is one of the few naturally occurring liquid alkaloids, which means 
that it has some unique chemical properties. Pure nicotine is clear and turns 
brown when exposed to air (Schevelbein, 1962), it is also soluble in water and 
readily forms aqueous salts, and the free nicotine is also soluble in organic 
media with a boiling point of 274.5°C. These properties are pH dependant and 
explain nicotine’s biological properties within the body; these can include 
increased pulse and blood pressure, mobilisation of blood sugar and an 
increase in plasma free fatty acids (Benowitz, 1988; Dani and Heinemann, 
1996; Waldum etal., 1996; Ashakumary and Vijayammal, 1991).
1.6.6.1 A b s o r p tio n  o f  N ic o t in e
There are many routes of nicotine absorption in the human body which 
include the oral cavity, skin, lungs and gastrointestinal tract (Schevelbein et 
al., 1973).
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Figure 1.6 A tobacco plant. Drawing made by John Gerard (1545-1612) and the 
chemical structure of nicotine
Absorption of nicotine across a biological membrane is a pH dependent 
process (Fowler, 1954; Schevelbein et al., 1973). Due to the presence of 
pyridine and pyrrolidine nitrogen, nicotine can be classed as dibasic with a 
pKa of 7.84 and 3.04 at 25°C. The proportion of uncharged nicotine increases 
as the pH of a solution increases. The uncharged organic bases are lipophilic 
(readily permeable to membranes), whereas charged organic bases are 
hydrophilic (not permeable to membranes) and consequently, the rate of 
absorption of nicotine increases as the pH increases (Yildiz, 2004).
This is demonstrated by the differences between smokers that inhale and 
smokers that do not inhale. The pH of cigarette smoke is generally in the 
range of 5.5, where the nicotine fraction at this pH is largely positively 
charged. Smokers that inhale have the primary route of absorption through 
the alveoli; this site has a pH of 7.4 and 31% of nicotine will be uncharged and 
able to pass through the membranes into the blood circulation. Very little 
nicotine will be absorbed at the buccal mucosa (primary route of absorption 
for smokers that do not inhale). The lipophilic nature of nicotine at a pH of 7.4 
results in nicotine plasma levels reaching 40rig/ml compared to nicotine
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plasma levels of 2.5-8r|g/ml for non inhaling-smokers (Russel et al., 1980; 
Figure 1.7).
Alveoli Buccal mucosa
0 0 0 0 0  Nicotine o ° o °  0  0
P l a s m a
Figure 1.7 Principle sites of nicotine exposure. Schematic overview of the pH 
dependent absorption of nicotine at two of the principle sites of absorption
1.6.6.2 M e t a b o l is m  o f  N ic o t in e
Studies of nicotine metabolism have been conducted over several decades 
but problems have occurred due to investigators using different names for the 
same metabolite (e.g. Trans- 3’-hydroxycotinine has been called 
Hydroxycotinine, 3’-Hydroxycotinine and 3-hydroxy-1-methyl-5-(3-pyridinyl) 
(Hukkanen et al., 2005). The liver extensively metabolises nicotine into a 
number of metabolites (Figure 1.8). The metabolic pathways elucidated have 
identified the participation of cytochrome P450 and flavin adenine dinucleotide 
(FAD) containing monooxygenases (Peyton et al., 1988) in nicotine 
metabolism. Present day studies, (Lee et al., 2005) have made advancements 
in understanding nicotine metabolism with improved enzyme purification 
combined with a number of immunochemical and biochemical techniques.
Quantitatively, the most important metabolite of nicotine in most mammalian 
species is cotinine. In man, 70-80% of nicotine is converted to cotinine 
(McKennis et al., 1963). This transformation involves two steps. The first is 
mediated by a cytochrome P450 system (mainly CYP2A6 and CYP2B6) to
MEMBRANE
Non-inhaled pH 5.5
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produce nicotine iminium ion (Nakajimi et al., 1996; Messina et al., 1997). The 
second step is catalyzed by aldehyde oxidase (AOX; Brandage and Lindblom, 
1979). Nicotine N'-oxide (NNO) is another primary metabolite of nicotine, 
although only about 4-7% of nicotine absorbed by smokers is metabolized via 
this route (Byrd et al., 1992; Benowitz et al., 1994); the enzyme responsible 
has not yet been identified (Yildiz, 2004).
Nicotine
Nornicotine
Nicotine-Gluc
Cotinine Glue
Nicotine-Gluc Nicotine Nornicotine
(QGTTAfri
Nicotine Iminium Ion
Cotinine
Cotinine-Gluc
Norco tinine
3HC-Gluc
\ 5HC
*| CNO
Cotinine
Norco tinine
Figure 1.8 Pathway showing metabolism of nicotine in human liver.
Adapted from Ring et al. (2005)
The conversion of nicotine to NNO involves a flavin-containing 
monooxygenase 3 (FM03; Cashman et al., 1992; Park et al., 1993). It 
appears that NNO is not further metabolized to any significant extent, except 
by reduction back to nicotine, which may lead to recycling of nicotine in the 
body (Duan etal., 1991).
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1.6.6.3  B io lo g ical  E f f e c t s  o f  N ic o t in e
The effect of nicotine in the animal and cell system has been comprehensively 
researched (e.g. Yildiz, 2004; Hukkanen et al., 2005). Nicotine has been 
shown to elict a variety of physiological effects (i.e. cardiac contractility, 
mobilisation of blood sugars and increased free fatty acids) but for the 
purpose of this study only the thrombogenic mechanisms of nicotine will be 
documented. The thrombogenic effects of nicotine can be attributed to 
interactions with platelets and prostaglandins. To date, extensive research 
has been carried out to investigate the associations with nicotine and 
platelets, although this association has not been proved in vitro (Pfueller etal., 
1988). One proposal for this interaction, as suggested by Pfueller (1988), is 
that the narrowing of the arterial lumen could cause a turbulent flow that 
would lead to damaged red blood cells and platelets. The consequence of this 
damage would cause the release of adenosine diphosphate (ADP) which 
promotes platelet aggregation (Figure 1.9).
Studies investigating platelets in smokers have shown conflicting results but 
this could be due to the complex and chemical constituents in cigarettes 
beside nicotine that may promote platelet aggregation (Benowitz et al., 1993). 
Experiments have shown that nicotine administered intravenously raises 
plasma adrenalin, which is due to the release of adrenalin from the adrenal 
medulla. The presence of epinephrine stimulates platelet aggregation and 
thrombus formation by alpha-adrenergic mechanisms (Kershbaum and Bellet, 
1964). These conditions are likely to be exacerbated by cigarette smoking, 
leading to sudden coronary death (Folts and Bonebrake, 1982).
The numerous experiments investigating nicotine and the effects on the 
cardiovascular system only elucidate its possible mechanisms, but the effects 
of nicotine combined with components of cigarette smoke have the potential 
to produce a hypercoagulable state via platelet aggregation that may well 
accelerate atherosclerosis and acute cardiovascular events (Benowitz et al., 
1993; Figure 1.10).
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- Nicotine + Nicotine
Release of ADP 
Narrowing of lumen
Figure 1.9 Proposed interaction of nicotine and platelets by Pfuller 
(1988). (Adapted from Lotrel Pharmaceutical 2005)
NICOTINE
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Endothelial Injury
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Figure 1.10 Role of nicotine in atherosclerosis. (Adapted from Kilaru et al., 
2001). Key: PG1-2, prostaglandin 1-2; TXA-2, thromboxane 2; VSMC, vascular smooth 
muscle cells
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1.6.7 U re th a n e
Urethane (NH2COOCH2CH3) or ethyl carbamate (EC) is the ethyl ester of 
carbamic acid (NH2COOH). Urethane has a melting point of 48-50°C and a 
boiling point of 182-184°C. Urethane is water soluble (2gml‘1) and its solubility 
decreases slightly in solvents (IARC, 1974). In the 1940’s urethane was used 
as a hypnotic in man, for treatment of a host of diseases including chronic 
leukaemia, and as an anaesthetic for laboratory animals (Field and Lang,
1988). The aforementioned use led to the discovery of its carcinogenicity in 
animals in 1943 (Nettleship etal., 1943).
Three more years passed before the activity of urethane within humans was 
described by Zimmerli and Schlatter (1991), and since 1948, urethane was 
known to be mutagenic in Drosophila melanogaster (Zimmerli and Schlatter, 
1991). Exposure may also occur from the production of textiles, pesticides, 
fumigants and cosmetics (Zimmerli and Schlatter, 1991; Benson and Beland, 
1997).
Diet is the most common route of human exposure to urethane. It is formed as 
a by-product of fermentation, distillation and long-term storage processes, 
which infers that food-types such as bread and alcohols contain urethane 
(Zimmerli and Schlatter, 1991). It is also a natural constituent in tobacco 
leaves (Schmeltz et al., 1978). Urethane is classified as ‘reasonably 
anticipated to be a human carcinogen’ (National Toxicology Program, 2000).
1.6.7.1 A b s o r p tio n  a n d  M e ta b o lis m  o f  U r e t h a n e
Regardless of the route of exposure EC is rapidly distributed throughout the 
body. In excess of 90% of EC is degraded into C 0 2, H2O and NH3 within 24 
hours (Zimmerli and Schlatter, 1991), with only 6% remaining as EC. The 
remaining EC is then excreted. Rates of EC metabolism have been 
researched; Yamamoto et al. (1988) showed that radio-labelled EC almost 
disappeared from the blood within 4 hours. However, a single dose of ethanol 
(5g/kg b.w.) leads to a high consistent blood level of EC that exists in excess
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of 8 hours (Waddell et al., 1987; Yamamoto et al., 1988). This data implies 
that high doses of ethanol may postpone the metabolism of EC by blocking 
the metabolising enzymes including the group of cytochrome P450’s 
(Schlatter and Lutz, 1990).
Gupta and Dani (1989) investigated the generation of vinyl carbamate (VC) 
and an epoxy derivative (Figure 1.11). These electrophilic metabolites are 
thought to be responsible for genetoxicity and carcinogenicity. This research 
indicated the existence of oxidation reactions at the ethyl group and was 
carried out in vitro using microsomes from rat lung.
This area of research has been further enhanced by the ability to study the 
bioactivation and/or detoxification of a xenobiotic by a single enzyme with the 
advent of genetically engineered mice (Gonzales, 1998; Gonzales and 
Kimura, 1999). Present day research on urethane focuses on the assessment 
of the role of CYP2E1 in urethane metabolism utilising the availability of 
CYP2E1-null and wild type mice.
1.6.7 .2  B io lo g ical  E ff e c t s  o f  U r e t h a n e
Extensive research has been prompted into the potential biological effects of 
urethane given its tumourigenesis in humans. The principle target/site being 
the liver (Siemiatycki et al., 2004) in animals has prompted extensive research 
into EC’s mechanisms of action. As mentioned in Section 1.6.7.1, the current 
accepted hypothesis is the chemical activation from EC to VC and 
subsequently vinyl carbamate epoxide (VCO); a prerequisite for tumour 
development (Hoffler et al., 2003). Epoxide intermediates are highly reactive 
electrophiles that easily bind to macromolecules such as DNA, RNA and 
proteins leading to the production of adducts (Figure 1.11; Melnick, 2002). 
This led to the hypothesis that CYP2E1 -mediated metabolism is a 
requirement for urethane induced cell proliferation, genotoxicity and 
carcinogenicity.
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Urethane (Ethyl carbamate)
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N NHNH
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A/2,3-Etheno-dG 1,A/6-Etheno-dA 3,/V4-Etheno-dC 7-(2-Oxoethyl)-dG
Figure 1.11 Metabolic pathways and DNA adducts derived from urethane 
(ethyl carbamate). (Adapted from Beland etal., 2005) Key: dG.deoxyguanosine; 
dA,deoxyadenosine; dC, deoxycytidine; dR, deoxyribose.
1.6.8 F or m ald ehyde
Formaldehyde (FA) is a colourless, flammable gas at room temperature, with 
a chemical structure of CH20  (Figure 1.12). It has a pungent, distinct odour 
and can cause a burning sensation to the eyes, nose and lungs at high 
concentration (Cassanova et al., 1988). FA is a naturally occurring biological
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component present in cells and tissues (Heck et al., 1985). As an aqueous 
solution known as ‘formalin,’ it is widely used in hospitals and many industries 
as a fixing agent (i.e. preservative). It is used in the production of fertilizers, 
paper, plywood and urea-formaldehyde resins. FA is mixed with methanol and 
buffers to make embalming fluid (WHO, 1989; Heck etal., 1985).
FA is a volatile organic compound (VOC) and has received attention as the 
chemical irritant responsible for ‘sick building syndrome’. VOCs are organic 
solvents that evaporate at room temperature and diffuse into rooms from 
building materials and furnishings, and thus, attributing to indoor air pollution 
(Gustafson et al., 2007).
Experiments carried out by Beall and Ulsamer (1984), suggested inhaled FA 
may induce developmental toxicity, immunotoxicity and hepatotoxicity. Inhaled 
FA and links with cancer was first published by Soffritti (1989). The IARC 
reported FA to be a potent respiratory and conjunctival irritant, genotoxicant 
and a nasal carcinogen in rats exposed to high airborne concentrations 
(15ppm; IARC, 1995).
Figure 1.12 Chemical structure of Formaldehyde.
A recent large scale epidemiology study has shown a significant excess of 
deaths from nasopharyngeal cancer in industrial workers. These workers 
were exposed to acute high level and lower cumulative levels of FA 
(Hauptmann et al., 2004). This work supports data from previous studies of 
U.S. embalmers (Hayes et al., 1990), and an excess of nasopharyngeal 
cancer observed in a Danish study amongst workers involved in companies 
that manufactured or used FA (Hansen and Olsen 1995). Although there have 
been other studies that have reported fewer cases of nasopharyngeal cancer
0
H
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than expected (Pinkerton etal., 2004; Coggon etal., 2003), these variations in 
nasopharyngeal cancer were deemed to be small by the IARC who have in 
turn re-classified FA to carcinogenic to humans (group 1), based on evidence 
from the Hauptmann et al. studies. This classification, in 2005, is higher than 
those previously issued by the IARC (IARC 1982,1987 and 1995).
FA can be emitted from incomplete combustion processes and is emitted in 
the smoke from cigarettes. Approximately 1.5mg of formaldehyde was found 
in the total smoke from one cigarette, which was distributed between the 
MS and SS in the ratio of 1:50 (i.e. 30pg in the MS and 1526pg in the SS) 
[Jermini et al., 1976]. Other investigators measured FA MS concentrations of 
60-130pg/m3. For an individual smoking 20 cigarettes per day, this would 
lead to an exposure in excess of 1 mg/day (WHO 1989), compared with an 
occupational exposure of 2-6pg/m3 for persons living in a suburban area 
(Agency for Toxic Substances and Disease Registry [ATSDR], 2006).
1.6.8.1 A b s o r p tio n  o f  F o r m a l d e h y d e
Formaldehyde vapours are easily absorbed; more than 90% of inhaled FA is 
absorbed in the upper respiratory tract (Heck et al., 1985). Due to the 
hydrophilic nature of FA, the nasal mucosa and proximal trachea are the 
primary targets of inhaled FA (Kerns et al., 1983; Woutersen et al., 1987). At 
these locations FA is swiftly metabolised (oxidised) to formate and carbon 
dioxide or can be incorporated into biological macromolecules (IARC, 2005). 
Therefore, a very small change in FA (2.77±0.28pg/g) can be detected in 
human and animal blood post-exposure, compared to a FA concentration 
(2.61 ±0.41 pg/g) pre-exposure (Casanova et al., 1988; Heck et al., 1985). FA 
concentrations at the primary target (nasal mucosa) and liver are found at 2 to 
4-fold higher than that found in the blood (Heck et al., 1982). All remaining FA 
is excreted in urine and faeces (Heck et al., 1983).
1.6.8.2 M eta b o lism  o f  F o r m a l d e h y d e
The metabolism of FA to formate (Figure 1.13) takes place in all tissues of the 
body, as an effect of its endogenous formation via formaldehyde
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dehydrogenase (FDH). FDH is a metabolic enzyme distributed throughout 
animal tissues (particularly in the nasal mucosa of the rat), specifically for the 
glutathione adduct of FA (ATSDR, 1999a). The FA not metabolised by FDH 
has a number of fates (Figure 1.13):
• Formation of cross linkages between protein and single stranded DNA 
(DPX)
• Enter the one-carbon metabolic pool by initially binding to 
tetrahydrofolate (Bolt, 1987)
• Non-enzymatic reaction to form urea hydroxy I methyl adducts in urine.
Although FDH is the primary enzyme, there are at least 7 enzymes that 
catalyze the oxidation of FA in animal tissues, namely, aldehyde 
dehydrogenase, xanthinoxidase, catalase, peroxidase, glycerinaldehyde-3- 
phosphate dehydrogenase, aldehyde oxidase, and a specific DPN-dependent 
formaldehyde dehydrogen-ase (Cooper & Kini, 1962). The activity of FDH is 
not induced when exposed to FA (Casanova-Schmitz et al., 1984).
1.6.8 .3  B iolo gical  E f f e c t s  o f  F o r m a l d e h y d e
Formaldehyde is mutagenic and genotoxic (de Serres and Brockman, 1999). 
The mutagenic and genotoxic potential of FA is consistent with its ability to 
form DPX. The presence of DPX has been shown in the nasal mucosa of 
monkeys exposed to FA (Casanova et al., 1991). The existence of DPX has 
not been associated to pro-mutagenic tendencies but DPX has been 
associated with clastogenicity, i.e. chromosomal aberrations, deletions and 
sister chromatid exchanges (Merk and Speit, 1998; Speit and Merk, 2002). 
Numerous studies have demonstrated that FA does not cause point mutations 
in vivo (Craft et al., 1987; Merk and Speit, 1998; Speit and Merk, 2002). 
Several studies have shown evidence of point mutations in vitro and a limited 
number of p53 mutations in some rat nasal mucosa tumours post-FA- 
exposure (Crosby et al., 1988; Recio et al., 1992). These results are 
consistent with a mechanism in which DPX acts as a replication block (Heck 
and Casanova, 2004; Merk and Speit, 1998; Permana and Snapka, 1994);
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this mechanism could lead to numerous deleterious effects. FA inhibition of 
DNA replication has previously been reported in vivo (Casonova et al., 1989; 
Casonova-Schmitz et al., 1984) and in vitro (Permana and Snapka, 1994; 
Snyder and Van Houten, 1986).
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Figure 1.13 Biological reactions and metabolism of formaldehyde.
(Adapted from Bolt, 1987) Key: TH4 = Tetrahydrofolic acid, SFGH = S-Formyl Glutathione, 
NAD+ = Nicotinomide adenosine dinucleotide, DNA = Deoxyribonucleic acid, FDH = 
Formaldehyde Dehydrogenase
1.6.9 Ca d m iu m
Cadmium (Cd) is a widespread heavy metal and exists in the 0 or 2+ oxidation 
state. Large-scale use of Cd began in the 1940’s (Stoeppler, 1991) and recent 
uses of Cd include nickel-cadmium batteries, pigments and plastic stabilisers 
(Waisberg et al., 2003). Other sources of concern are phosphate fertilizers 
which often contain high levels of Cd depending on the origin of the rock 
(Thornton, 1992). Estimates of 25,000 to 30,000 tonnes of Cd are released
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into the environment each year; human activities play a huge part of this by 
contributing 4000 to 13,000 tonnes per year with mining and burning fossil 
fuels (ATSDR, 1999b). Cd in the environment naturally exists as an inorganic 
salt such as cadmium oxide (CdO), cadmium chloride (CdCh) or cadmium 
sulphate (CdS0 4 ; ATSDR, 1999b). Although Cd may change chemical forms, 
the metal ion is not removed from the environment (Morselt, 1991) which 
leads to an increase in risk to humans and has earned Cd a place on the US 
Environmental Protection Agency (EPA) list of 126 priority pollutants.
Among non-smokers the major source of Cd exposure is through ingestion of 
Cd contaminated food. Contaminated fish, offal and cereal products usually 
contain the higher quantities of Cd (ATSDR, 1999b). Cigarette smoke remains 
the greatest source of Cd exposure for the human population. Each cigarette 
may contain 1-2pg of Cd and 40-60% of the Cd inhaled will pass through the 
pulmonary epithelium into systemic circulation (ATSDR, 1999b; Elinder et al., 
1976). Studies have demonstrated the half life of Cd in humans to be 15-20 
years (Jin et al., 1998) this can potentiate an array of disease states which 
include emphysema and irreversible renal tubular damage (Waisberg et al., 
2003). In addition to the cytotoxic effects Cd has on the primary organs 
(apoptotic/necrotic events), it is a potent carcinogen with associations to 
cancers of the lung, prostate, pancreas and kidney, earning Cd a category 1 
human carcinogen status (IARC, 1993; National Toxicology Program, 2000).
1.6.9.1 A b s o r p tio n  o f  Ca d m iu m
As mentioned in Section 1.6.9 there are two main routes of Cd exposure, 
inhalation and ingestion. There is a possible third route, absorption via the 
skin but this has been shown to be relatively insignificant and the exposure 
would have to be over a prolonged period of time (Wester et al., 1992). 
Cadmium exposure from ingestion is generally due to contaminated food or 
drinking water with CdCh in particular, due to it being highly soluble in water 
when compared with CdO, which is mainly associated with inhalation 
(ATSDR, 1999b; Oberdorster, 1992).
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When comparing absorption Moore et al. (1973), demonstrated up to 60% of 
Cd from the inhaled dose (Cd carbonate) was translocated to the 
gastrointestinal tract in rats. This is thought to be due to the mucociliary 
clearance and subsequent ingestion. Absorption of Cd via ingestion is greatly 
reduced with peak absorption at 16% in ovine (Miller et al., 1969) and a 1-2% 
absorption in rodents (Ragan etal., 1977).
1.6.9.2 M eta b o lism  o f  Ca d m iu m
A number of factors contribute to the cellular toxicity of Cd and include dose, 
route and duration of exposure. The mode of Cd transport into target cells is 
not fully understood but several hypotheses exist. The first hypothesis, and 
most scientifically favoured, suggests Cd interacts and competes for binding 
sites on the membrane proteins involved in the transport of vital elements 
(e.g. Calcium, Zinc and Iron) into epithelial cells of the route of exposure e.g. 
lung or gut via ionic mimicry (Zalups and Ahmad, 2003). A second hypothesis 
suggests endocytosis of proteins containing Cd could be the mechanism by 
which it enters epithelial cells (e.g. Cd ions bind to metallothionein, albumin or 
other proteins; these conjugates act as substrates for endocytotic transport) 
[Zalups and Ahmad, 2003]. Both hypotheses imply the use of mimicry, this 
can be described as the process by which the Cd ion binds to an essential 
homeostatic molecule and the function of this molecule remains unchanged,
i.e. mimicking the endogenous molecule (Cannon et al., 2000, 2001). This is 
depicted in Figure 1.14, illustrating the intricate pathways for handling Cd in 
the body post-oral/pulmonary exposure. Also shown are the potential species 
of Cd that may be utilised in its transport and elimination.
1.6.9.3 B io lo g ic a l  E ff e c t s  o f  Ca d m iu m
There are many biological effects exerted by Cd on membranes, 
mitochondrial structure and function, DNA and gene expression (Pinot et al., 
2000). Oxidative stress is initiated by Cd in many cell types, this has been 
determined by decreased activity of antioxidants (Manca et al., 1994; Yang et 
al., 1997). The toxic effects of reactive oxygen species (ROS) are further
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enhanced by the depletion of glutathione and protein bound sulfhydryl groups 
(Skoczynska, 1997).
This is highlighted at the mitochondrial level, with the inhibition of cellular 
respiration by Cd, which binds to the sulfhydryl groups, particularly those 
found within the hydrophobic region of the mitochondrial membrane (Rikans 
et al., 2000; Figure 1.15). This initiates a cascade effect with the thiol group 
inactivation leading to oxidative stress, with mitochondrial depolarisation and 
permeability transition contributing to mitochondrial dysfunction.
Following the opening of the permeability transition pores, ROS and 
cytochrome c are released from the mitochondria into the cytosol where they 
activate caspases, the final effectors of apoptosis (Pinot et al., 2000). The 
severe depletion of ATP leads to cell necrosis, modest depletion leads to 
protein degradation by ROS. This in turn, reduces the free heat shock protein- 
70 (Hsp70) pool, and results in activation and induction of the Hsp70 gene 
(Pinot et al., 2000; Figure 1.15). These Hsp are molecular chaperones 
essential for ‘normal’ cells and survival during injury especially oxidative 
stress (Polla et al., 1988; Polla et al., 1996). Heat shock proteins bind 
polypeptides, stabilise emerging polypeptides and facilitate their transport 
(Gething et al., 1995). The Hsp response attenuates oxidative and 
inflammatory injuries in pulmonary cells and whole lung (Villar et al., 1993; 
Wong et al., 1996).
1.7 E piA ir w a y ™ Tis s u e  M o d el
Traditionally, in vivo studies are used to investigate toxicant effects in the 
lung, however, public opinion and government legislation is leading to a 
decrease in the popularity of animal testing. A growing number of scientists 
are now working towards the Three R’s principles of Russell and Burch 
(1959), which refers to the “reduction, refinement and replacement” of animal 
experiments. Consequently, viable alternatives need to be developed which 
can reproduce in vitro, toxic events that may occur in the human lung.
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Figure 1.14 The interactions of Cd in the body after oral/gastrointestinal 
and pulmonary exposure to Cd. Potential pathways are highlighted with the handling 
and excretion of the different forms of Cd that maybe present in the relevant organs of the 
body adapted from Zalpus and Ahmad (2003); (1) GSH S conjugates Cd are degraded along 
the biliary tree to Cd-(Cys)2; (2) Cd-MT released into sinusoidal blood from hepatocytes after 
induction of necrosis or apoptosis by Cd. Key to figure: MT = Metallothionein, CYS= Cysteine, 
GSH = Glutathione, /V-Acetyl-Cys = N-acetylcysteine, homocys = Homocysteine
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Figure 1.15 Interactions of Cd on mitochondria. The events lead to necrosis, 
apoptosis and/or activation of Hsp70 (adapted from Pinot et al.} 2000)
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The target tissue for toxic gases and particles in the ambient air is the 
epithelial lining of the upper and lower airways of the lung. Consequently, the 
biological activity of airborne substances is usually studied using cells types 
such as alveolar type II or, bronchial epithelial cells and macrophages 
(Steimer et al., 2005). There are some perceived disadvantages to this 
approach. Firstly, it is difficult to isolate and culture functional cells from 
human pulmonary tissue (Schwarze et al., 1996), and despite attempts to 
immortalise human pulmonary cells, there is a major drawback in that these 
cells can have a limited life-span. In contrast, transformed cell lines have an 
unlimited lifespan allowing prolonged studies (Steimer etal., 2005). However, 
these cell lines may not accurately represent the in vivo situation, as the 
phenotype of transformed cells differs from that of normal cells. For example 
A549 cells (alveolar) lose the ability to form tight junctions and secrete 
pulmonary surfactant which eliminates the capacity to produce in vivo-like 
barrier properties (Winton et al., 1998). BEAS-2B cells (bronchial) express 
cytokines, indicating the capacity to model inflammatory responses, but fail to 
secrete mucus and form tight junctions (Steimer et al., 2005). In contrast 
16HBE14o cells (bronchial) successfully form tight junctions and ciliated cells 
(Cozens et al., 1994), but fail to secrete mucus (Steimer et al., 2005). The 
Calu-3 cell (bronchial) monolayer is popular because it can form tight 
junctions, develop cilia, and express mucins (Grainger et al., 2006). However, 
it is derived from an adenocarcinoma, which may present an abnormal 
phenotype, and is lacking in metabolic activity (Foster et al., 2000). In 
addition, individual cell types may respond quite differently to a complex 
mixture like tobacco smoke (Andreoli et al., 2003), as they may lack the 
requisite biotransformation enzymes (e.g. P450s; Castell et al., 2005). 
Similarly, cell lines may show altered expression of a range of secretory and 
signalling molecules (Forbes et al., 2005). Overall, there are large in-built 
biases when using these kinds of experimental systems. The advent of mixed 
population cultures and multi-differentiated cultures provides a better 
indication of cell-cell interactions to generate more in wVo-like characteristics 
(Gruenert et al., 1995). A highly differentiated, 3-dimensional system is 
desirable because it models not only the different effects of toxins on specific 
cell types, but also the interaction between the cells. Moreover, epithelium
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cultured at the air-liquid interface would facilitate in wVo-like chemical 
exposures. These requisites are met by a human derived, primary, upper 
airway, culture known as the EpiAirway™ Tissue Model (Figure 1.16: MatTek 
Corporation; BeruBe etal., 2006).
Figure 1.16 LM Comparison of a human epithelium and an EpiAirway™ 
Tissue model. (A) LM image of a human biopsy section (20X objective: provided by K. 
BeruB6), fully-differentiated epithelium, cilia present on apical surface (C) and Goblet cell (G). 
(B) H&E stained cross-sections of EpiAirway™ tissue (10X objective: MatTek Corporation), 
cilia present on apical surface (C) and Goblet cell (blue oval)
1.8 B io m a r k e r s
Lung toxicology is demonstrated by functional assessment and pathology. 
The development of successful biomarkers requires the combination of a 
number of disciplines and skills, such as models of different types of toxicity to
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generate regiospecific biomarkers, analytical/bioinformatic capability to 
identify and characterise them, and ability to develop and validate appropriate 
assays to confirm “fit for purpose”.
Respiratory disease has huge healthcare cost. Over £12 billion is spent on 
medicines for asthma, cystic fibrosis, chronic obstructive pulmonary disease 
and idiopathic pulmonary fibrosis in the USA each year (Personal 
communcation Dr P. Bach). Validated biomarkers are needed to replace 
insensitive functional and labour intensive pathological methods, which only 
reflect advanced toxicity. Robust (specific and selective) biomarkers will 
include those used to assess disease, but never validated for toxicology, and 
novel peptides from proteomics will help improve safety assesment and 
reduce animal usage.
The advent of ‘omic technology developed from the use of polymerase chain 
reaction (PCR) and other molecular biology techniques. Genomics facilitated 
the identification of target genes for an extensive range of toxicological 
endpoints. The development of transcriptomics and proteomics then further 
identified whether observed gene changes were effectual on a cellular level 
(Pandey and Mann, 2000). Genomics and proteomics can be useful tools 
when monitoring interactions between genes, gene products and the 
environment (Afshari, 2002; Waters et al., 2003). Loosely termed the ‘omics’, 
these research tools are then combined in Systems Biology in order to gain a 
broader understanding of the mechanistics of the test system. These new 
technologies are being adapted rapidly throughout industry and academia to 
investigate a range of endpoints and the identification of ‘intelligent 
biomarkers’ (Aardema and MacGregor, 2002).
1.8.1 To x ic o g e n o m ic s
Exposures of chemical and xenobiotics to biological systems and the 
mechanistics involved in the effects these toxins play are the basis of 
toxicological investigations. Closer scrutiny of the exposure, harm and repair 
pathways at the molecular level is essential in the understanding of 
mechanistic behaviour. Toxicogenomics can broadly be defined as “the study
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of the relationship between the structure and activity of the genome (the 
cellular complement of genes) and the adverse biological effects of 
exogenous agents” (Aardema and MacGregor, 2002).
1.8.2 G e n e  Ex p r e s s io n  S tu d ie s
Toxicant exposure, including inhalation of xenobiotics, can alter gene 
expression either directly or indirectly and the majority of toxicological effects 
are achieved under molecular control. Gene profiles can be constructed and 
the toxicological profiles of uncharacterised xenobiotics can be compared to 
established patterns, minimising testing costs and time compared to 
conventional toxicological methods (Figure 1.17). Application of this 
technology could benefit end-users in many other ways, including making 
improvements to public health policy (Henry, 2002) and risk analyses (Pennie 
and Kimber, 2002; Olden, 2004).
Mechanisms of toxicity can be also elucidated by analysing patterns of gene 
expression initially used as a ‘fishing’ tool. This can lead to identification of 
molecular targets of toxicants, biomarkers (important for effect and exposure) 
and improved mechanistic understanding (Pennie, 2000; Pennie et al., 2000). 
The use of this technology can also enhance toxicological understanding 
through identification of dose-response relationships from induction of toxicity. 
Utilisation of these data can provide the basis for chemical screening tools 
and predictive toxicology. Toxicogenomics has already been successfully 
applied to evaluating human bronchial epithelial cell response following 
exposure to cigarette smoke in vivo (Spira et al., 2004) and in vitro (Fields et 
al., 2005; Maunders etal., 2007).
There are limitations with this technology; this technique generates a vast 
amount of data and during the data mining stages small/subtle genes can be 
ignored and could lead to misinterpretation and error. Without concurrent data 
regarding the relative up- or down-regulation of the functional proteins, 
significant findings can be overlooked and false positives followed. An
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example of this is the lack of separation between downstream (secondary) 
transcriptional changes in gene expression and causative (primary) changes.
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Figure 1.17 An overview of the array process. The RNA is biotin labelled during a 
reverse transcription reaction and the labelled cDNA copy is then hybridised to the DNA 
sequences bound to the array. Detection and quantification of the array information is 
achieved using software specific to the type of array used (SuperArray). Finally, global 
normalisation and robust statistical analyses are applied (SAM; Stanford University). This 
enables the relative abundance of each of the gene sequences in two or more biological 
samples to be compared
1.8.3 Pr o teo m ic s
Proteomics is used to separate and identify proteins in a complex mixture for 
the purpose of quantitative and functional analyses of all the proteins present 
(Abbott, 1999, Hunter et al., 2002). It has proven to be a powerful tool for 
identifying early changes at the protein level in a variety of disease states 
(Kvasnicka, 2003). It can also provide a non-invasive technique for evaluating
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body fluids in the search for pertinent or specific biomarkers of toxicity 
(Kennedy, 2001).
Genomics is the study of genes, their DNA sequence and variations of that 
sequence, their expression patterns in normal and diseased tissues, and their 
function in the organism. Every cell within a given organism contains all the 
genetic information necessary to make an exact copy of itself. That is, each 
cell contains a complete ‘genome’, however, not all the genes are expressed 
at the same time. Genomics offers a snapshot of expression of some or all of 
the genes in a given cell/tissue, but the level of mRNA does not necessarily 
predict the levels of the corresponding proteins in the cell, due to differing 
(Liebler, 2002):
1. Stability of mRNA
2. Efficiencies in translation
3. Stability and turnover rates
4. Post-translational modifications
The relative abundance of thousands of different proteins along with their 
cleaved/modified forms is a reflection of the ongoing physiological and 
pathological events (e.g. cells will leave a different protein signature 
depending on their condition such as health, disease, growth rate and drug 
treatment; Liotta et al., 2003). The Human Proteome Organisation has a goal 
to catalogue every distinct human protein, all protein-protein interactions and 
levels of proteins in different cells and tissues (www.hupo.org).
1.8.4 N an o  Liquid C h ro m a to g ra p h y
The major development of microcolumns using fused silica capillaries with 20- 
250pm inner diameters transformed high pressure liquid chromatography 
(HPLC) in the 1980’s. This radical change gave HPLC greater sensitivity and 
greater separation efficiency (Takeuchi and Ishii, 1980, 1981; Kennedy et al.,
1989). The recent development of nano liquid chromatography (nano-LC) 
separation was coupled to a Nobel Prize technique, matrix-assisted laser
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absorption/ionisation (MALDI; Karas and Hillenkamp, 1988), by continuous 
spotting of the eluate from the nano-LC onto the MALDI plates (Lee et al., 
2002; Figure 1.18).
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Figure 1.18 Proteomic analysis. A flowchart of the proteomic process involved in 
identification of proteins and potential biomarkers: (1) exposed cells harvested and lysed, (2) 
proteins denatured and labelled, (3) fractionation of labelled peptides, (4) fractionated protein 
spotted on a LC-MALDI sample plate, (5) MS was performed using a MALDI TOF/TOF (6) 
MS/MS queries were performed using the MASCOT Database search engine, embedded into 
Global Proteome Server (GPS) Explorer software on the Swiss-Prot database
Although current nano-LC coupled with a tandem mass spectrometry (MS/ 
MS) has the throughput ability of 4000 peptides per run (2 hours; Ishihama,
| Nano L c"] MS TOF/TOF
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2005), it is not able to analyse a complex peptide mixture from a whole cell 
lysate. Therefore, additional steps are required to reduce the complexity of the 
peptides. Ultra-centrifuging and the use of sucrose gradients can increase the 
number of proteins identified by purifying the cellular component of interest 
(Lee et al., 2002). Size exclusion chromatography, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and isoelectrical focusing 
have all been used as protein separation. In this project, peptide separation 
post-digestion will be carried out using a strong cation exchange (SCX) 
column and reverse phase technologies (Cargile et al., 2004; Winnik and 
Ortiz, 2008).
1.9 A im s  a n d  Objec tives  o f  the  S tu d y
1.9.1 Th e  H y p o th e s is
The hypothesis for this investigation was three-fold:
1. The use of human respiratory epithelia (normal tracheal-bronchial epithelia) 
is a viable in vitro alternative to the rat lung model (in vivo)
2. Exposure of the human respiratory epithelia to tobacco smoke components 
(vapour and particle phases) causes harm
3. Genomics and proteomics can be utilised to identify biomarkers of 
exposure and harm in the human respiratory epithelia to tobacco smoke 
components
1.9.2 P r o j e c t  A im s  a n d  O b je c t iv e s
The objective of the proposed research was to identify intelligent biomarkers, 
these are genomic/proteomic biomarkers with the corresponding protein and 
gene expression data in the human respiratory epithelia following exposure to 
selected particle (e.g. cadmium and nicotine) and vapour phase (e.g. 
formaldehyde and urethane) tobacco smoke components (TSC). The key
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components were selected for their thrombogenic capacity (nicotine), 
cytotoxicity (cadmium) and production of reactive metabolites during 
xenobiotic metabolism (formaldehyde and urethane). Thus, providing a 
holistic approach towards the identification of biomarkers in the pulmonary 
epithelium (i.e. cells derived from human primary explant tissue) in vitro.
Conventional toxicological analysis will be used, at the first instance, to 
establish the dose of the various TSC required to induce alterations in 
epithelial resistance, secreted surface proteins and release of inflammatory 
markers. It was imperative that the final working doses used were sub-toxic, 
since the objective was to identify the important biomarkers involved with 
toxicant stress and to avoid studying dead or dying cells. Following the 
establishment of the dose required to achieve these different biological 
endpoints, the toxicogenomic investigations will be initiated.
Toxicogenomic experiments will be designed to identify early molecular 
markers for events in pulmonary injury (i.e. 24 hours). Microarray technology 
will be employed to compare the patterns of mRNA expression of human 
genes associated with stress, simultaneously from control and TSC treated 
lung tissue. The major candidate genes will be classified (e.g. growth factors, 
inflammation, and xenobiotic metabolism) and associated with the biological 
endpoints. Stringent lists of candidate genes associated with these changes 
will be generated, thereby providing data on the mechanisms of the biological 
endpoints, i.e. biomarkers.
Finally, mRNAs levels do not necessarily predict the levels of the 
corresponding proteins in a cell. Consequently, proteomic analysis will be 
used to correlate candidate gene responses with a specific protein. The main 
interest of the study was the proteins involved in the early stress phase of 
toxicant challenge. Once a protein function had been identified, this provided 
an insight into the mechanism of action of the responsive genes or the 
“intelligent biomarkers” of TSC exposure in lung epithelia (Figure 1.19).
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Figure 1.19 The general research project aims. Flowchart of the project aims 
involved in identification of genomic and protein biomarkers of exposure in the respiratory 
epithelia to tobacco smoke components. Tissue provided by K.Sexton
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2.1 In tr o ductio n
Scientific reviews by Coggins (2002 and 2007) of the chronic inhalation 
studies of mainstream cigarette smoke in all five species of laboratory animals 
(e.g. rats, mice, hamster, dog, non-human primates) used to evaluate 
carcinogenic potential, revealed no statistically significant increase in the 
incidence of malignant lung tumours and atherosclerosis following exposure 
to smoke. Furthermore, these findings were not consistent with the 
epidemiological results observed in human smokers. The outcome of the 
comprehensive animal studies reviewed by Coggins does support the idea 
that research should focus on the use of human tissue to try to corroborate 
the epidemiological findings. This obviously limits what can be achieved using 
acute/chronic exposure studies to cigarette smoke and/or various tobacco 
components. It is also difficult to study environmental contaminants such as 
tobacco smoke because of methodological problems in testing entire 
atmospheres. Most investigations are based on in vivo and in vitro 
experiments that use model substances and surrogate mixtures to simulate 
the real life situation. In this respect, in vitro systems, in particular, offer the 
possibility of using human target cells and comparing the results with human 
data. This eliminates any difficulties in extrapolating animal data to humans, 
and reduces the need for animals in testing such atmospheres.
The target tissue for toxic gases and particles in the ambient air is the 
epithelium lining the upper and lower airways. Therefore, different cells types 
such as alveolar type II cells, bronchial epithelial cells or macrophages have 
been used to study the biological activity of airborne substances (e.g. Steimer 
et al., 2005). However, there are perceived disadvantages of this approach in 
that cell lines typically exhibit several abnormal characteristics in addition to 
their immortality and those abnormalities can impede toxicological studies. 
For example, certain airway cell lines have lost the ability to form tight 
junctions, thereby eliminating their capacity to produce in wVo-like barrier 
properties (e.g. A549 cell line; Steimer etal., 2005). It would be much better to 
have a more complex interactive system like the normal human bronchial
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epithelium (NHBE; Forbes and Ehrhardt, 2005). The NHBE is a mixed cell 
population of cells with differing phenotypes representative of the proximal 
airways. Their primary role is to maintain defence systems e.g. muco-ciliary 
transport, P450,s, cytokines and basal stem cells. In addition, individual cell 
types may respond quite differently to a complex mixture like tobacco smoke; 
they may lack biotransformation enzymes which are necessary to produce 
toxic metabolites (Castell etal., 2005).
In searching to remove these disadvantages, a commercially available, 
primary, upper airway, culture has become available, known as the 
EpiAirway™ Tissue Model (ETM; MatTek Corp.). ETM consists of cells 
derived from human primary explant tissue from three donors, requiring no 
animal tissue/product. It has been cultured to form a pseudo-stratified, highly 
differentiated, 3-dimensional (3-D) tissue that closely resembles the epithelia 
of the human respiratory tract. This model is not developed from lung 
tumours/disease tissue, thus cells are genotypically/phenotypically more 
representative of normal epithelia than other commonly used models. It 
provides a novel, toxicological tool that offers a means of assessing various 
respiratory tract issues while avoiding species extrapolation and the use of 
laboratory animals (e.g. BeruBe etal., 2006).
In the following work, conventional toxicological analysis (e.g. trans-epithelial 
electrical resistance [TEER], cell viability [MTT] and protein assay) was used 
to establish the dose of TSC needed to cause changes in epithelial 
resistance, secreted surface proteins and release of inflammatory markers. By 
applying conventional toxicology techniques, a dose-response range could be 
established and the toxic effect of the TSC thus characterised. This dose 
range was considered important for gaining an understanding of potential 
protective mechanisms, and would be utilised in further toxicogenomics and 
proteomic investigations (Chapters 4 and 5).
A key feature to note is that it was imperative that the final doses used were 
sub-toxic, since the research objective was to identify important biomarkers 
involved with toxicant stress, rather than studying dead or dying cells.
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2.2 Ma ter ia ls  a n d  S to c k  S o lutions
2.2.1 Ce l l s  a n d  M a t e r ia l s
Materials: Supplier:
The EpiAirway™ Tissue Model MatTek, Ashland, USA
MTT 100 Kit MatTek, Ashland, USA
Growth Media MatTek, Ashland, USA
EVOM World Precision 
Instruments
ENDOHM-12 World Precision 
Instruments
Bradford Reagent (B6916) Sigma-Aldrich
Dulbecco’s Phosphate Buffered Saline (+Mg*+ + 
Ca2+; D8662)
Sigma-Aldrich
Cadmium Chloride (28811-1 ml-f) Sigma-Aldrich
RNAIater (R0901) Sigma-Aldrich
(-) Nicotine (N3876) Sigma-Aldrich
Formaldehyde (433284) Sigma-Aldrich
Urethane (U2500) Sigma-Aldrich
Proteoplex Human (71414-3) Merck Biosciences, 
Germany
Table 2.1 Materials used and their suppliers. All suppliers are UK based unless 
stated
2.2.2 S t o c k  a n d  TSC S o lu t io n s
Bovine Serum Albumin (BSA) was supplied as a 2mg/ml stock solution 
(Sigma; P0834). A dilution range (0-10pg/ml) was prepared as required and 
stored at 4°C.
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Cadmium Chloride was supplied as a 0.1 M solution (Sigma; 28811). A 
series of dilutions (0-400pM) in PBS was prepared as required and stored at 
4°C.
Nicotine was supplied as a solution (Sigma; N3876). A dilution range of (0- 
125mM) was prepared in PBS as required and stored at 4°C.
Formaldehyde was supplied as a 35% weight in water (Sigma; 433284). A 
series of dilutions (0-25mM) was prepared in PBS as required and stored at 
4°C.
Urethane was supplied as a solid (Sigma; U2500). A series of dilutions (0- 
2M) was prepared in PBS as required and stored at 4°C.
2.3  M etho ds
2.3.1 C e l ls , C u ltu r e  and  E x p o s u re
Upon receipt of the EpiAirway™ cell cultures from MatTek Corporation in the 
USA, the cells were handled according to the manufacturer’s specifications as 
follows. Briefly, cells were removed from transport packaging immediately 
after being received, the basal surfaces rinsed in pre-warmed PBS (37°C) and 
placed into 0.9ml pre-warmed culture medium (37°C) in a 6-well culture plate. 
They were equilibrated at 37°C with 4.5% C 0 2 for 24 hours. After this time, an 
initial transepithelial electrical resistance (TEER, Section 2.3.2) value was 
recorded to assess the tissue integrity. Following this culture preconditioning, 
the cells were deemed ready for exposure to TSC. Individual TSC were 
prepared by adding them to sterile phosphate buffered saline with Mg2+ and 
Ca2+ (PBS) and shaken to ensure full solubilisation and mixing. The four 
different TSC solutions were prepared fresh on the day of use. TSC solutions 
were then warmed to 37°C before use. Apical exposure of the cells (n = 4 
wells per dose) consisted of placing a 100pl volume of a solution onto the 
apical surface. Final working solution concentrations were determined during
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the conventional toxicology studies (e.g. TEER and MTT assay [Section 2.3.2 
and 2.3.3]).
2 .3 .2  Tr a n s -E p it h e l ia l  E l e c t r ic a l  R e s is t a n c e
Trans-Epithelial Electrical Resistance (TEER) was used as a primary indicator 
of tissue stress by measuring the integrity (i.e. maintenance) of the cellular 
tight junctions. MatTek provides cultures with an established TEER value 
between 400-500 Ohms cm2.
Briefly, the electrodes of the Endohm tissue resistance chamber needed to be 
equilibrated 24 hours before use, by filling the chamber with PBS and 
connecting the electrodes to the base unit with the power off. Immediately 
before use (and subsequently every 12 measurements), the calibration is 
checked and zeroed (if necessary) by altering the potentiometers. Following 
equilibration, the cultures were washed by placing 2ml of PBS into each well 
of a 6-well plate and the cultures then placed into these wells, with an 
additional 0.3ml of PBS added to the apical surface. The wash was 
subsequently aspirated and retained (Section 2.3.4). A further 0.25ml of PBS 
was then added to the apical surfaces. A blank culture insert (with 0.25ml 
PBS on the apical surface) was then placed into the Endohm tissue 
resistance chamber and a measurement taken (Figure 2.1). The cultures were 
tested in sequence, with a blank measurement being taken every 6 test 
measurements.
After TEER measurements, the PBS was aspirated from the culture surface 
and discarded; the culture was then placed in RNAIater (Chapter 4, Section 
4.3.1; unless used for a MTT assay). All cultures were then kept at -20°C until 
further use in the genomics and proteomics investigations (Chapters 4 and 5).
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Figure 2.1 Diagrammatic overview of the ENDOHM chamber. This figure 
displays the EpiAirway™ culture in the ENDOHM chamber for a TEER reading. Control 
cultures have a TEER value between 400-500 Ohms cm2, a culture with a loss of cellular 
integrity will have a TEER value >100 Ohms cm2
2.3.3 M tt
The MMT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
assay for cellular growth and survival (Mossman, 1983), was used as an 
additional indicator of tissue viability. On the day of use, the MTT reagent and 
diluent (MTT 100 Kit, MatTek Corp.), were warmed to 37°C and kept in the 
dark. Immediately before use, these solutions were mixed and 300pl of the 
resultant solution added to the necessary number of wells in a 24-well plate. 
The cultures were taken from the wash-step of the TEER protocol (Section 
2.3.3) and placed in the MTT solution. These were then protected from the 
light and incubated at 37°C, 4.5% CO2 for 3 hours. Meanwhile, 2ml of MTT 
extractant solution was aliquoted into each necessary well of a further 24-well 
plate, and after the incubation period, the cultures were inserted into the 
extractant. These were sealed and left in the dark for 24 hours, after which 
time triplicate 100pl aliquots of solution from each test culture were put into a 
96-well assay plate, to each of which was added a further 100pl of MTT
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extractant solution. These plates were then read on a plate-reader at 590nm 
and 620nm. The readings at 620nm were subtracted from those taken at 
590nm, and converted into a percentage viability using control viability as 
100%. Samples of MTT extractant alone were used as blanks.
2 .3 .4  P r o t e in  A s s a y
The aspirated material from the first wash step of the TEER protocol was kept 
in sealed 1.5ml sample tube at 1-4°C until use. At time of use, triplicate 50pl 
aliquots of each sample were added in sequence to a 96-well plate. These 
were diluted to 200pl using PBS, after which 50pl of Bradford Reagent was 
added and mixed by pipetting (Bradford, 1976). The plates were sealed and 
protected from the light for 5 minutes in order to allow the colour to fully 
develop and then read at 540nm on a plate reader (Opsys MR, Dynex). 
Results were converted to concentrations using a graph of standards 
generated by assaying known concentrations of bovine serum albumin (BSA) 
and the dilution factors were then accounted for. Samples of PBS alone were 
used as blanks.
2 .3 .5  C y t o k in e  a s s a y
The production and release of endogenous cytokines into the basal medium 
of the cultures was tested using the Proteoplex™ 16-well Human Cytokine 
Array. Each well of the Proteoplex™ Array contains an identical microarray of 
the 12 anti-cytokine capture antibodies, each spotted in quadruplicate (Figure 
2.2). The detection strategy is a standard ‘sandwich’ immunoassay that relies 
on biotinylated detection antibodies and streptavidin-conjugated fluorophore 
for detection (Figure 2.3).
The culture medium from each culture post-exposure to TSC (0.9ml) was kept 
in sealed 1.5ml sample tubes at 1-4°C until use. At time of use, 100pl aliquots 
of each dose were added in sequence to the microarray and processed as 
described in the user protocol. Firstly the human cytokine standard was
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reconstituted in 1.25ml PBS, the microarray slide was then washed two times 
with PBS-tween (PBST). The sample and cytokine standard was added to the 
appropriate well and incubated at room temperate (RT) with gentle agitation 
for 60min. The sample and cytokine standard was then removed and the slide 
was washed 4 times with PBST. Detection was carried out using 
SensiLight™; 100pl was added to each well and incubated at RT for 90min. 
The SensiLight™ was aspirated and the slide was washed 4 times with PBST. 
At this point the well support was removed from the glass slide; the slide was 
then placed in the rinse solution for 10sec. The slide was dried by placing the 
slide in a slide dryer and where it was centrifuged for 1min at 200x g. The 
microarray was then scanned at 633nm excitation (Ex) and 660nm emission 
(Em) at 10pm (GenePix 4000B, Molecular Devices). All samples were run in 
triplicate.
2.3.6 S tatistical  A nalysis
The statistical difference between data points was determined using a two- 
tailed Student’s t-test. Standard deviation was used to represent experimental 
variation. Significance was accepted at P< 0.05.
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Figure 2.2 Proteoplex™ Microarray layout. 16 identical arrays on each slide and 
map of each array, showing the arrangement of the 12 capture antibodies, alignment spots 
(AS), positive control spots (PS) and negative control spots (Blank)
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Figure 2.3 ‘Sandwich’ immunoassay format. The detection strategy is a standard 
immunoassay that relies on biotinylated detection antibodies and streptavidin-conjugated 
fluorophore for detection
2.4 R e s u lts
2.4.1 Ca d m iu m
A cadmium dose response was established by using a concentration range of 
0-400pM.
2.4.1.1 Tr an s -E pith elial  E lec tr ic a l  R e s is t a n c e
The average control TEER value (post exposure) was 210 Ohms cm2 a 
cadmium dose response produced a small increase of resistance at 80pM 
with a significant peaking at 160pM. Subsequent concentrations produced a 
decrease in resistance (Figure 2.4).
2 .4 .1 .2  M T T
The MTT assay indicated significant decreases in tissue viability with an 
increased concentration of cadmium. This trend reversed at 240pM with an 
increase of viability. Subsequent concentrations of cadmium resulted in a 
decrease of viability (Figure 2.5).
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Figure 2.4 Cadmium dose response on TEER readings. The asterisk (*) 
denotes significant (p^0.05), I denotes standard deviation and n=3
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Figure 2.5 Cadmium dose response on ceil viability. The asterisk denotes 
significant (p^0.05), I denotes standard deviation and n=3
2 .4 .1 .3  P r o te in  Secretio n
At 80|jM cadmium, a small increase of protein was detected. Protein secretion 
increased significantly by 50% at the 160pM dose, followed by a brief plateau 
before increasing to a second peak of protein secretion at 320pM cadmium 
(Figure 2.6).
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A comparison of the TEER versus protein secretion data (Figure 2.7) could be 
used to identify the zone of differentiation between secreted protein and 
cellular debris. The zone where the two graphs cross-over marked the 
transition between active protein secretion (below cross-over point) and the 
secondary rise in protein secretion This could be due to cellular debris (above 
cross-over point) but the TEER values at the second peak of protein secretion 
had reduced to the control level suggesting ETM integrity.
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Figure 2.6 Cadmium dose response with protein secretion. The asterisk 
denotes significant (p^0.05), I  denotes standard deviation and n=3
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Figure 2.7 Differentiating protein secretion (red data series) and cell 
debris using TEER data (blue data series). The protein levels increased with TSC 
concentration, but the Bradford assay measured total protein concentration, and as such, no 
distinction could be made between secreted protein and potential cellular debris. However, 
there was visual confirmation of a viscous substance on the apical surface of the cells. A 
plateau in protein levels occured shortly after the peak in TEER which may have suggested a 
change in cellular activity; from protein (possibly mucus) secretion to accumulation of limited 
cell debris. Also the TEER values at this concentration returned to the control level inferring 
ETM integrity
2.4 .1 .4  C y t o k in e  S e c r e t io n
The cytokine release response following cadmium challenge is depicted in 
Table 2.2. A standard curve was produced from the human cytokine standard 
(figure 2.8).
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CYTOKINE CADMIUM DOSE RANGE
0 uM 80 uM 160 uM 240 uM 400 uM
IL-1a 15.8 ±0.6 26.6 ±2.6 8.7 ±0.7 9.7 ±0.2 15.6 ±1.7
IL-1 b 2.6 ±0.2 3.9 ±0.3 1.2 ±0.19 0.5 ±0.1 1.7 ±0.1
IL-2 0.8 ±0.1 * * * 1.3 ±0.1
IL-4 * * * 0.6 ±0.04 *
IL-6 54.8 ±3.8 60.9 ±2.4 56.8 ±0.9 41.1 ±0.9 89.4 ±12.5
IL-7 1.8 ±0.4 3.3 ±0.7 2.5 ±0.04 5.8 ±0.4 *
IL-8 1045.8 ±41.8 1045.4 ±19.1 1020.6 ±11.3 1045.2 ±42.3 1045.3 ±43.5
IL-10 1.5 ±0.3 1.9 ±0.3 * 1.2 ±0.1 2.2 ±0.3
IL-12 * * * 1 ±0.33 *
GMCSF 28.2 ± 1.7 38.8 ±1.6 10.7 ±0.9 18.3 ±1.3 51.5 ±4.6
IFN-g 14.3 ±2.4 4.3 ±0.3 * * 11.4 ±2.1
TNF-a 1.0 ±0.1 * * * 1.2 ±0.2
Table 2.2 Cadmium-specific cytokine secretion (pg/ml). The asterisk indicates 
data point is below the limit of detection, ± indicates SD and data values for which SD is 
greater than 15% of predicted concentration (italics)
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Figure 2.8 Standard curves of the cytokines. The 12 cytokine R2 values ranged 
from 0.97-1.00
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2 .4 .1 .4 .1  lNTERLEUKIN-1 A &  1 B
An increase in cadmium produced a significant increase in Interleukin (IL) -1a 
followed by significant deceases of IL-1 a in relation to the control with 
subsequent concentrations, finishing at a control level at the highest dose. IL- 
1b although at low levels showed an initial increase with dose followed by 
significant decreases with successive concentrations ending with an increase 
at the final concentration of 400pM.
2.4.1.4.2 In t e r l e u k in -6
A cadmium dose range produced an initial increase in IL-6 with a subsequent 
decease back to control levels; increased dosing resulted in a significant 
decrease finishing with a significant increase at the highest concentration.
2 .4 .1 .4 .3  In t e r l e u k in -7
Again at low concentrations IL-7 was increased at the initial dose of cadmium, 
ensuing doses caused a decrease followed by a significant increase of IL-7 at 
240pM.
2 .4 .1 .4 .4  In t e r l e u k in -8
IL-8 levels were consistent across all cadmium concentrations.
2.4.1.4.5 Granulocyte Macrophage Colony Stimulating Factor (GMCSF)
An initial concentration 80pM cadmium caused an increase of GMCSF; further 
concentrations of cadmium produced a significant decrease followed by a 
significant increase at 240pM and a highly significant increase above the 
control level at 400pM.
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2.4.1.4.6 O t h e r  C y t o k in e s
IL-2, IL-4, IL-10, IL-12, IFN-g and TNF-a showed a variable response across 
the cadmium dose range.
2.4 .2  F o r m a ld eh y d e
A FA dose-response was established by using a concentration range of 0- 
25mM.
2.4.2.1 Tr an s -E pith e lia l  E le c tr ic a l  R e s is ta n c e
The average control TEER value (post exposure) was 210 Ohms cm2, the FA 
dose-response produced a small decrease in resistance at doses 0.5-1 mM 
with a significant peak at 5mM. Subsequent concentrations produced a 
decrease in resistance (Figure 2.9).
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Figure 2.9 Formaldehyde dose response on TEER readings. The asterisk 
denotes significant (p^0.05), I denotes standard deviation and n=3
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2 .4 .2 .2 M T T
The MTT assay indicated decreases in tissue viability with an increased 
concentration of formaldehyde. Concentrations of 5mM and above resulted in 
a significant decreases of viability (Figure 2.10).
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Figure 2.10 Formaldehyde dose response using MTT assay. The asterisk 
denotes significant (p^O.05), I  denotes standard deviation and n=3
2.4 .2 .3  P r o tein  Sec r etio n
Initial concentration of 1mM FA resulted in a decrease of protein secretion. 
Concentrations of 5mM and above (except 20mM), caused a significant 
increase of protein. The significant protein coincided with the peak in TEER 
and significant decreases in cell viability (Figure 2.11).
2.4.2 .4  C yto kin e  sec retio n
The cytokine release response following formaldehyde challenge is depicted 
in Table 2.3.
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Figure 2.11 Formaldehyde dose response with protein secretion. The
asterisk denotes significant (p^0.05), I  denotes standard deviation and n=3
CYTOKINE
0 mM
FORMALDEHYDE DOSE RESPONSE 
1 mM 5 mM 7.5 mM 10 mM 15 mM
IL-1 a 4.9 ±2.6 6.6 ±0.4 8.1 ±0.4 17.3 ±0.6 70.1 ±6.3 46.7 ±2.8
IL-1 b 0.7 ±0.04 * 1.0 ±0.2 2.4 ±0.4 4.6 ±0.3 3.1 ±0.1
IL-2 1.6 ±0.1 0.6 ±0.1 1.3 ±0.2 1.0 ±0.2 0.3 ±0.05 0.4 ±0.05
IL-4 * * * 0.4 ±0.06 0.4 ±0.05 0.8 ±0.1
IL-6 19.3 ±0.8 22.3 ±0.7 15.1 ±0.6 14.4 ±0.3 18.6 ±0.9 53.3 ±2.7
IL-7 * * * 3.1 ±0.2 * 4.9 ±0.4
IL-8 1219.2 ±12.2 1218.6 ±16.4 1219.3 ±12.1 1219.1 ±24.2 1210.8 ±12.2 1218.6 ±14.6
IL-10 1.2 ±0.2 0.8 ±0.2 0.5 ±0.1 1.4 ±0.2 * 0.7 ±0.06
IL-12 2.3 ±0.4 1.8 ±0.3 * 2.2 ±0.4 * 1.6 ±0.3
GMCSF 4.0 ±0.2 * 5.1 ±0.4 3.9 ±0.2 0.6 ±0.4 4.3 ±0.1
IFN-g 33.2 ±8.3 6.7 ±1.1 17.0 ±0.9 20.7 ±1.4 * 3.0 ±0.2
TNF-a * * * 0.6 ±0.1 * *
Table 2.3 Formaldehyde-specific cytokine secretions (pg/ml). The asterisk 
indicates data point is below the limit of detection, ± indicates SD and data values for which 
SD is greater than 15% of predicted concentration (italics)
2 .4 .2 .4 .1  In te r le u k in -1  a  & 1b
An increase in FA produced significant increases in IL-1 a peaking at 10mM 
this was followed by significant decline of IL-1 a at 15mM. IL-1 b although at 
lower levels showed the same profile with significant increases of IL-1 b at 
concentration 7.5mM and above and a reduction of IL-1 b at 15mM.
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2A.2A.2 In t e r le u k in -6
A FA concentration range produced an initial significant increase in IL-6 a 
dose of 5mM and 7.5mM caused decease below initial control levels; further 
concentrations resulted in an elevated level observed in the control and a 
significant increase peaking at 15mM.
2.4.2.4.3 Interleukin-8
IL-8 levels were consistent across all FA dose concentrations.
2A.2AA  O t h e r  c y t o k in e s
IL-2, IL-4, IL-7, IL-10, IL-12, GMCSF, IFN-g and TNF-a showed either low 
(>2pg) or variable responses across the FA concentration range.
2 .4 .3  N ic o t in e
A nicotine dose response was established by using a concentration range of 
0-125mM.
2 .4 .3 .1  Tr a n s -E p ith elia l  E lec tr ic a l  R e s is t a n c e
The average control TEER value (post exposure) was 210 Ohms cm2, the 
nicotine dose-response produced a small decrease in resistance at a 
concentration of 25mM. The resistance later increased with a peak at 50mM. 
Subsequent concentrations produced a significant decrease in resistance 
(Figure 2.12).
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Figure 2.12 Nicotine dose response on TEER readings. The asterisk denotes 
significant (p^0.05), I denotes standard deviation and n=3
2.4 .3 .2  M T T
The MTT assay indicated decreases in tissue viability with an increased 
concentration of nicotine. A concentration of 75mM created a significant 
increase in viability; subsequent concentrations resulted in significant 
decreases of viability (Figure 2.13).
2.4 .3 .3  P r o tein  Sec r etio n
Initial concentrations of nicotine resulted in a decrease of protein secretion (0- 
50mM). Concentrations of 75mM and above caused a significant increase of 
secreted protein (Figure 2.14).
2.4 .3 .4  C yto k in e  Sec r etio n
The cytokine release response following nicotine challenge is depicted in 
Table 2.4.
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Figure 2.13 Nicotine dose response using MTT assay. The asterisk denotes 
significant (p^0.05), I denotes standard deviation and n=3
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Figure 2.14 Nicotine dose response with protein secretion. The asterisk 
denotes significant (p£0.05), I  denotes standard deviation and n=3
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CYTOKINE NICOTINE d o s e  r a n g e
0 mM 25 mM 50 mM 75 mM 125 mM
IL-1a 8.4 ±0.6 9.6 ±0.6 69.7 ±1.9 23.6 ±0.7 74.8 ±2.2
IL-1 b 0.7 ±0.1 0.5 ±0.1 5.8 ±1.0 1.4 ±0.2 2.7 ±0.5
IL-2 * * * 1.0 ±0.2 0.9 ±0.1
IL-4 * * * * *
IL-6 21.0 ±2.1 11.0 ±1.0 21.6 ±1.7 13.2 ±1.2 14.6 ±0.7
IL-7 3.7 ±0.6 2.1 ±0.4 1.3 ±0.2 * 3.0 ±0.5
IL-8 1045.2 ±1.0 1045.6 ±2.1 1045.0 ±1.0 1045.3 ±2.1 1045.4 ±2.1
IL-10 1.5 ±0.1 1.3 ±0.3 * * 1.1 ±0.1
IL-12 * * * * *
GMCSF 4.2 ±0.3 5.8 ±0.4 54.0 ±5.3 12.4 ±0.6 19.7 ±1.4
IFN-g 3.5 ±0.6 * * 6.5 ±0.9 *
TNF-a 0.2 ±0.1 * * * 0.6 ±0.3
Table 2.4 Nicotine-specific cytokine secretions (pg/ml). The asterisk indicates 
data point is below the limit of detection, ± indicates SD and data values for which SD is 
greater than 15% of predicted concentration (italics)
2.4.3.4.1 In te r le u k in -1  a
An Initial 25mM concentration of nicotine had little effect on IL-1 a; subsequent 
concentrations caused a significant rise followed by a drop in IL-1 a before 
peaking at the highest concentration (125mM).
2.4.3.4.2 In te r le u k in -6
The lowest concentration of nicotine (25mM) produced an initial significant 
decrease in IL-6, subsequent concentrations of 50mM produced levels seen 
in the control; increased concentration resulted in a significant decreases.
2.4.3.4.3 In te r le u k in -8
IL-8 levels were consistent across all nicotine concentrations.
2.4.3.4.4 Granulocyte Macrophage Colony Stimulating Factor
With a similar profile to IL-1 a, an initial concentration of nicotine caused a 
small but significant increase of GMCSF further concentrations caused
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another significant rise followed by a decrease and finally rising at the highest 
concentration.
2.4.1.4.5 O t h e r  c y t o k in e s
IL-1 b, IL-2, IL-4, IL-7, IL-10, IL-12, IFN-g and TNF-a showed either low (>2pg) 
or variable responses across the nicotine concentration range.
2.4.4 Ur eth a n e
The urethane dose response was established by using a concentration range 
of 0-4M.
2.4.4.1 Tr an s -E pith elial  Ele c t r ic a l  R e s is t a n c e
The average control TEER value (post exposure) was 210 Ohms cm2, 
urethane dose response produced a significant increase in resistance with a 
significant resistance peak at 500mM. All subsequent concentrations 
produced a decrease in resistance (Figure 2.15).
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Figure 2.15 Urethane dose response on TEER readings. The asterisk 
denotes significant (p<0.05), I  denotes standard deviation and n=3
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2.4A.2 MTT
The MTT assay indicated a slight increase in tissue viability with an increased 
concentration of urethane. A concentration of 2000mM created a decrease in 
viability that was extended with a 4000mM concentration, resulting in a 
significant decrease in viability (Figure 2.16).
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Figure 2.16 Urethane dose response using MTT assay. The asterisk denotes 
significant (p^0.05), I  denotes standard deviation
2.4.4 .3  P ro te in  S e c re t io n
Initial concentrations of urethane resulted in no changes of protein secretion 
(0-100mM). A concentration of 250mM produced a significant increase in 
protein secretion prior to a reduction of protein at the 500mM concentration. 
Subsequent concentrations resulted in significant increases in protein 
detected (Figure 2.17).
2 .4 .4A  C yto kin e  Secr etio n
The cytokine release response following urethane challenge is depicted in 
Table 2.5.
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Figure 2.17 Urethane dose response with protein secretion. The asterisk 
denotes significant (p^0.05), I denotes standard deviation and n=3
CYTOKINE
0 mM 100 mM
URETHANE DOSE RANGE 
250 mM 500 mM 2000 mM 4000 mM
IL-1a 15.8 ±0.6 15.9 ±1.6 9.7 ±0.9 * 25.7 ±1.0 99.6 ±8.9
IL-1 b 1.3 ±0.1 2.4 ±0.4 0.1 ±0.04 0.4 ±0.1 1.3 ±0.2 4.4 ±0.8
IL-2 0.7 ±0.1 1.5 ±0.3 1.4 ±0.1 0.5 ±0.1 2.1±0.1 1.8 ±0.3
IL-4 * * 1.1 ±0.1 * * 1.1 ±0.2
IL-6 33.5 ±2.3 38.9 ±1.6 11.9 ±0.1 4.7 ±0.8 20.0 ±1.4 57.7 ±3.5
IL-7 * * 8.9 ±0.4 * * 9.7 ±0.8
IL-8 1471.0 ±58.8 1475.6 ±29.5 1781.1 ±53.4 1514.0 ±53.0 1473.3 ±29.5 1830.0 ±27.5
IL-10 * * 1.4 ±0.1 * * *
IL-12 * * 1.0 ±0.2 * 1.7 ±0.4 2.1 ±0.4
GMCSF 39.3 ± 3.1 42.1 ±2.1 5.1±0.2 * 6.9 ±0.6 18.2 ±0.7
IFN-g 19.2 ±3.1 24.5 ± 4.7 27.0 ±0.8 * 26.9 ±1.3 23.0 ±3.7
TNF-a * 0.8 ±0.1 0.5 ±0.1 * 1.8 ±0.4 0.9 ±0.2
Table 2.5 Urethane-specific cytokine secretions (pg/ml). The asterisk 
indicates data point is below the limit of detection, ± indicates SD and data values for which 
SD is greater than 15% of predicted concentration (italics)
2.4.4.4.1 IL-1A
An initial concentration of urethane caused no change in IL-1 a; a subsequent 
concentration of 250mM caused a significant decrease. Increased 
concentrations of urethane resulted in significant rises, peaking at the highest 
dose (4M).
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2A.4A.2 In te r le u k in -6
With a similar profile to IL-1 a, initial dosing had no effect, further 
concentrations found a significant decrease with a final increase at the highest 
dose.
2.4A 4.3 In te r le u k in -8
IL-8 levels were consistent across except for two significant peaks at 250mM 
and 4M.
2.4.4.4.4 G r a n u lo c y te  Ma c r o p h a g e  C o l o n y  S t im u l a t in g  Fa c to r
As witnessed in IL-1 a and IL-6 an initial dose of 250mM had little effect, 
subsequent concentration caused a significant decrease that reversed with a 
peak at the highest dose. This GMCSF level was still below the control level.
2.4.1.4.5 O t h e r  c y to k in e s
IL-1 b, IL-2, IL-4, IL-7, IL-10, IL-12, IFN-g and TNF-a showed either low (>2pg) 
or variable responses across the urethane concentration range.
2.5 D isc u ssio n
The objective of this study was to use conventional toxicology to measure the 
responses of a commercial in vitro, human tissue equivalent model of 
respiratory epithelia to well-characterised components of tobacco smoke. To 
be considered an appropriate model for toxicological studies, it was important 
that the system originated from normal (non-immortalised) cells. It was equally 
important to choose a human-derived tissue model, in order to avoid 
inevitable species-related differences, which would compromise experimental 
results (Coggins, 2002). The cell-cell interactions that occur in vivo (but are 
not generally present in single-cell cultures) can significantly alter the cellular
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effects of many toxins (Andreoli et al., 2003). The range of these effects can 
only be fully-investigated in a biological system capable of transcribing and 
translating genes in response to the action of toxins. The ETM consisted of 
cells derived from healthy, human, primary-explant tissue, normal human 
bronchial epithelium (NHBE), as opposed to lung tumour or diseased tissue. 
Consequently, the cells were genotypically and phenotypically more 
representative of normal epithelia than other commonly used models (e.g. 
A549; Padar et al., 2005, BEAS-2B; Penn et al., 2005, CALU-3; Grainger et 
al., 2008, 16HBE140-; Grumbach et al., 2008). The overiding advantage of 
this system was that the human tracheo-bronchial epithelium was cultured to 
form a 3-dimensional, pseudo-stratified state, that exhibited a functional 
muco-cilliary phenotype with tight junctions (Berube et al., 2006); as observed 
in vivo. When compared to standard epithelial monolayer culture, this system 
much more closely resembled human bronchioles, both morphologically and 
physiologically (Hermann etaI., 2004; BeruBe et al., 2006; Berube et a /2009).
The comparison of TEER measurements in this study highlighted similar 
trends with the four TSC, despite differences in their physicochemistry (i.e. 
vapour or particle phase components). Initial doses caused a small reduction 
in TEER; this was followed by a significant peak before falling to zero. This 
reaction pattern was indicative of a loss of cellular tight junctions, and 
consequently, degradation of the tissue model. This response could be 
described as biphasic ‘hormesis’, which is characterised as a low dose 
stimulation, followed by a high dose inhibition (Rozman and Doull, 2003; 
Calabrese, 2004; Balharry et al., 2008). This consistent biphasic appearance 
of the TEER was vital for determining the sub-toxic doses.
The MTT assay for cell viability was used as an additional indicator of cell/ 
tissue integrity. The MTT data profile was not consistent across the different 
TSC components. Vapour phase components (formaldehyde and urethane) 
had no similarities at the lower doses but both components decreased in 
viability at the higher doses. The particle phase components (cadmium and 
nicotine) had similar profiles with an initial decrease in viability followed by a
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peak before falling to zero. The peaks observed using MTT consistently 
occurred after the peaks observed with TEER measurements. A comparison 
of both sets of data led to the conclusion that the TEER readings acted as an 
early indicator for the deterioration of the tissue model. That is, the loss of 
tight junctions increased the cell activity but this was not sustained with the 
increase in dose.
When cells are under stress they often secrete proteins into the culture 
medium. Following this, more severe damage may occur and membrane 
components are released and eventually the cell may die. Thus, it is 
necessary to identify all of these endpoints in relation to the dose of a 
toxicant. In the case of this investigation, the genomic and proteomic studies 
would be superior to identify the “intelligent biomarkers” of the early stress 
response (Chapters 4 and 5).
The protein secretions collected were consistent for all four TSC with almost 
identical profiles observed; a small decrease in protein was followed by a 
sharp rise with a subsequent plateau before a final rise in protein. The 
Bradford assay was used to measure protein concentration, and as such, no 
distinction was made between secreted protein and potential cellular debris. 
However, there was visual confirmation of a viscous substance on the apical 
surface of the cells. This material had the characteristics of mucin, (i.e. clear 
and thick viscous), as reported by other investigators (Chemuturi et al., 2004; 
Greenwell et al., 2005; Balharry et al., 2008). It appeared that the pattern of 
increased TEER followed the rise in secreted proteins. The reduction in TEER 
corresponded with a secondary increase in proteins detected; this may be 
explained by the Bradford assay detecting partial cell debris and cellular 
secretion. This debris/secretion may have been easier to remove by this brief 
wash step due to the reduction of the TEER and therefore tissue integrity. The 
potential to differentiate between secreted proteins and cellular debris was 
investigated further by using immuno-histochemistry (IHC) techniques 
(Chapter 3).
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The levels of cytokines expressed by the ETM were determined as a further 
measure of cellular activity and cell-cell interactions. Although due to the 
experimental samples being run as a triplicate it is imperative that these 
results were considered as being ’trends’ rather than empirical data. There 
were a number of similarities between the four TSC, with the pro-inflammatory 
cytokines IL-1 a, IL-1 b, IL-6 and GM-CSF induced by all the TSC. The main 
difference between the particulate and vapour phase components was that 
cadmium and nicotine induced IL-7 expression, while formaldehyde and 
urethane induced IL-2 and IFN-g secretion. Interleukin-2 and IL-7 are both 
thought to be involved in T-cell homeostasis (Boyman et al., 2007). Therefore, 
the difference could be due to alternate mechanisms for achieving the same 
goal, which may be to induce NK-cell activity (Williams et al., 1998). IFN-g is 
also thought to be indirectly involved in T-cell homeostasis and has been 
demonstrated to enhance T-cell mediated immune responses (Boyman et al., 
2007). The apparent link between elevated cytokine secretion and TEER 
could be related to the increase in cell numbers within the ETM. Simply, the 
higher the cell numbers, the greater the concentration of cytokines being 
expressed (Emad and Emad, 2007). The elevated expression of cytokines 
suggested that the ETM was functioning in an in v/Vo-like manner, with the 
induction of signalling cascades and various immune responses (Kolsuz et al., 
2003). This permitted further speculation into whether xenobiotics, such as 
the TSC, play a role in inducing respiratory defence mechanisms, as well as 
biotransformation events.
Using these conventional toxicology techniques as a measure of the 
functionality of the model epithelium, it was possible to compare this new 
model with established cell culture models (Forbes and Ehrhardt, 2005). In 
general, the ETM appeared to be more toxicologically resistant to these TSC 
toxicants than individual cell cultures. For example, IC10 (median inhibition 
concentration which produces a 10% reduction in cell viability determined by 
MTT uptake) for cadmium chloride was ten times greater in the ETM than in 
monolayers of mammalian pulmonary cells (e.g. A549; Watjen et al., 2002). 
Both nicotine and urethane demonstrated IC50 (50% reduction in cell viability) 
values that were approximately 100 times higher than in mammalian
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monolayer cultures (ICCVAM, 2001). This is probably due to the interactions 
between the different cell types within the model (e.g. mucus secretion) and 
was more representative of the situation in the human lung than monolayer 
cultures. However, the protective response to formaldehyde was induced by 
only two-fold compared to a monolayer of A549 cells (Lestari etal., 2005).
It was also important to note that the concentrations of TSC used in this study 
are much higher than the concentrations in mainstream smoke. The amount 
of these compounds inhaled from a single cigarette can vary greatly 
depending on the type of cigarette and the smoking habits of an individual 
(Andreoli et al., 2003). Numerous studies have shown a wide range of 
concentrations for each TSC: nicotine; 1-3mg/cigarette (Willems et a/., 2006), 
cadmium; 0-6.67pg/cigarette (Smith etal., 1997), urethane; 20-48ng/cigarette 
(Zimmerli etal., 1991), formaldehyde; 3.4-283pg/cigarette (Smith etal., 2000). 
In each case the maximum concentration was used to calculate the daily 
intake of a 20-a-day smoker (mg/m2 lung tissue) and compared to the 
experimental dose (mg/m2 ETM) required to generate an IC10 (determined by 
MTT). Both the particulate phase compounds (nicotine and cadmium) were 
overdosed by approximately 20,000 times (roughly equivalent to a lifetime 
dose, assuming 50 years of smoking 20-a-day). However, the vapour phase 
compounds were strikingly different from both the particulate phase 
compounds, and each other. Formaldehyde was dosed approximately 400 
times more than the daily intake of a smoker (roughly 40 times less than a 
lifetime dose). By contrast, urethane required dosing at over a million times 
the daily dose of a smoker. Despite the ETM having known metabolic capacity 
(Hayden et al., 2006), this extreme over-dosing could be due to the absence 
or lack of activation of the specific P450 (CYP2E1) required to metabolise 
urethane to its active form, vinyl carbamate.
Despite the physical differences between the particulate and vapour phase 
TSC, this model has shown no real distinction between the two phases. The 
only area in which there was an obvious difference in the concentrations 
required to elicit the desired toxic response. This may be partially due to the 
protective response (increased mucus secretion resulting from hyperplasia
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and hypertrophy and cytokine mediated immune responses) observed in the 
model, the bioavailability of the TSC or possibly the lack of activation of 
specific metabolism mechanisms. Subtle differences between the particle and 
vapour phase components may have been masked by the requirement to 
solubilise the TSC and application to the apical cell surface in liquid form.
Despite the drawback of limited P450 activity, the model hallmark was the 
ease of its use. The model arrived fully-differentiated and screened for 
metabolic activity and tissue integrity prior to dispatch. The ETM was low 
maintenance, only requiring feeding every other day with EpiAirway™ 
maintenance medium (included), to provide viable tissue for up to 27 days 
(Hayden et a/., 2006). The multi-well (24-well/96-well) format was ideal for 
multiple dosing experiments and screening; with easy access to both the 
apical and basal surfaces of the cells. This model had the added advantage of 
derivation from normal human tissue, thus circumventing the need for 
extrapolation of data from in vivo studies in different species. As such, the 
ETM could provide a novel, toxicological tool to assess various respiratory 
tract issues while avoiding species extrapolation and the use of laboratory 
animals.
2.6 C o n c l u s io n
TSC induce a toxic response within the EpiAirway™ model causing loss of 
cell viability, tight junction degradation and stimulation of secretory processes. 
At the sub-toxic doses, a reaction to the compounds was induced which may 
result in protection against toxicity. This response has not been reported in 
single-cell cultures, which suggested that the ETM model may generate a 
closer representation of the human in vivo environment resulting from cross­
talk between cells. The nature of the ETM (multi-well plate format) also meant 
that it was easily accessible for the application of experimental techniques. 
From this investigation, it appeared that the ETM was a viable in vitro 
alternative for modelling human responses to inhaled toxicants.
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Chapter  3:
M o r p h o l o g ic a l  C h a n g e s  in th e  
EpiA ir w a y ™ m o d e l
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3.1  In t r o d u c t io n
Morphological analysis was required to complement the conventional 
toxicology studies (Chapter 2), and to increase the understanding on the 
mechanisms of TSC’s toxicity. The histological assessment involved 
examination of the changes in the general cell tissue morphology, i.e. 
maintenance of pseudo-stratification, presence of a mucociliary phenotype 
and vacuolization, in both control and treated tissues. The primary objectives 
of the following experimental work presented in this chapter were to examine 
physiological responses that could not be measured using conventional 
toxicology, e.g. mucin secretion and cell differentiation. Furthermore, by 
investigating the morphological and physiological changes involved in 
differentiation, the cellular kinetics during toxicant challenge could also be 
deciphered, to provide better resolution of the mechanisms of toxicity.
3 .2  M a t e r ia l s  a n d  S t o c k  S o l u t io n s
3.2.1 M a te r ia l  an d  S u p p lie rs
Materials: Supplier:
Araldite CY212 (R1040) Agar Scientific
Glutaraldehyde (25 %) (R1010) Agar Scientific
Osmium Tetroxide (R1015) Agar Scientific
Propylene Oxide (R1080) Agar Scientific
Leica Q550IW Image Analysis System Leica Ltd.
Leica DM2500 Light Microscope Leica Ltd.
Leica RM2135 Microtome Leica Ltd.
Leica EG1140 Embedding Centre Leica Ltd.
Vacuum Tissue Processor Leica Ltd.
Leica DFC320 Camera Leica Ltd.
Aqueous Eosin (1%) (LAMB/100-D) R A Lamb
Mayers Hematoxylin (S1275) Sigma-Aldrich
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Materials: Supplier:
PBS pH 7.4 with 0.05% Tween (P3813) Sigma-Aldrich
BSA in PBS pH 7.4 with 0.05% Tween (P3688) Sigma-Aldrich
Toluidine Blue Stain (198161) Sigma-Aldrich
Tracheobronchial Mucin (sc-52329) SantaCruz 
Biotechnology, USA
Mouse ABC Staining System (sc-2017) SantaCruz 
Biotechnology, USA
p63 4A4 (559951) BD Pharmingen
Mouse Anti-Human Cytokeratin 5/6 (M7237) Dako
Biotinylated Goat Anti-Mouse (E0433) Dako
Streptavidin AB/HRP (K0377) Dako
DAB (K3466) Dako
Normal Goat Serum (X0907) Dako
Table 3.1 Materials used and their suppliers. All suppliers are UK based unless 
stated)
3.2.2 S to c k  S o lu tio n s
Neutral Buffered Formalin (NBF; 10%) was prepared by the Cardiff School 
of Biosciences Histology Unit.
Glutaraldehyde Fixative was prepared as a 1x working solution containing 
3% Glutaraldehyde, 0.1M Cacodylate and 3mM Calcium Chloride. Fixative 
was made as required and stored at 4°C.
3 .3  M e t h o d s
3.3.1 Fixing th e  ETM
The exposed ETM (Chapter 2) were immersed in 10% NBF and placed at 4°C 
for 24 hours. The ETM was then excised from the Millicell insert (Chapter 2,
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Section 2.3.2) in preparation for paraffin embedding and sectioning. Tissue 
processing, i.e. paraffin embedding, sectioning and staining, was carried out 
by a histotechnologist, Mr Derek Scarborough, at the School of Biosciences, 
Cardiff University. A brief overview of these procedures has been outlined 
below in Sections 3.3.2 to 3.3.5.
3 .3 .2  Tis s u e  P r o c e s s in g
Once the tissue has been fixed (Section 3.3.1), it must be processed into a 
form in which it can be made into thin microscope sections. This was 
achieved by embedding tissues in paraffin that was similar in density to tissue 
and could be sectioned between 3 to 10 microns. The main steps in this 
process, when dealing with wet-fixed tissue, included ‘dehydration’, ‘clearing’ 
and ‘paraffin infiltration’.
Wet-fixed tissues, such as ETM samples from this study, can not be directly 
infiltrated with paraffin. The water from the tissues must be removed by 
‘dehydration’ via a series of alcohols (e.g. 70% to 95% to 100%). Following 
dehydration, the next step was ‘clearing’ and consisted of replacement of the 
dehydrant, i.e. alcohol, with a substance that would be miscible with the 
paraffin. The common clearing agent was xylene and the tissues were 
processed through several changes of xylene. The final step in processing 
was to infiltrate the tissue with molten paraffin wax at 60°C. Tissues were 
placed in plastic processing cassettes prior to loading on the automatic 
processing machine. All the above processes were automated using a fully- 
enclosed Vacuum Tissue Processor (Leica, UK).
3 .3 .3  P a r a f f in  E m b e d d in g
It was important for the tissue to be fully-supported by paraffin wax to prevent 
the tissue shredding during sectioning. This was achieved by placing the 
‘cleared’ tissue into a vacuum to remove all air pockets. The ETM was then 
placed into a plastic ‘embedding mould’, and a Leica EG1140 Embedding 
Centre was used to embed the tissue in warm paraffin wax. After allowing the
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wax to set (30 minutes on a cold plate), the tissue was removed from the 
embedding mould and the sample was ready for sectioning.
3 .3 .4  S e c t io n in g
Following tissue processing and paraffin embedding, the ETM had to be cut 
into sections that could be placed on a glass slide for the purpose of light 
microscopy (LM). Sectioning was achieved using a Leica RM2135 Microtome 
(i.e. a knife with a mechanism for advancing a paraffin block standard 
distances across it). The embedded lung tissue samples were placed on ice 
to ensure uniform sections were obtained. The ice hardened the wax and 
softened the tissue so the entire sample was of the same consistency for 
sectioning. The tissue was then cut into 5|nm sections via the microtome.
Once the sections were cut, they were floated on a warm water bath (40- 
50°C) that facilitated the removal of any wrinkles and air bubbles produced 
during sectioning. The paraffin embedded sections of lung tissue were then 
collected on to a pre-coated glass microscope slide. The slides used were 
coated in poly-L-lysine to improve adhesion of sections. The samples were 
then left to bind to the slides on a hot plate for 15-30 minutes, then in an oven 
at 37-45°C for a minimum of 24 hours.
3 .3 .5  Ha e m a t o x y l in  a n d  E o s in  S ta in
The embedding process must be reversed in order to remove the paraffin wax 
from the tissue and allow water soluble dyes to penetrate the sections. 
Therefore, before any staining could be done, the slides were ‘deparaffinized’ 
by running them through xylene followed by series of graded alcohol (100% to 
70%). The dewaxed tissue sections were stained with Mayer’s haematoxylin 
for 1.5 minutes. Sections were washed in running tap water for 5 minutes, and 
then stained with 1% aqueous eosin for 10 minutes, and a final 20 second 
wash in running tap water (Bancroft and Gamble, 2001).
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The stained slides were taken through the reverse process that they went 
through from paraffin section to water, i.e. series of graded alcohol to xylene, 
at which point the mountant DPX was placed over the section and the 
coverslip on top of the mountant. The stained sections were then ready to 
view by LM (Bancroft and Gamble, 2001).
3 .3 .6  Im m u n o -H is t o c h e m is t r y  o f  L u n g  Tis s u e
In order to determine the presence of mucin and kinetic patterns of 
differentiation, immuno-histochemistry (IHC) techniques were conducted (e.g. 
p63, cytokeratin 5/6 and tracheobronchial mucin). The removal of paraffin wax 
from the lung tissue, to allow attachment of a primary antibody and water 
soluble dyes to penetrate the tissue sections, was carried out as described in 
Section 3.3.5.
3.3.6.1 Tr a c h e o -B r o n c h ia l  M u c in
The tracheobronchial mucin (TBM) was detected using an immunoperoxidase 
staining procedure (mouse ABC staining system containing normal blocking 
serum, biotinylated secondary antibody, avidin and biotinylated horseradish 
peroxidase), briefly described below. All steps were performed at room 
temperature. Endogenous peroxidase activity was blocked using 6% H20 2 for 
10 minutes; slides were then washed in buffer for 5 minutes. To stop non­
specific binding of the secondary antibody the cells/tissues were incubated 
with 1.5% blocking in serum PBS for 60 minutes. Excess serum was removed 
and replaced with the tracheobronchial mucin antibody (mucin 4, cell surface 
associated; 2pg/ml) and the tissues were incubated for 60 minutes. The 
specimens were then washed in buffer wash for 10 minutes and the wash was 
repeated two more times. The slides were then incubated with biotinylated 
secondary antibody (1:100) for 30 minutes, and washed in buffer wash for 10 
minutes the wash was repeated two more times. Tissues were then incubated 
with avidin and biotinylated horseradish peroxidase enzyme for 30 minutes, 
followed by a wash in buffer wash for 10 minutes and washed two more times. 
Peroxidase/diaminobenzidine reaction (DAB) was then used to identify where
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the antibody had bound to the tissue; upon oxidation DAB forms a brown 
product at the site of the target antigen. The samples were finally washed with 
distilled water and counterstained with haematoxylin and mounted in DPX 
(Section 3.5.5).
3.3.6.2P63
The protein 63 (p63) was detected using an immunoperoxidase staining 
procedure, briefly described below. All steps were carried out at room 
temperature. Endogenous peroxidase activity was blocked using 6% H2O2 for 
10 minutes; slides were then washed in buffer for 5 minutes. To stop non­
specific binding of the secondary antibody the tissues were incubated with 
20% normal goat serum for 20 minutes. Excess serum was removed and 
replaced with the p63 antibody (1:100) and the slides were incubated 
overnight at 4°C. Specimens were then washed in buffer wash for 10 minutes; 
the wash was repeated two more times. The tissues were then incubated with 
biotinylated goat anti-mouse secondary antibody (1:100) for 20 minutes, and 
then washed in buffer wash for 10 minutes; this was repeated two more times. 
Samples were then incubated with an antibody/streptavidin horseradish 
peroxidase (AB/HRP) complex for 20 minutes followed by 3 buffer washes for 
10 minutes each. DAB was then used to identify where the antibody had 
bound to the tissue; upon oxidation DAB forms a brown product at the site of 
the target antigen. Tissues were then washed with distilled water and 
counterstained with haematoxylin and mounted in DPX (Section 3.5.5).
3.3.6.3 C yto k era  tin  5/6
The detection of the cytokeratin 5/6 (CK 5/6) was detected using an 
immunoperoxidase staining procedure, briefly described below. All steps were 
carried out at room temperature. Tissues were submerged in 1mM EDTA pH 
9.0 and heated until the buffer boiled. Endogenous peroxidase activity was 
blocked using 0.5% H2O2 in methanol for 10 minutes; tissues were then 
washed in buffer for 5 minutes. To stop non-specific binding of the secondary 
antibody, the tissues were incubated with 20% normal goat serum for 20
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minutes. Excess serum was removed and replaced with the CK 5/6 antibody 
(1:25) and the tissues were incubated for 60 minutes. Specimens were then 
washed in buffer (3 times) for 10 minutes. The tissues were incubated with 
biotinylated goat anti-mouse secondary antibody (1:100) for 20 minutes with 3 
buffer washes for 10 minutes. Tissues were then incubated with Streptavidin 
AB/HRP complex for 20 minutes followed by washing in buffer (3 x 10 
minute). Liquid DAB was then used to identify where the antibody had bound 
to the tissue. Specimens were then washed with distilled water and 
counterstained with haematoxylin and mounted in DPX (Section 3.5.5).
3.3.7 Image A nalysis  and  Sta tistic a l  A nalysis
ETM sections were viewed using a DM2500 light microscope (Leica). Image 
analysis (IA) software was used to capture digitised LM images from a 
DFC320 digital camera (Leica) of control and treated ETM sections. LM 
images (x40 and x100 magnification) were saved as TIFF files and imported 
into the Leica Q550IW IA System, for image processing. IA was also used for 
the quantification of the total number of the nuclei per unit length (200pm), 
using the Qwin analysis software to calculate nuclei and cell numbers. Ten 
TIFF images were captured of random areas of ETM sections for each dose. 
The resulting data (n=3) was imported into Excel (Microsoft Office 2003). A 
two-tailed Student’s t-test was then applied to determine any statistical 
differences.
3.3.8 P rocessing  ETM for  S em i-thin  S ectio ning
3.3.8.1 F ix a t io n  o f  ETM
The ETM were excised from the Millicell plastic insert, as detailed in Section 
3.3.1. The ETM was submerged in cold (4°C) glutaraldehyde (3%) fixative for 
15 minutes. The ETM was then removed and immersed in more fresh fixative 
for 1 hour at 4°C. The gluteraldehyde fixative was replaced with phosphate 
buffer and washed overnight (~12 hours), at 4°C.
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3 .3 .8 .2  Tis s u e  P r o c e s s in g
Tissue processing and staining for semi-thin sectioning was carried out by an 
electron microscopist, Mr Chris von Ruhland, at the Medical Microscopy 
Sciences, School of Medicine, Cardiff University. A brief overview of these 
procedures has been outlined in Sections 3.3.10.2 and 3.3.10.3. Once the 
lung tissue was fixed (Section 3.3.10.1), it had to be processed into a form in 
which it could be made suitable for semi-thin sectioning. This was achieved by 
embedding the fixed lung tissue in a resin (Araldite), that acted as a support 
matrix for the lung tissue, permitting ultra-thin (e.g. 60 to 90 nm) sections to 
be cut. Prior to tissue processing, a piece of fixed ETM (PTFE membrane and 
lung tissue) was cut into 4mm2 pieces. The tissue was placed into a glass, 
sample vial that was used to carry the tissue through the various stages of 
‘dehydration’, ‘post-fixation’ and ‘resin infiltration’. The sample vials were kept 
on a rotating wheel inside a fume cupboard.
Post-fixation was carried out by osmicating (1% osmium tetroxide in 
phosphate buffer) for 60 minutes at 4°C. The tissue was then passed through 
a series of graded alcohols (30%-90%: 15 minutes in each, then 2 x 100%: 30 
minutes each). Once dehydrated, the lung tissue samples were placed into 
new sample vials and immersed in propylene oxide for 30 minutes (Glauert 
and Lewis, 1998). This was followed by overnight (~12 hours) rotation in a 
fume cupboard in a 50/50 mix of propylene oxide and Araldite CY212. During 
this time the propylene oxide dissipated leaving only the Araldite. The 
following day the tissue was infiltrated with Araldite for 8 hours.
The ETM samples were embedded in fresh Araldite. This process involved 
placing one section of tissue into a plastic/disposable, embedding capsule 
and topping up the capsule with fresh Araldite. The capsule was then placed 
into a resin oven and polymerised at 60°C for 48 hours.
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3 .3 .8 .3  Se c t io n in g  a n d  To l u id in e  Bl u e  sta in in g
Following resin polymerisation, the capsule was cut away from the 
resin/tissue block using a disposable razor blade. Excess resin was trimmed 
from the blocks until the tissue was exposed. Semi-thin survey sections (2 
pm) were taken using a diamond knife and mounted onto glass slides, and the 
tissue stained with toluidine blue (TB). TB staining was performed by drying 
the sections on to the slide by placing them on a slide warmer. Once the 
slides had dried, several drops of staining solution was placed the sections for 
1-2 minutes depending on depth of colour required (slides remained on the 
slide heater throughout this process). The excess stain was removed by 
gently rinsing the slide with distilled water, the slides were then air dried and 
mounted in DPX.
3.3.9 H istopathology
A series of LM micrographs were produced of the TSC and control exposed 
ETM (n=3 per slide). The images were then pathologically evaluated by chief 
pathologist, Dr Martin Foster (Astra Zeneca, Charnwood, Leicestershire. UK).
3 .4  R e s u lt s
3.4.1 G e n e ra l M o rp h o lo g y
For a complete overview of the morphological changes (toluidine blue and 
Haematoxylin and eosin staining) and physiological changes (cell specific 
markers) in the ETM model following exposure to TSC, see Table 3.2.
3.4.2 H is to p a h th o lo g y  o f  TSC E xposed  ETM
Haematoxylin and eosin (H+E) staining was carried out on ETM sections from 
the five exposures which included PBS, as a visual confirmation to the 
conventional toxicology (described in Chapter 2); Figure 3.1 and 3.2.
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Cell Marker / Stain Control Cadmium (uM) Formaldehyde (mM)
80 160 240 320 1 5 7.5 10
H+E (Nuclei) 44 ±3 39 ±2 68 ±7 42 ±4 38 ±3 48 ±2 65 ±4 32 ±1 26 ±3
H+E (Depth 6%) 100 133 100 183 83 133 183 150 83
p63 (+ive) 4 ±1 0 0 0 0 0 5 ±1 8 ±2 0
CK 5 /6 + - — — - ++ +++ ++ +
TBM +
Toluidine blue FN BCH BCH B C H / FN RH BCH B CB
Cell Marker / Stain Control Nicotine (mM) Urethane (mM)
25 50 75 100 100 250 500 2000
H+E (Nuclei) 44 ±3 48 ±2 37 ±1 21 ±2 17 ±3 45 ±3 52 ±5 42 ±5 19 ±3
H+E (Depth 6%) 100 183 167 200 150 150 167 133 80
p63 (+ive) 4 ±1 8 ±3 10 ±2 22 ±3 10 ±2 29 ±2 0 2 ±1 3 ±1
CK 5 /6 + +++ ++ + + ++ ++ ++ ++
TBM + - +++ ++ ++
Toluidine blue C C LV PR RH B B B
Table 3.2 Overview of the histological analysis. The overview of cell specific markers and histological stains to access morphological and 
physiological changes to the ETM. Key: Nuclei -  the mean number of nuclei counted per unit length (Section 3.3.9), depth 5% - the percentage change 
in the depth of the tissue compared to the control, p63 -  mean number of p63 positives per unit length, CK 5 / 6 and TBM -  (--) lowest expression to 
(+++) highest expression of cell marker / stain, toluidine blue -  (FN) focal necrosis, (BCH) basal cell hyperplasia, (RH) regional hypertrophy, (B) 
Blastoid changes, (CB) cytoplasmic blebbing, (C) cytolysis, (LV) lipid vacuolation, (PR) end stage plaque reaction, (±) Standard deviation
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3.4 .2 .1  Ca d m iu m
Initial ETM concentrations of 80|jM and 160|jM cadmium revealed ‘normal’ 
pseudo-stratification of three cell layers. In the subsequent concentration of 
240pM, the tissue reached its maximum thickness. Mean nuclei (MN) per unit 
length (MN = 68) suggested the cells appeared to increase in volume, as well 
as to multiply in number. Further increases in concentration of cadmium led to 
a thinning of the tissue and a significant reduction of nuclei (p>0.0001; NM 
320pM = 38; Figure 3.1; Table 3.2).
3 .4 .2 .2  F o r m a ld e h y d e
A 1mM exposure of formaldehyde demonstrated ‘normal’ pseudo-stratification 
of three cell layers. A concentration of 5mM caused the tissue to reach its 
maximum thickness (MN = 65). Additional increases in formaldehyde 
concentrations resulted in a breakdown of cellular structure, thinning of the 
tissue and eventual sloughing of the cells off the insert membrane, leading to 
a significant reduction of nuclei (p>0.0001) (MN 10mM = 26; Figure 3.1; Table 
3.2).
3 .4 .2 .3  N ic o t in e
A nicotine concentration of 25mM induced an increase in the thickness of the 
model and a concomitant increase in cell number (MN = 48), causing a 
doubling in size compared to the control (40pm). Further concentrations of 
nicotine resulted in a dramatic deterioration of the cellular structure and loss 
of cell contents, with eventual cell sloughing from the membranes leading to a 
significant reduction of nuclei (p>0.0001) (MN 50mM = 37; MN 75mM = 21; 
MN 100mM = 17; Figure 3.2; Table 3.2).
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3 .4 .2 .4  Ur e t h a n e
The 100mM concentration of urethane induced an increase in the thickness of 
the model, denoted by an increase in cell number (MN = 45). The tissue 
thickness increased by 150% when compared to the control cultures. 
Additional doses of urethane caused destruction of the cellular structure, with 
a final dose of 2000mM causing a significant thinning of the tissue to two 
layers (p>0.05; 13pm), featuring cells with reduced size, when compared to 
the initial dose (100mM; Figure 3.2; Table 3.2).
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Figure 3.1 H+E stained 
section of ETM treated with 
increasing concentrations of 
cadmium and formaldehyde.
Cadmium and formaldehyde exposure 
of the ETM induced hyperplasia and 
an increase in tissue depth; Table 3.2; 
scale bar 10um
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Figure 3.2 H+E stained 
section of ETM treated with 
increasing concentrations of 
nicotine and urethane.
Nicotine and urethane exposure of 
the ETM induced hyperplasia and an 
increase in tissue depth; Table 3.2; 
scale bar 10pm
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3.4 .3  To lu id in e  B lu e  S tain ing
Semi-thin survey sections of resin-embedded ETM samples were stained with 
toluidine blue to enable visualisation of tissue architecture following the 
control and TSC doses; Figures 3.3 - 3.7.
Figure 3.3 Semi-thin (2pm) section of ETM stained with toluidine blue.
ETM exposed to PBS maintained the pseudo-stratified, highly differentiated multi-layered 
model supported on a collagen membrane (M). Toluidine blue staining confirmed the 
presence of basal cells (BC), intermediate cells (1C), ciliated cells (CC), Goblet cells (GC), the 
presence of cilia on the apical surface (Cl) and the expulsion of mucin (MU)
3.4.3.1 Ca d m iu m
Cadmium treatment with 80pM yielded focal regions of damage denoted by 
chromatin condensation and cytosolic retractions. A concentration of 160pM 
induced basal cell hyperplasia (BCH) and further de-composition of the 
cellular integrity. At 240pM of cadmium, BCH was markedly increased. The 
tissue exhibited a non-viable architecture (disrupted cellular junctions) at 
320pM (Figure 3.4).
Suprabasal
Region
Apical
Layer
Basal
Layer
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3 .4 .3 .2  F o r m a l d e h y d e
A 1mM concentration of formaldehyde created regional hypertrophy (RH; 
Figure 3.5). A concentration of 5mM initiated early degradation of the tissue 
along side reactive cell synthesis (Figure 3.5). Further increased challenges 
caused changes in early cellular development, cell swelling and disruption of 
the plasma membrane. At the 10mM dose, there was evidence of 
vacuolations leading to cytoplasmic blebbing, thinning of the tissue and 
eventual sloughing-off of the cells (Figure 3.5).
3 .4 .3 .3  N ic o t in e
A 25mM concentration of nicotine induced cytolysis of the cell components. 
Tissue degeneration was denoted by disruption of the intracellular junctions, 
presence of vacuoles and disordered tissue architecture. This form of 
decomposition continued with further incremental of nicotine treatments 
effecting diffuse lipid vacuolation and thickening of membranes (Figure 3.6).
3 .4 .3 .4  U r e t h a n e
Diffuse cellular swelling and regional tissue degeneration occurred with a 
100mM urethane concentration. Increased concentrations generated region- 
specific (basal region only) alterations in cells. Quantitative observations of 
the tissue histopathology suggested that the nucleus-to-cytoplasmic ratios 
were enlarged (versus lower doses; Figure 3.7).
3 .4 .4  D e t e c t io n  o f  p63
Protein 63 staining was carried out on ETM sections from the four TSC 
exposures and PBS. This was conducted for a visual assessment of the 
expression of p63 in the basal cells of the ETM; Figure 3.8 and 3.9.
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C adm iu m
Figure 3.4 Semi-thin (2|jm) section of ETM stained with toluidine blue 
treated with increasing concentrations of cadmium. Black circle (80|jM) - focal 
regions of damage observed (chromatin condensation and cytosolic retractions), purple circle 
(160pM) -  basal cell hyperplasia, black circle (240pM) -  area of necrosis, red circle -  areas of 
hyperplasia, complete loss viable architecture at 320pM; scale bar 10pm
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Fo r m a ld e h yd e
Figure 3.5 Semi-thin (2pm) section of ETM stained with toluidine blue 
treated with increasing concentrations of formaldehyde. Red circle (im M) - 
area of regional hypertrophy, red circle (5mM) - area of reactive cell synthesis, black circle 
(5mM) - area tissue degradation, red circle (7.5mM) -  changes in early cellular development, 
cell swelling and disruption of the plasma membrane leading to early necrosis, blue circles -  
progression of cytoplasmic blebbing with increased dose, red circle (10mM) -  vacuolation; 
scale bar 10pm
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N ic o tin e
Figure 3.6 Semi-thin (2pm) section of ETM stained with toluidine blue 
treated with increasing concentrations of nicotine. Red circle (25mM) -  
(evidence of burst cells due to an osmotic imbalance) cytolysis further increases in nicotine 
induced disruption of the intracellular junctions and diffuse lipid vacuolation leading to 
thickening of membranes; scale bar 10pm
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U rethane
Figure 3.7 Semi-thin (2pm) section of ETM stained with toluidine blue 
treated with increasing concentrations of urethane. Black circle -  indicates 
diffuse cellular swelling with regional hypertrophy. Additional concentrations (250mM and 
500mM) resulted changes in basal cellular development, characterised by expansion of the 
cytoplasm and enlargement of the cell nucleus; scale bar 10pm
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3.4 .4 .1  Ca d m iu m
All ETM exposures (80pM, 160pM, 240pM and 320pM) of cadmium revealed 
no expression of p63, when compared to the PBS control, which showed 
limited expression, in the basal cells (Figure 3.8).
3.4 .4 .2  F o r m a ld e h y d e
The initial 1mM concentration of formaldehyde initiated a reduction in p63 
expression. Subsequent concentrations of 5mM and 7.5mM produced a basal 
increase in p63 expression. A final dose of 10mM formaldehyde caused a 
thinning of the model and no observed p63 expression (Figure 3.8).
3 .4 .2 .3  N ic o t in e
A 25mM nicotine exposure elicted an elevated presence of p63 compared to 
the levels observed in the control cell cultures. However, due to a change in 
the organisation of the ‘normal’ pseudo-stratification, the expression was 
detected in the suprabasal region. Additional doses of 50mM and 75mM both 
produced increases in p63 expression in similar higher, suprabasal regions of 
the ETM. The 100mM dose caused a thinning of the ETM and a reduction of 
p63 expression, but the expression was higher than that in the controls and 
the initial dose (Figure 3.9).
3 .4 .2 .4  U r e t h a n e
The ETM exposure of 100mM urethane produced a dramatic increase in p63 
expression at the basal and intermediate levels of cell organisation. Doses of 
250mM and 500mM urethane resulted in a marked reduction to below the 
control culture levels of p63. A 2000mM dose caused a thinning of the ETM to 
a maximum of two cells layers thick but limited expression of p63 was 
observed (Figure 3.9).
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Figure 3.8 p63 stained section 
of ETM treated with increasing 
concentrations of cadmium 
and formaldehyde. p63 stained 
brown, red circle - p63 positive in the 
control ETM. Cadmium exposure of the 
ETM did not inhibit p63 expression and 
formaldehyde (purple circle) exposure 
of the ETM induced p63 at the higher 
concentrations; Table 3.2, scale bar 
10pm
Cadmium
80jjM
Formaldehyde
1mM
2000mM
50mM
75mM
100mM
250mM
500mM
Figure 3.9 p63 stained section 
of ETM treated with 
increasing concentrations of 
nicotine and urethane. p63
stained brown, red circle - p63 positive 
in the control ETM. Nicotine (blue 
circle) and urethane (purple circle) 
exposure of the ETM initially induced 
p63; Table 3.2, scale bar 10pm
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3 .4 .5  C yto K e r a t in  5 /6  D e t e c t io n
Cytokeratin 5/6 (CK 5/6) staining was carried out on ETM sections from the 
four TSC exposures and PBS. This was performed for a visual assessment of 
the expression of CK5/6 at the basal and suprabasal cells of the ETM; Figures 
3.10 and 3.11.
3.4.5.1 Ca d m iu m
Cadmium concentrations of 80, 160 and 240pM revealed limited expression of 
CK 5/6 when compared to the levels expressed in the PBS control. The 
subsequent exposure of 320pM demonstated a marked increase in the CK 
5/6 detection, which remained below control expression levels (Figure 3.10).
3 .4 .5 .2  F o r m a l d e h y d e
A 1mM dose of formaldehyde produced an increased expression of CK 5/6. 
The 5mM concentration resulted in the highest expression levels of CK 5/6 
staining which was distributed throughout the tissue, except for the apical 
surface. A subsequent concentration of 7.5mM formaldehyde caused a 
reduction in the CK 5/6 expressions when compared to the 5mM dose but this 
was detected throughout the entire tissue area, i.e. diffuse staining. A final 
concentration of 10mM formaldehyde caused a thinning of the tissue but CK 
5/6 was diffusely expressed throughout the remaining cell layers (Figure 
3.10).
3 .4 .5 .3  N ic o t in e
An ETM challenge of 25mM nicotine yielded a marked increase in CK 5/6 
expression. It was differentially expressed, i.e. throughout the tissue except 
the apical region. Further concentrations of nicotine produced incremental 
decreases in CK 5/6 positive cells. It was also noted that with increased dose, 
the location of the expression became more basal (Figure 3.11).
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3 .4 .5 .4  Ur e t h a n e
A concentration of 100mM urethane produced an increase CK 5/6 
expressions throughout the basal and intermediate levels of the tissue. The 
concentrations of 250mM and 500mM urethane generated a reduction in 
detection levels but still remained higher than that found in the control 
cultures. The final concentration of 2000mM urethane thinned the tissue down 
to two cell layers and the CK 5/6 staining was diffuse i.e. encompassed all 
tissue (Figure 3.11).
3.4.6 Tr a c h e o b r o n c h ia l  M u c in  Vis u a l is a t io n  o f  Tis s u e
Tracheo-bonchial mucin (TBM) staining was carried out on ETM sections from 
the four exposure and PBS; Figure 3.12.
3.4 .6 .1  N ic o t in e
A 25mM concentration of nicotine did not elicit significant levels of TBM 
expression. The successive increases in concentration produced tissue wide 
increases in non-specific staining (Figure 3.12).
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Figure 3.10 Cytokeratin 5/6 stained 
section of ETM treated with 
increasing concentrations of 
cadmium and formaldehyde. CK5/6 
expression is denoted by brown stain, 
cadmium inhibited CK5/6 expression except 
for the highest dose, formaldehyde induced 
CK5/6 expression; Table 3.2; scale bar 10pm
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Figure 3.11 Cytokeratin 5/6 
stained section of ETM treated 
with increasing concentrations of 
nicotine and urethane. CK5/6 
expression is denoted by brown stain, 
nicotine induced CK5/6 expression at the 
lowest dose, urethane induced CK5/6 this 
expression reduced with dose urethane 
induced CK5/6 throughout all doses; table 
3.2, scale bar 10pm
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Figure 3.12 Tracheobronchial 
mucin stained section of ETM 
treated with increasing 
concentrations of nicotine. Red
circle -  area of TBM being released from 
a Goblet cell, ETM exposure to nicotine 
induced TBM but this could not be 
quantified due to a lack of specificity 
(yellow circles), scale bar 10pm
3 .5  D is c u s s io n
Histological (LM level) examination was utilised to investigate the 
morphological changes in cellular-tissue organisation in the ETM, following 
exposure challenges with the TSC. In conjunction with this, targeted IHC 
assays were performed in order to better characterise the tissue response at 
the cellular level, i.e. basal, ciliated, intermediate and Goblet cells.
H+E staining was carried out on ETM sections to monitor any morphological 
changes in the lung tissue (Balharry et al., 2008). This study revealed that 
thickening of the tissue was induced which was concurrent with elevated 
TEER outputs (section 2.4.1.1, 2.4.2.1, 2.4.3.1 and 2.4.4.1). Image analysis
50mM
75mM
100mM
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of the tissue sections confirmed that the low concentrations of all TSCs 
induced an increase in the number of cells, as well as an increase in cell size 
for the majority of the cells. These findings were consistent with studies that 
have identified Goblet cell hypertrophy and hyperplasia in human smokers 
(Innes et al., 2006). This could further account for the changes in TEER, 
given that an increase in cell volume can lead to a rise in TEER, due to an 
obliteration of the intercellular space (Madara, 1998). It would be of interest to 
note (future work) whether repeated exposure to these toxins would disrupt 
the normal progression of hyperplasia (and hence, epithelial recovery), which 
would result in the development of diseases such as asthma, chronic 
bronchitis and cancer (Tesfaigzi, 2003); as observed with tobacco smoking 
(Patel et al., 2008). The histological analysis enabled the differentiation 
between secreted proteins (i.e. mucin) and cellular debris. The morphological 
alterations induced at low TSC concentrations could be associated with mucin 
hypersecretion. In contrast, at the higher TSC concentrations changes in 
tissue architecture (i.e. damage) could be related to the accumulation of 
cellular debirs, (Section 2.4.1-2.4.4; Balharry et al., 2008).
Semi-thin sectioning of the ETM with toluidine blue staining was carried out on 
TSC exposed ETM. This allowed detailed morphological changes of cellular 
and tissue architecture at more than adequate levels of resolution (i.e. one 
step below transmission electron microscopy (TEM). On closer examination of 
the individual TSC, there were four main pathological developments: (1) 
hyperplasia, (2) hypertrophy, (3) cytolysis, and (4) necrosis. Cadmium 
exposed ETM revealed evidence of apoptosis and necrosis at the initial dose; 
this was substantiated by the biochemical mode of action of cadmium on cells 
resulting in apoptosis and necrosis (Pinot, et al., 2000). Further exposures of 
cadmium identified evidence of necrosis and focal areas of hyperplasia. The 
existence of hyperplasia infered that the ETM was attempting to repair and/or 
regenerate (McDowell etal., 1979; Zahm et al., 1997). Exposure of the lowest 
concentration of formaldehyde (1mM) to the ETM revealed regional 
hypertrophy at the basal level. This pathological abnormality was also 
observed in a study by Innes et al., (2006), where they identified Goblet cell
104
M o r p h o l o g ic a l  C h a n g e s  in  t h e  E p iA ir w a y  M o d e l
hypertrophy in smokers compared to non-smokers. Further increments of 
formaldehyde initiated tissue degeneration and necrosis, as denoted by a loss 
of the basal and columnar cells; features that have also been observed in 
inflammatory airway diseases (Trautmann et a/., 2005). These observations of 
hypertrophy and regional degeneration were also noted in the ETM exposed 
to urethane, where the basal degeneration was very pronounced at the 
250mM exposure. Degeneration at this level may suggest the ETM would fail 
to replenish the cells that had been damaged (Barbieri and Pietenpol, 2005). 
The presence of cytolysis was only observed in the nicotine treated cells. 
Previous studies by other investigators, regarding the removal of inflammatory 
cells from airway tissues, implied that the removal process was solely due to 
apoptosis (Haslett, 1999; Henson et al., 2001). Investigations conducted by 
Uller et al., (2004), demonstrated that cells may also be cleared through
primary cytolysis, where necrosis was secondary to apoptosis. The
mechanism of squamous metaplasia has been described by other 
researchers (Puchelle et al., 2006) as being a component of the protective 
response, leading to regeneration and repair post-injury.
IHC analysis was conducted to confirm epithelial differentiation and
identification of protective mechanisms (e.g. p63). The first cell-specific 
marker used was protein 63 (p63), a transcription factor in the development 
and maintenance of stratified-epithelium. It was investigated since
deregulated growth of stratified-epithelium is a major cause lung disease 
(Barbieri and Pietenpol, 2005). This marker was located in the basal layers of 
stratified epithelial tissues (Dellavalle et al., 2001). The basal layers were 
thought to include cells of high proliferative capacity, which replenish the 
terminally differentiated populations in the suprabasal regions (Pellegrini et 
al., 2001).
Analysis of the cadmium exposure revealed no expression of p63. The role of 
p63 in apoptosis remains controversial but studies have demonstrated that an 
induction of p63 results in a reduction of apoptosis (Barbieri and Pietenpol, 
2006; Liefer et al., 2000). The interactions of cadmium on the mitochondria
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can lead to apoptosis (Pinot et al., 2000). Therefore, it may be assumed that 
an increase of apoptosis could decrease p63 expression.
Examination of the ETM exposure to formaldehyde demonstrated an initial 
down-regulation of p63. This could be indicative of an increase in apoptosis 
and necrosis. The subsequent doses of formaldehyde produced an increase 
of p63 expression, suggesting that the model was attempting to repair and 
counteract apoptotic functions, such as DNA damage (Chilosi et al., 2002). 
This repair process was deemed to be overwhelmed (e.g. cell swelling and 
disruption of the plasma membrane), as there was no p63 expression and 
there was morphological evidence of necrosis with the final formaldehyde 
exposure.
The response of the ETM to nicotine had a completely different exposure 
profile. The p63 expression increased with the incremental exposures which 
have indicated that the ETM was attempting to repair and inhibit the apoptotic 
functions (Chilosi et al., 2002). The expression location of p63 was altered for 
each concentration of nicotine exposure, and moved into the suprabasal 
region. On further examination, it was possible to view structural changes 
(e.g. disruption of the intracellular junctions, presence of vacuoles) to the ETM 
and a marked reduction in the pseudo-stratification of the epithelia. The 
change of structure may be classified as squamous metaplasia, i.e. 
squamous morphology (Gray et al., 2007). A change in cell structure is not 
necessarily associated with a specific disease but can be observed in 
smokers (Peters etal., 1993; Murarescu etal., 2007).
Finally, urethane elicited an increase in p63 expression at the lowest 
concentration (100mM). It was believed to have an anti-apoptotic protective 
mechanism, with the model attempting to repair damage by maintaining 
cellular propagative capacity (Yang et al., 1998). Further increments of 
urethane exposure created a stark reduction in the p63 expression that 
corresponded to widespread tissue degradation. It should be noted that 
urethane (ethyl carbamate) has the capacity to be carcinogenic (Gupta and
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Dani, 1989) and deregulation of p63 has been associated with early stages of 
invasive cancers (Comperat etal., 2007; Urist etal., 2002).
The second cell-specific marker examined was cytokeratin 5/6 expression. 
Cytokeratins are a family of cytoskeletal proteins in all epithelia (Presland and 
Dale, 2000). They are expressed in epithelial cells and self-assemble to form 
a three-dimensional array of filaments that extend from the nucleus to the cell 
membrane and are significant for maintenance of cell shape and viability 
(Presland et al., 2002). Cytokeratin 5 is expressed in the basal region of the 
stratified tissue. This is the region thought to replenish the higher regions 
(Gomperts et al., 2007). Cytokeratin 6 can be expressed in the suprabasal 
region; this region is associated with differentiation and is often paired with 
cytokeratin 16 (Presland and Dale, 2000).
Analysis of the cadmium exposure to the ETM showed limited expression of 
CK 5/6. This decrease may be indicative of an inhibition of cytokeratin’s role in 
the repair process (Bloor et al., 2001; Gomperts et al., 2007). Increasing 
concentrations of cadmium increased the expression of CK 5/6 at the 
suprabasal region but all expression was below the control levels, suggesting 
that this region had limited differentiation (Chu and Weiss, 2002). Examination 
at the ETM of the lowest concentration of formaldehyde (1mM) revealed an 
initial increase in CK 5/6 at the basal region, which may infer that the ETM 
was viable and attempting to repair via replenishment of the cells injured post­
exposure (Pierce et al., 1994; Gomperts et al., 2007). The subsequent 
concentration of formaldehyde (5mM) caused a dramatic increase of CK 5/6, 
in the basal and suprabasal regions, which may be interpreted as a repair 
response to counteract any apoptotic functions (Chilosi et al., 2002). The final 
formaldehyde concentration (10mM) induced a reduction in CK 5/6 expression 
back to control level but the model was notably thin in cell layers with eventual 
sloughing-off of cells, as the repair/maintenance process had been over­
whelmed. CK 5/6 expression in nicotine treated cells (25mM) caused an 
increased expression at the basal and suprabasal regions compared to the 
control cells. This induction of the repair/maintenance mechanisms was 
followed by subsequent decreases of expression with increased
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concentrations of nicotine (50, 75 and 100mM). This expression pattern was 
finalised with a control level expression at the basal region of the ETM. 
However, it was believed that the expression was really suprabasal 
cytokeratin 6, due to the re-structuring of the ETM post-nicotine exposure. 
This unique expression was also observed with cadmium and urethane. 
However, there was one subtle difference with urethane (2000mM) in that CK 
5/6 expression was throughout all regions of the post-exposure tissue 
indicating that the ETM was attempting to ‘survive’. Further examination 
concluded that the apical surface had been sloughed-off, with only the 
cytokeratin stained regions of viable cells remained.
The final IHC technique used was the detection of TBM. It constituted the 
most characteristic glycoproteins of mucus and was synthesized by the 
Goblet cells of the epithelium and the mucosal cells of submucosal glands. TB 
secretions coat the respiratory tract epithelium and protect the airways by 
binding or trapping pathogens. Over-expression of this gene could be 
indicative of a protective mechanism being initiated, due to exposure of a 
xenobiotic or pathogen (Wang et al., 2008). This IHC technique was not 
sensitive enough to quantify due to the antibody used was generic (MUC4) 
rather than a more specific TBM antibody e.g. MUC5B (Kesimer et al., 2009)
3.6 C o n c lu s io n
Histological evaluations, in conjunction with IHC, enabled identification of the 
mechanisms of TSC injury and repair. Three discrete zones of tissue injury 
and repair could be delineated: (1) apical region and its Goblet cells; (2) 
suprabasal region reactive intermediate cells; and (3) basal zone, where basal 
cells acted as progenitors cells. The data from this Chapter also confirmed the 
findings in Chapter 2, in that the concentrations of TSC used in this study 
were intended to achieve a full range of responses from the ETM, from sub­
toxic concentrations to widespread cell death.
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4 .1  In t r o d u c t io n
In Chapter 3, the biological and related morphological responses to TSC in 
the ETM were evaluated. The conventional toxicological evaluations 
suggested that the four TSC elicited a similar response from the ETM, i.e. 
biphasic; Balharry et al., (2008). An alternative approach was now required to 
assess the early/protective biological responses and highlight potential 
biomarkers of harm for specific mechanisms of injury attributed to smoking. 
This could be achieved by using genomics, where the study of transcriptional 
changes could be determined.
In the following work, the toxicogenomic or transcriptional changes to TSC 
challenge was determined; thus providing a holistic toxicological approach. 
The use of human tissue equivalent models of respiratory epithelium provided 
human mRNA transcript data, allowing identification of biomarkers that could 
be related to many respiratory diseases (Sexton et al., 2008). To measure 
potential genomic markers of injury, differential gene expression was 
investigated using a standard, microarray platform; OligoGEArrays® 
(SuperArray). The Oligo GEArray® Human Toxicology & Drug Resistance 
Microarray profiled the expression of 263 genes related to the metabolic 
processes of cell stress, cell toxicity, drug resistance and metabolism. Genes 
critical in drug metabolism resistance and, such as those encoding enzymes 
important for drug transport and phase I metabolism (specifically P450- 
mediated oxidation) were included.
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4 .2  M a te r ia ls  and  S to c k  S o lu tio n s  
4 .2 .1  M a te r ia ls  a n d  S u p p lies
Materials: Supplier:
QIAzol Lysis Reagent (79306) Qiagen
RNeasy Mini Kit (74104) Qiagen
QIAshredders (79654) Qiagen
QuantiTect® Reverse Transcription Kit (205311) Qiagen
QuantiTect® SYBR Green PCR Kit (204143) Qiagen
RNAIater (76104) Qiagen
Oligo GEArray® Human Toxicology & Drug 
Resistance Microarray (OHS-401)
SuperArray, USA
cRNA Cleanup Kit (GA-012) SuperArray, USA
Gene Expression Analysis Suite (GA-022) SuperArray, USA
Biotin-11-UTP (NEL543001EA) Perkin Elmer
Significance Analysis of Microarrays Stanford University, 
USA
SDS Solution (Ultra Pure) (20%) National Diagnostics
SSC Solution (Ultra Pure) (20x) National Diagnostics
Water (W4502) Sigma-Aldrich
Ethidium Bromide (E1510) Sigma-Aldrich
Loading Dye (G2526) Sigma-Aldrich
RNAIater (R0901) Sigma-Aldrich
NuSieve™ Agarose Cambrex
StrataClone™ (240205) Sratagene, Netherlands
Wizard® Plus Miniprep DNA Purification System 
(A1340)
Promega
Thermo-fast® 96 Detection Plates (AB-0800) ABgene
Ultra Clear Cap Strips (AB-0866) ABgene
Table 4.1 Materials used and their suppliers. All suppliers are UK based unless 
stated
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Gene Symbol Qiagen Ref Entrez Gene ID Amplicon (bp)
BAX QT00031192 581 111
CCND1 QT00495285 595 96
CYP20A1 QT00065394 57404 120
CYP4F3 QT00018039 4051 98
GAPDH QT01192646 2597 119
HMOX1 QT00092645 3162 99
HSPA8 QT00030079 3312 79
SULT1A1 QT00000112 6817 76
TOP1 QT00085400 116447 92
TNFRSF11A QT00035434 8792 70
Table 4.2 QuantiTect® Primer Assay for qPCR
4 .2 .2  S to c k  S o l u t io n s
4.2 .2 .1  M ic r o a r r a y
Wash Solution 1 was prepared as a 1x working solution containing 2x SSC 
and 1% SDS. This working solution was stored at room temperature.
Wash Solution 2 was prepared as a 1x working solution containing 0.1x SSC 
and 0.5% SDS. This working solution was stored at room temperature.
Annealing Mix (per sample):
RNA 0.1-3.0pg of total RNA
Truelabeling Primer 1pl
RNase-Free H20 to a final volume of 10pl
Table 4.3 Preparation of annealing mix solution. Microarray procedure detailed
in Section 4.3.2.1
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cDNA Synthesis Master Mix (per reaction):
RNase-free H2O 4pl
5X cDNA Synthesis Buffer 4pl
RNase Inhibitor 1 pi
cDNA Synthesis Enzyme Mix 1 Ml
Final Volume 10pl
Table 4.4 Preparation of cDNA Synthesis Master Mix solution. Microarray
procedure detailed in Section 4.3.2.1
Amplification Master Mix (per reaction):
2.5X RNA Polymerase Buffer 16pl
Biotinylated-UTP, 10mM 2pl
RNA Polymerase Enzyme 2mI
Final Volume 20|il
Table 4.5 Preparation of Amplification Master Mix solution. Microarray
procedure detailed in Section 4.3.2.1
4.2.2.2 Q u a n t ita t iv e  PCR
Genomic DNA Elimination Reaction Mix (per reaction):
7X gDNA Wipeout Buffer 2pl
Template RNA Variable (up to 1pg)
RNase-free Water Variable
Final Volume 14pl
Table 4.6 Preparation of Genomic DNA Elimaination Mix solution. qPCR
procedure detailed in Section 4.3.6.1
113
 T r a n s c r ip t io n a l  c h a n g e s  o f  E T M  e x p o s u r e  t o  t o b a c c o  s m o k e  c o m p o n e n t s
Reverse Transcription (RT) Reaction Mix (per reaction):
Quantiscript Reverse Transcriptase 1pl
5X Quantiscript RT Buffer 4pl
RT Primer Mix 1pl
Entire genomic DNA elimination reaction 14pl
Final Volume 20pl
Table 4.7 Preparation of Reverse Transcription Reaction Mix solution.
qPCR procedure detailed in Section 4.3.6.1
Ligation Reaction Mix (per reaction):
StataClone™ Cloning Buffer 3pl
PCR Product or Control Insert 2pl
StataClone™ Vector Mix 1 Ml
Final Volume 6pl
Table 4.8 Preparation of Ligation Reaction Mix solution. qPCR procedure 
detailed in Section 4.3.6.2
SYBR Green PCR Mix (per reaction):
Plasmid DNA 1pl
2X SYBR Green PCR Master Mix 12.5pl
QuantiTect Primer Assay 2.5pl
PCR Grade Water 9pl
Final Volume 25pl
Table 4.9 Preparation of SYBR Green PCR Mix solution. qPCR procedure
detailed in Section 4.3.6.1
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4.3 M ethods
4.3.1 RNA E x t r a c t io n  a n d  P r e p a r a t io n
4.3 .1 .1  RNA Is o la tio n  u s in g  Q IA z o l  P r o to c o l
RNA from ETM was isolated using QIAzol (Qiagen) as outlined in the QIAzol 
Lysis Reagent Handbook (Qiagen, 2). This is a single step, liquid phase 
separation procedure, which allows the simultaneous extraction of RNA, DNA 
and protein. The technique is based on an extraction outlined by 
Chomczynski and Sacchi (1987) and works well on large or small amounts of 
starting material.
Briefly, the cells were harvested then lysed in QIAzol, the sample was 
homogenised by passing the lysate (several times) through a 20-gauge 
needle fitted to a syringe, followed by centrifugation (>8,000 x g, two minutes) 
in a QIAshredder column resulting in a mono-phase solution of guanidine 
thiocyanate and phenol. All insoluble material and high molecular weight 
DNA was removed by centrifugation (12,000 x g). After the addition of 
chloroform, the solution was mixed thoroughly and then centrifuged (12,000 x 
g). This resulted in the separation of the solution into three layers, a red 
organic phase (protein), an interphase (DNA) and colourless upper aqueous 
phase (RNA). The aqueous layer was carefully removed and an equal volume 
of isopropanol added. After centrifugation (12,000 x g) the RNA precipitate 
formed a pellet. The pellet was washed in 70% ethanol, and then reformed by 
centrifugation (7,500 x g). The pellet was air dried to remove all residual 
ethanol before being resuspended in RNase/DNase-free water (20pl).
4.3.1.2 Q u a n t if y in g  t h e  RNA Is o l a t e
The purity and yield of all RNA samples were assessed using the Ultraspec 
2100pro (Amersham). Purity was established by measuring the 260:280nm 
absorption ratio. A ratio of 2.0 was indicative of a very pure RNA sample 
(Ultraspec 2100 RNA/DNA Calculator User Manual). However, a ratio of over
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1.8 was considered acceptable for subsequent gene analysis. Lower ratios 
can indicate contamination in the sample. The yield of the sample was 
calculated from the absorbance of the sample at a wavelength of 260nm.
4 .3 .1 .3  Ch e c k in g  In t e g r it y  o f  R N A : R u n n in g  a n  A g a r o s e  G el
A sample of the RNA was run on a 1% agarose gel (0.5g in 50ml 1x TBE with 
3pl of 10mg/ml ethidium bromide). Each well was loaded with 500ng RNA, 
2pl loading dye, and made up to a total of 10pl in high purity RNase/DNase 
free water. The gel was electrophoresed (approximately 40 minutes, 90 volts) 
and viewed under UV using the UVP Gel doc System.
4 .3 .2  M ic r o a r r a y s
4.3.2.1 P r e p a r a t io n  o f  B io t in  l a b e l l e d  cDNA P r o b e
Isolated RNA (500ng) was mixed with Truelabeling primer (1pl). The 
annealing mix stock (Table 4.3) and RNA were incubated at 70°C for 10mins. 
The solution was then cooled and cDNA synthesis master mix (Table 4.4) was 
added to the annealing mix and incubated at 42°C for 50mins followed by 
75°C for 5mins then allowed to cool to 37°C. The amplification mix (Table 4.5) 
was added to the cDNA synthesis master mix and incubated at 37°C 
overnight.
The reaction mixture contained a large excess of unincorporated nucleotide 
that would interfere with the calculation of the yield of labelled cRNA product 
required for the array hybridisation. The Superarray cRNA clean up kit was 
used for purification. The kit incorporated small scale chromatography and 
centrifugation to give a quick and reproducible separation of the probe from 
contaminants. The probe was eluted in 10mM Tris Buffer pH 8.0 and stored 
on ice prior to quantification of the purified probe (described in Section 
4.3.1.2). Each array required 2pg of probe for the hybridisation step to 
produce a strong signal for chemiluminescent imaging.
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4 .3 .2 .2  H y b r id is a t io n  o f  th e  P r o b e  to  th e  A r r a y
The microarray membranes were moistened and placed in the supplied 
hybridisation tube containing 5ml of deionised water. After 5 minutes the 
water was discarded and replaced with 2ml of pre-warmed (60°C) GEAhyb 
hybridisation solution. These hybridisation tubes were then placed within 
standard hybridisation cylinders and placed within the hybridisation oven at 
60°C for 60mins at a slow agitation (5rpm).
Target hybridisation mix was prepared by adding 2pg of the biotin-labelled 
cRNA to 0.75ml GEAhyb hybridisation solution. The pre-hybridisation solution 
from the hybridisation tube was discarded and was replaced by the target 
hybridisation mix. This target was hybridised overnight at 60°C with slow 
agitation (5rpm).
Wash solution 1 and 2 we prepared as described in Section 4.2.2.1, the target 
was removed from the hybridisation tube and replaced with 5ml wash solution 
1. The hybridisation was placed back in the hybridisation oven with a faster 
agitation (20rpm) for 15mins. This first wash was discarded and replaced with 
5ml of wash solution 2 (high stringency) and placed back in the hybridisation 
oven for 15mins at fast agitation (20rpm). After the allotted time the wash 
solution was removed and the membrane was allowed to cool to room 
temperature.
4 .3 .2 .3  C h e m il u m in e s c e n t  D e t e c t io n
All of the following detection steps were carried out at room temperature. The 
first step of detection was to block the array this was carried out by adding 
2ml of GEAblocking solution Q to the hybridisation tube and incubated for 
40mins. The blocking solution was discarded; the next step was to bind with 
alkaline phosphatase-conjugated streptavidin (AP-SA) by adding 2ml AP-SA 
buffer and incubating for 10mins with gentle agitation (5rpm). The AP-SA 
buffer was then discarded and the membrane was washed several times with 
buffer F and buffer G (supplied with array). Finally 1ml of CDP-Star
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chemiluminescent substrate was added to the hybridisation tube and 
incubated for 5mins with gentle agitation (5rpm). Using forceps the membrane 
was removed and placed into a zip-lock bag prior to imaging.
4 .3 .2.4 C h e m il u m in e s c e n t  Im a g in g
The chemiluminescence was detected using an UVP Biospectrum imaging 
system. This system incorporated a high resolution Hama 12 bit CCD cooled 
camera and Visionworks LS software. Images were detected using dynamic 
integration set to take 20 images over a 20min period maximum sensitivity 
(1x1). The image was then selected on the parameters of maximum number 
of spots detected without bleeding/overexposure.
4 .3 .3  Ex p r e s s io n  A n a l y s is  o f  Ex p o s e d  E T M
Each insert was apically treated/exposed with 100pl warm TSC solution. The 
dose for each TSC was determined from previous studies (Chapter 2). The 
doses were as follows: Nicotine: 30mM; Cadmium (cadmium chloride):
0.1mM; Urethane: 70mM; Formaldehyde: 1.2mM. Each dose was replicated 
(n=5). After 24 hours the toxin (TSC) was removed from the surface and the 
tissue was stored in RNAIater (Qiagen, UK) prior to RNA isolation (Section
4.3.1.1).
4 .3 .4  D a ta  N o rm a lis a tio n  an d  S ta t is t ic a l  A n a ly s is
The data obtained from control (PBS), nicotine, FA, urethane and cadmium 
exposed ETM’s were generated using the GEArray Expression Analysis 
software. The data comprised the intensity of the spot, the background 
intensity of the membrane and an adjusted intensity that was taken to be a 
quantitative measure of gene expression (i.e. spot intensity minus background 
intensity). In order to compare hybridisation signal intensities across the 
membranes normalised signal intensity for each spot was obtained. 
Normalisation can be defined as the process of removing certain systematic
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biases from microarray data; including corrections for differences in overall 
array intensity i.e. background noise.
Preliminary statistical analysis using an Anderson Darling test for normality 
(p>0.05) on 30 genes (11%) confirmed the raw array data was normally 
distributed. Following this step global normalisation between membranes was 
carried out which involved dividing the spot intensity of each gene by the 
median spot intensity of the whole array to correct for variations between 
arrays. As the mean value can be distorted by the effects of a few extreme 
outliers, the median value was considered the most accurate basis for 
normalisation, thus reducing the possibility of data variance due to anomalous 
data points (Balharry et al., 2005). As a final assessment, the data was 
analysed using SAM (Significance Analysis of Microarrays; Stanford 
University) analysis. SAM correlates gene expression data to a wide variety 
of parameters and uses data permutations to provide an estimate of false 
discovery rates for multiple testing. Changes in gene expression were 
expressed as a ratio (fold-change). The lower cut off point for identifying 
relevant genes was set at a ratio of 1.5 (deVos et al., 2003; Treadwell and 
Singh 2004).
The significance of differentially expressed genes could only result when 
statistical analyses were applied. The appropriate statistical analysis in this 
instance was a 2 class unpaired t-test. The two-tailed student’s t-test is a test 
used to examine a difference between mean values of two groups of data. A 
null hypothesis of no expression-level difference in individual genes between 
control and nicotine, FA, urethane, cadmium ETM exposure was adopted. 
The resultant statistical value could then be used to determine which genes 
were significantly differentially expressed. A p value of ^0.05 was deemed 
significant. Genes were grouped and annotated according to the functional 
classification allocated by GEArray Expression Analysis software.
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4.3.5 F u n c t io n a l  G r o u p in g
Each of the genes present on the array could be categorised under functional 
group headings. These groups are listed in Table 4.10. The purpose of 
looking at the functional groups was to assess whether genes were 
contributing to the same type of responses.
GEArray® Human Toxicology & Drug Resistance Microarray
Apoptosis 
Cell Cycle
Cell growth, Proliferation and Differentiation 
Transporters 
Response to Stress 
Chaperones and Heat Shock Proteins 
Transcription Factors and Regulators 
Drug Metabolising Enzymes
Table 4.10 The main functional gene classes. The Oligo GEArray® Human 
Toxicology & Drug Resistance Microarray has eight classes of genes
4.3.6 Q u a n t it a t iv e  PCR to  Va l id a t e  Tr a n s c r ip t io n a l  Ch a n g e s
PCR amplifies DNA exponentially, doubling the number of molecules present 
with each amplification cycle. The number of amplification cycles and the 
amount of PCR end-product enables calculation of the initial quantity of 
genetic material, but numerous factors complicate this calculation.
The ethidium bromide staining typically used to assess a successful PCR 
prevents further amplification, and is only semi-quantitative. The polymerase 
chain reaction may not be exponential for the first several cycles, and 
furthermore, plateaus eventually, so care must be taken to measure the final 
amount of DNA while the reaction remains in the exponential growth phase. 
To overcome these difficulties, several different quantitative methods have
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been developed. The most sensitive quantification methods are achieved by 
real-time polymerase chain reaction (qPCR; Figure 4.2), where the amount of 
DNA is measured after each cycle of PCR by use of fluorescent dyes (SYBR 
Green; QuantiTect primer assay handbook, Qiagen).
A standard curve was constructed from the starting concentration of cDNA 
target (1qg -  1fg) plotted against their CT value, the fractional PCR cycle at 
which the fluorescent signal significantly rises above the background signal 
(Figure 4.1). This technique was carried out on ten genes selected by 
methods outlined in Section 4.3.2.
oo
co
o Log-linear phase
Base ine2o3
ij-
20 25 305 10 15
Cycle number
Figure 4.1 Example of data for real-time RT-PCR Shows an exponential 
increase in the amount of cDNA present in each sample with sample A having the greatest 
amount of cDNA target (1 ng) and sample D the least amount of cDNA target (1 pg)
4.3.6.1 RT-PCR
The samples previously used in the array procedure were used to synthesise 
cDNA by a reverse transcription reaction. Purified RNA (500r|g) was briefly
121
T r a n s c r ip t io n a l  c h a n g e s  o f  E T M  e x p o s u r e  t o  t o b a c c o  s m o k e  c o m p o n e n t s
incubated in gDNA Wipeout buffer at 42°C for 2 minutes to effectively remove 
genomic DNA (Table 4.6). The complete genomic DNA elimination reaction 
was then placed on ice for 10 minutes; it was then added to the reverse 
transcription reaction (Table 4.7) and incubated at 42°C for 30 minutes. The 
reaction was terminated by heat inactivating the reverse transcription reaction 
at 95°C for 3 minutes. Next, a 25pl SYBR Green PCR reaction (Table 4.9) 
was carried out as detailed in the QuantiTect primer assay handbook (Qiagen, 
2007). This involved a two-stage PCR reaction (Figure 4.2). The PCR product 
was loaded on to a 2% NuSieve™ agarose gel, the product was extracted by 
excising the resultant band and heating the excised band at 65°C for 2 
minutes.
Initial denaturation
Denature
Anneal and extend
Final extension
95°C (15 minutes)
i
95°C (15 seconds)
i
55°C (30 seconds)—
i
72°C (30 seconds)
x 40 cycles
Figure 4.2 Two-stage PCR cycling parameters. This PCR reaction is classed as 
two-stage due to the removal of the extension step throughout the 40 cycles
4 .3 .6 .2  L ig a t io n  o f  P C R  P r o d u c t  in t o  P la s m id  Ve c t o r
Purified PCR product was ligated into a StrataClone PCR cloning vector 
(pSC-A) using the StrataClone PCR cloning kit. This method is detailed in the 
StrataClone PCR cloning kit manual (Stratagene, 2007). In brief the ligation 
reaction mix was prepared as detailed in Table 4.8 and incubated at room 
temperature for 5 minutes.
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4 .3 .6 .3  Tr a n s fo r m a  tio n  in t o  E. c o li
A tube containing StrataClone SoloPack competent cells was thawed on ice 
for each ligation reaction and 1pl of the ligation prepared in section 4.3.6.2 
was added to the competent cells. The transformation mixture was then 
placed on ice for 20 minutes. The reactions were then heated shocked at 
42°C for 45 seconds and then returned to ice for a further 2 minutes. Pre­
warmed SOC medium (250pl) was added and then placed at 37°C with gentle 
agitation to allow the cells to recover for 1 hour. The transformed E.coli 
(1 OOfjl) was plated on pre-prepared LB/ampicillin/X-gal agar plates. The plates 
were then cultured overnight at 37°C.
4.3.6.4 S c r e e n in g  Tr a n s f o r m a n t s  f o r  In s e r t s
Successful cloning of an insert into the pSC-A vector interrupts the coding 
sequence of (3-galactosidase. This results in a colour change between clones 
which contain PCR product, and those that do not. Recombinant clones can 
therefore be identified by a white colouring, compared to uncloned vectors 
which remain blue.
Luria broth (LB; 10ml) containing 1 mg/ml ampicillin was inoculated with a 
white colony, and incubated overnight at 37°C. The culture containing the 
recombinant clones was plated onto LB agar/ampicillin plates and sent for 
sequencing whilst the remainder was stored as a 20% glycerol stock.
4.3.6.5 P la s m id  DNA P u r if ic a t io n
Purification of plasmid DNA from the bacterial cells was undertaken using the 
Wizard Plus SV Miniprep DNA Purification System. LB containing the 
recombinant E.coli (1.5ml) was centrifuged (10000 x g) for 5 minutes. The 
resulting pellet was resuspended in 250pl resuspension buffer and vortexed. 
Cell lysis solution (250pl) was added and mixed by inverting. The sample was 
incubated at room temperature until the cell suspension had cleared
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(maximum of 5 minutes). Alkaline protease solution (10pl) was added and 
mixed by inverting, then incubated at room temperature for 5 minutes. After 
incubation, 350pl neutralisation solution was added and immediately mixed by 
inversion. The sample was then centrifuged at maximum speed for 10 
minutes, and the cleared lysate decanted into a prepared spin column. This 
was centrifuged at maximum speed for 1 minute. The columns were then 
washed with 750pl column wash solution and centrifuged for a further 1 
minute. A final wash was carried out by adding 250pl column wash solution to 
the column and centrifuging for 2 minutes. To elute the plasmid, 50pl 
nuclease-free water was added to the column, and centrifuged for one minute. 
The concentration of DNA in the resultant eluant was measured using a 
Ultraspec 2100pro (Amersham).
4.3.6.6 S er ia l  D ilu t io n s  o f  S ta n d a r d s
When the sequence of the insert was confirmed, standards were created for 
each gene. The Ultraspec measurement of the eluted DNA (Section 4.3.6.5) 
was used to calculate the dilution factor necessary to obtain a concentration 
of 1ng/pl. Serial dilutions were then carried out to obtain a series of standards 
ranging from 10fg/pl to 100pg/pl.
4.3.6.7 Q u a n tita t iv e  PCR o f  Ex p e r im e n t a l  G e n e s
RNA was isolated from the exposed and control ETM (Section 4.3.1.1), and 
cDNA was synthesised from this, by a reverse transcription reaction (Section
4.3.6.1). Samples and standards were prepared for qPCR using the 
QuantiTect SYBR Green PCR Kit (Table 4.9). Each sample and standard 
was loaded in triplicate (25pl per well) into a Thermofast 96 well PCR 
detection plate. The plate was analysed on an MJ Research Opticon 
(BioRad, Hercules, CA).
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4.4  R es u lts
4.4.1 RNA P u r it y  a n d  In t e g r it y
The integrity and yield of the RNA from control and exposed ETM (n=5) [Table 
4.11] indicated that each sample was within the desired ratio with a sufficiently 
high yield. Isolated RNA was loaded and run on an agarose gel (1%) and 
viewed under UV (Biospectrum imaging system) to confirm RNA integrity and 
genomic contamination (Figure 4.3). There was very little or no genomic 
contamination, with the observed bands free from smears (which is an 
indication of RNA degradation).
28 S 
18 S
Figure 4.3 Typical agarose gel depicting RNA integrity.
4.4.2 M ic r o a r r a y  A n a lysis
Microarray data from the exposed cell cultures was analysed to show 
differential gene expression for the different TSC (Table 4.12; Figure 4.8). 
When comparing gene expression in cadmium, formaldehyde and urethane to 
PBS, 18 genes were up-regulated by >3-fold. Some of the largest changes, as 
shown in Table 4.12, were responses to DNA damage stimulus (CHEK2), cell 
stress (CTPS), chemokines (CXCL10), oxidoreductases (CYP20A1, PTGS). 
Nine genes with the largest change were seen in genes involved in cell cycle 
(CCND1).
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Exposure of 
ETM
Absorbance
(260nm)
RNA concentration 
(ng/ul)
Ratio
A260/A280
Nicotine3 0.234 562 1.7
Nicotineb 0.454 1090 1.5
Nicotine0 0.377 905 1.8
Nicotined 0.469 1126 2.0
Nicotine® 0.350 840 1.8
Cadmium3 0.223 535 1.7
Cadmiumb 0.337 809 1.8
Cadmium0 0.144 346 1.8
Cadmiumd 0.707 1682 1.5
Cadmium® 0.683 1639 2.0
Urethane3 0.347 833 1.9
Urethaneb 0.322 773 1.9
Urethane0 0.432 1037 1.9
Urethaned 0.141 338 1.6
Urethane® 0.250 600 1.6
Formaldehyde3 0.352 845 1.9
Formaldehyde13 0.347 833 1.9
Formaldehyde0 0.321 770 1.8
Formaldehyded 0.261 626 1.8
Formaldehyde® 0.166 398 1.9
Control3 0.500 1200 1.9
Control 0.344 826 1.9
Control0 0.323 775 1.9
Control 0.287 689 1.8
Control® 0.375 900 1.9
Table 4.11 Concentrations and ratios of RNA. (n=5) isolated from control and 
exposed ETM
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In contrast, when comparing the gene expression of nicotine to PBS fewer 
changes in mRNA expression were induced with 5 genes being up-regulated 
by >1.5-fold with the largest change observed in sulfotransferases 
(SULT2A1). Eleven genes were down regulated by >1.5-fold with the greatest 
change observed in oxidoreductases (CYP7A1) and transporters (TPMT).
Further analysis placed the genes of interest into functional groups (annotated 
by SuperArray): drug metabolism; transcription factors & regulators, stress 
response; cell growth/proliferation & differentiation; and transporters. These 
groups were common for all compounds. Nicotine also contained the 
functional group DNA repair (Figure 4.4), and cadmium, urethane and 
formaldehyde had genes in the apoptosis and cell cycle functional grouping 
(Figure 4.5, 4.6 and 4.7).
Another technique was used for graphical representation of gene expression 
data in response to cadmium, FA, nicotine and urethane exposure of the ETM 
(Table 4.13). The data were plotted on a graph with the gene names along the 
x-axis and fold-change from the control on the y-axis to determine gene 
homology and expression trends.
Drug Metabolism 63%
Figure 4.4 Functional classification of the significant genes from 
nicotine exposure of the ETM. The functional group of DNA repairs genes was 
unique to nicotine
DNA repair 6%
Transporters 6%
Cell growth, proliferation & 
Differentiation
Stress response 6%
TF & regulators 6%
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Drug Metabolism 23%
TF & regulators 5%
Stress response 14%
Cell cycle 19%
Apoptosis 5%
Transporters 10%
Cell growth, proliferation & 
Differentiation 24%
Figure 4.5 Functional classification of the significant genes from 
cadmium exposure of the ETM.
Cell cycle 13% 
Apoptosis 13%
Transporters 13%
Drug Metabolism 18%
TF & regulators 6%
Stress response 13%
Cell growth, proliferation & 
Differentiation 24%
Figure 4.6 Functional classification of the significant genes from 
urethane exposure of the ETM.
Cell cycle 21%
Apoptosis 16%
Transporters 11%
Drug Metabolism 20%
TF & regulators 5% 
Stress response 11 %
Cell growth, proliferation & 
Differentiation 16%
Figure 4.7 Functional classification of the significant genes from 
formaldehyde exposure of the ETM.
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Gene ID
Nicotine
Fold P-value
Cadmium
Fold P-value
Urethane
Fold P-value
Formaldehyde
Fold P-value Gene name Functional group
ABCC1 5.31 0.010 4.44 0.0002 3.90 0.001 ATP-binding cassette, sub-family C (CFTR/MRP). member 1 Transporters -----
ABCC2 8.37 0.001 7.63 0.00001 6.60 0.000004 ATP-binding cassette, sub-family C (CFTR/MRP). member 2
BAX -3.29 0.008 3.27 0.009 -4.3C 0.006 BCL2-associated X protein Apoptosis
CASP10 3.82 0.0001 3.80 0.00005 Caspase 10. apoptosis-related cysteine protease Apoptosis
CCND1 5.27 0.002 0.003 -3.91 0.003 Cvclin D1 (PRAD1: parathyroid adenomatosis 1) Cell Cycle
CDKN2A -3.04 0.00002 Cvclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) Cell Cycle
CDKN2D -3.12 0.0001 -3.00 0.0002 Cvclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) Cell Cycle
CHEK2 18.66 0.015 18.23 0.00001 14.96 0.00002 CHK2 checkpoint homolog Cell Cycle
CRYAB 3.29 0.002 Crvstallin. alpha B Cell Growth. Proliferation and Differentiation
CSF2 4.34 0.000004 4.18 0.000002 3.67 0.0001 Colony stimulating factor 2 (granulocyte-macrophage) Cell Growth. Proliferation and Differentiation
CTPS 9.31 0.006 8.10 0.00000002 6.19 0.00000003 CTP synthase Stress Response
CXCL10
CYP1A1
CYP1B1
CYP2E1
CYP20A1
CYP4B1
CYP4F3
CYP7A1
E2F1
23.82 0.003 18.84 0.00002 15.46 0.00002
4.21 0.008
Chemokine (C-X-C motif) ligand 10 Cell Growth Proliferation anrl Differentiation
4.31 0.00002 4.28 0.001
0.002
Cytochrome P450, family 1. subfamily A, polypeptide 1
-1.99 0.032
Cytochrome P450, family 1, subfamily B, polypeptide 1
11.03 0.0005 9.0 0.000001 7.36 0.00004
Cytochrome P450, family 2, subfamily E, polypeptide 1
-3.14 0.004
Cytochrome P450, family 20, subfamily A. polypeptide 1
-2.67 0.037
Cytochrome P450, family 4, subfamily B. polypeptide 1
-3.73 0.006
Cytochrome P450. family 4, subfamily F, polypeptide 3
-4.18 0.00003
Cytochrome P450, family 7. subfamily A, polypeptide 1
E2F transcription factor 1 Apoptosis
Cell Growth, Proliferation and Differentiation
Transcription factors & regulators
DNA repair
Cell Growth. Proliferation and Differentiation
Cell Growth. Proliferation and Differentiation
Stress Response
Transcription factors & regulators
Stress
Cell Growth. Proliferation and Differentiation
Cell Growth. Proliferation and Differentiation
EGFR -3.32 0.00003 -4.30 0.00002 Epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog)
ELK1
ERCC3
0.001 3.15 0.007
-1.63 0.014
ELK1, member of ETS oncogene family
Excision repair cross-complementing, complementation group 3
HIF1A
HMOX1
HMOX2
MET
-2.16 0.044
-1.80 0.006
Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
-1.57 0.000
Heme oxygenase (decycling) 1
-4.53 0.000002 -3.17 0.000002
Heme oxygenase (decycling) 2
Met proto-oncogene (hepatocyte growth factor receptor)
MT3 3.15 0.021 Metallothionein 3 (growth inhibitory factor (neurotrophic))
MVP 3.65 0.035 Major vault protein
MYC
NNMT
PPARD
3.14 0.042
- 2.6 0.047
V-myc myelocytomatosis viral oncogene homolog
3.49 0.00001 3.95 0.001
Nicotinamide N-methyltransferase
Peroxisome proliferative activated receptor, delta
PPARGC1A 6.80 0.015 5.83 0.001 6.03 0.007
PTGS1 11.14 0.013 6.91 0.001 6.15 0.007
Peroxisome proliferative activated receptor, gamma, coactivator 1
RARA 1.79 0.023
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)
SULT1A1 1.78 0.022
Retinoic acid receptor, alpha
SULT2A1 2.23 0.038
Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1
SULT2B1 1.70 0.017
Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA) -preferring, member 1
TBXAS1 -1.74 0.005
Sulfotransferase family, cytosolic, 2B, member 1
TOP1 1.84 0.038
Thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A)
TPMT -2.99 0.018
Topoisomerase (DNA)
XDH 3.53 0.001
Thiopurine S-methyltransferase
Xanthine dehydrogenase
Table 4.12 Overview of microarray data from exposed cell cultures to show differential gene expression for the various 
TSCs. Coloured cells highlight gene homology between different exposures
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Figure 4.8 Graphical representation of differential gene expression. The comparison of fold-change 
between the various TSC with PBS controls permitted the determination of gene homology and expression trends
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4.4.3 Q u a n t it a t iv e  PCR
The aim of qPCR was to determine whether the changes in gene expression 
predicted by the arrays were accurate. A random selection of experimentally 
altered genes (10) was selected for qPCR (Table 4.2). All ten genes were 
successfully cloned for qPCR standards, these standards were confirmed by 
DNA sequencing of the recombinant clones containing the proposed insert. 
These were then used to make up a series of standards for each gene. The 
standards were made to concentrations of 10fg, 10Ofg, 1 pg, 10pg, and 100pg. 
The standards and unknown samples for each gene were analysed on an MJ 
Research Opticon Sequence Detection System. The PCR reactions for all 
genes were successful. The standard curves were of a high calibre (e.g. 
Figure 4.9), with the lowest R2 value equal to 0.96. The concentration of each 
gene in the samples was determined from the standard curves. The 
correlation between the microarray and qPCR experiments was very high, 
80% of the genes tested by qPCR confirmed data produced by microarray.
35 i ------------------------------------------------------------------------------------------
30
R = 0.98
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20
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cone (fg)
Figure 4.9 Standard curve for BCL2-associated X protein (Gene ID. 596).
Standards for other genes not shown
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4 .5  D iscussion
There are a number of lung related diseases associated with tobacco smoke 
(Smith et al., 2006). These studies were further complicated by the number of 
chemicals (~4500; (Andreoli et a i, 2003)) used in tobacco and individual 
smoking habits. Therefore, an alternative approach was required to assess 
the biological responses and to identify any potential biomarkers of exposure 
and harm for specific mechanisms of injury attributed to smoking. In this 
component of the research investigation, a subtoxic dose of nicotine, 
cadmium, urethane and formaldehyde had significant effects on epithelial 
gene-expression.
Various methods have been used to assess changes in gene expression, 
such as quantitative polymerase chain reaction (qPCR), in situ hybridisation 
and Northern blotting. There are, however, problems in selecting which genes 
to investigate, as important links may be missed between different gene 
activities. Despite the rapid advances in microarray technology permitting 
large-scale, chip-based gene profiling, analysis of gene expression patterns 
by nylon based cDNA microarray remains an important technique in molecular 
biology (Seliger, 2007; Sexton et ai., 2008). The persistence of this 
technology is partly due to its accessibility (used on the bench-top) and cost 
(expensive, specialised equipment not required). Importantly, for this study, 
nylon arrays also have high sensitivity and are useful for experiments with low 
RNA abundance. Moreover, this methodology has been used successfully in 
previous genomic studies in our laboratory to investigate toxicant effects in 
the lung (Balharry et al., 2005; BeruBe et ai, 2006; Wise et at, 2006).
The effect of nicotine in the animal and cell system has been comprehensively 
researched (Yildiz, 2004; Hukkanen et al., 2005). Nicotine has been shown to 
elicit a variety of physiological effects (i.e. cardiac contractility, mobilisation of 
blood sugars and increased free fatty acids) but for the purpose of this study 
only the thrombogenic and atherosclerotic mechanisms of nicotine have been 
documented. The majority of significantly altered genes from the nicotine
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exposure study were involved in drug metabolism; an additional DNA repair 
gene was expressed but not present in other exposure studies. Further 
examination of the nicotine gene-list found five of the sixteen genes are 
involved in atherosclerosis. These could be separated further into anti­
atherosclerosis and pro-atherosclerosis.
The anti-atherosclerosis genes CYP2E1, ELK1 and HIF1A have different 
mechanisms of action. The down-regulation of CYP2E1 would reduce reactive 
oxygen species (ROS), stabilising the initiation of inflammation (Parke and 
Sapota, 1996). Decreased expression of ELK1 in smooth muscle cells leads 
to an increase in the expression of proteins required for the differentiated 
function of these cells. Several disease states have been associated with a 
decrease in these muscle cell proteins e.g. atherosclerosis and asthma 
(Berger et al., 2002; Zhou et al., 2005). Down regulation of HIF1A inhibits 
foam cell formation, and hence, atherosclerosis (Jiang et al., 2007).
The pro-atherosclerosis genes were CYP7A1 and HMOX1. CYP7A1 encodes 
for a protein with a rate-limiting enzyme activity for bile acid synthesis (Cohen 
et al., 1992). Down regulation of CYP7A1 would result in a decrease of 
cholesterol absorption and would be classed as hypercholesterolemic, with a 
significant increase in the low density lipoprotein fraction (Pullinger et al., 
2002; Erickson et al., 2003); likely to result in an individual susceptibility to the 
development of atherosclerosis (Erickson et al., 2003). HMOX1 is a 
cytoprotective gene that reacts to oxidative stress. Induced expression of 
HMOX1 is one of the major defence mechanisms against oxidative stress 
(Brydun et al., 2007). This may indicate that reduced HMOX1 may be involved 
in the mechanism of atherosclerosis due to the over-production of ROS and 
increased inflammatory responses (Griendling and FitzGerald, 2003).
There are many biological effects exerted by cadmium on membranes, 
mitochondrial structure and function, DNA and gene expression (Pinot et al., 
2000). Oxidative stress is initiated by cadmium in many cell types; determined 
by decreased activity of antioxidants (Manca et al., 1994; Yang et al., 1997). 
The genes significantly altered by cadmium exposure were investigated for
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potential associations to cytotoxicity. Nine of a possible twenty genes were 
found to have cytotoxic associations; which could be further separated into 
pro- and anti-cytotoxic.
An anti-cytotoxic (i.e. a protective) mechanism was observed with ABCC1 and 
ABCC2; elevated levels of these genes in tumour cells leads to resistance to 
cytotoxic drugs (O'Connor, 2007). Another anti-cytotoxic mechanistic gene 
was BAX, down-regulation of which would inhibit the initiation of mitochondrial 
dysfunction (Wei et ai, 2001). Mitochondrial dysfunction could lead to the 
release of cytochrome c and which activation of DNA damage initiated 
apoptotic pathways (Shiu et al., 2007). The xenobiotic-metabolizing enzymes 
play a crucial role in the detoxification processes and bioactivation of several 
xenobiotic compounds (Lieber, 1997). CYP1A1 was elevated in this study, 
suggesting a cytoprotective role. Metallothioneins play a vital role in defending 
cells against heavy metals and oxidative stress (Kagi and Schaffer, 1988). In 
this study MT3 was elevated by 3-fold, similar to the results of a previous 
study with MT2A and cadmium exposure to lens epithelial cells, This resulted 
in a 20% protection against cadmium-induced oxidative stress (Hawse et al., 
2006). MVP is also known as a lung-resistance protein (Scheffer eta!., 1995), 
has a proposed role in drug resistance (Kowalski et al., 2007), and an up 
regulation may suggest a protective role.
Pro-cytotoxic genes, such as CCND1 is consistently inhibited in 
chemotherapy drug tests, when investigating development of resistance 
(Hernandez-Vargas et al., 2007). MET is also known as human growth factor 
receptor, protects cells from apoptosis (Kakazu et al., 2004), but in this study 
was down-regulated; indicating a decrease in protection against apoptosis. 
XDH  is associated with the reductive activation of chemotherapeutic agents 
and elevation of this gene observed in this study could lead to a greater rate 
of formation of oxygen radicals and significantly increased cytotoxicity (Yee 
and Pritsos, 1997).
Extensive research has been prompted into the potential biological effects of 
urethane given its tumourigenesis in humans (Ritchie et al., 2007;
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Strathopoulos et al., 2007). The principle targets/sites are the liver and lung 
(Siemiatycki et al., 2004) in animals, which has prompted extensive research 
into its mechanisms of action. The genes significantly altered by urethane 
exposure were investigated for potential associations to carcinogenicity. The 
urethane exposure study found ten of a possible sixteen significantly altered 
genes associated with carcinogenicity. Further analysis differentiated genes 
into pro- and anti-carcinogenicity.
Anti-carcinogenicity genes comprised of 90% of the significantly altered genes 
was demonstrated by BAX, also known as BCL2-associated X protein which 
suppresses DNA repair (Jin et al., 2006). In this investigation it was to be 
found the gene down-regulated, increasing genetic stability and inhibiting 
DNA damage. Inhibition of CASP10 is associated with the pathogenesis of 
trophoblast tumourigenesis (Fong et al., 2006), but in this study it was found 
at elevated levels, demonstrating anti-carcinogenicity. The CCND1 gene is 
elevated in human breast cancers (Wang et al., 2003), and yet it was 
observed to be inhibited. CHEK2 has been reported as an important signal 
transducer of cellular responses to DNA damage and a candidate tumour 
marker (Nevanlinna and Bartek, 2006). Significantly elevated levels of this 
gene would suggest increased anti-carcinogenicity. As observed in this study, 
elevated expression of CXCL10 has been to shown to limit the cancerous 
process (Palmer et al., 2001; Ben-Baruch, 2006). Also associations between 
increased EGFR and pulmonary adenocarcinomas have been reported 
(Nakamura et al., 2007). Down-regulation of this gene was observed, which 
could indicate an anti-carcinogenicity mechanistic action. This down- 
regulation was also observed with MET  (also known as HGFR), with similar 
consequences of an anti-carcinogenicity mechanistic role (Shia et al., 2005).
There were only two pro-carcinogenicity genes significantly altered in this 
investigation, CYP1A1 and PPARD. PPARD is a nuclear receptor implicated 
in tumourigenesis by the activation PTGS2\ a rate limiting enzyme for 
prostaglandin synthesis and tumour growth (Xu et al., 2006). Pro-carcinogens 
are substrates for CYP1A1, and up-regulation was observed in this study, and 
as such, thought to be associated to pro-carcinogenicity (Nebert and Dalton,
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2006). The low number of pro-carcinogenicity genes could be due to the 
bioavailability of the TSC or possible lack of activation of specific metabolic 
mechanisms (Balharry et al., 2008).
Formaldehyde is mutagenic and genotoxic (de Serres and Brockman, 1999). 
The mutagenic and genotoxic potential of formaldehyde is consistent with its 
ability to form cross-linkages between protein and single-stranded DNA (Merk 
and Speit, 1998). The genes significantly altered by formaldehyde exposure 
were investigated for potential associations to mutagenicity. The 
formaldehyde exposure study found six of a possible nineteen significantly 
altered genes associated with mutagenicity. Further analysis differentiated 
genes into pro- and anti-mutagenicity.
As mentioned previously, BAX suppresses DNA repair (Jin et al., 2006), and 
in this work, this gene down-regulated increased genetic stability and inhibited 
DNA damage. Investigation of the cell cycle regulatory protein CCND1 
suggested that it was found at elevated levels in tumour progression. The 
down-regulation of this gene inferred an anti-mutagenic role. CYP4B1 
activates amines that can be carcinogenic (Imaoka et al., 2001), and any 
down-regulation of this gene would be indicative of an inhibited activation of 
amine activity. Elevated E2F1 has been associated with increased sensitivity 
to apoptosis (Roos et al., 2007) and down-regulation of this gene may have 
an anti-mutagenic role.
Two genes of significant change have been associated with pro-mutagenicity 
(CDKN2A and CYP1A1). Inhibition of CDKN2A has been linked to specific 
activities that allow cells to evade differentiation processes; properties linked 
to malignancy (Berman et al., 2005). In comparison to literature searches on 
carcinogenicity of urethane, CYP1A1 has been associated with the mediation 
of ROS, which in turn creates an environment favourable to DNA damage 
(Hansen et al., 2007).
One specific gene (PTGS1) was not associated to the literature searches but 
was significantly induced in three out of the four compounds. PTGS1 is
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thought to be responsible for the production of prostaglandins that are 
responsible for a host of physiological responses (e.g. inflammation and 
platelet aggregation; Park et al., 2006).
This study identified nine genes; CCND1, CDKN2A, CYP7A1, CYP1A1, 
HMOX1, MET, PPARD, PTGS1 and XDH  that could be linked directly to the 
specific mechanisms of toxicity identified in this study (i.e. carcinogenic, 
cytotoxic, mutagenic and thrombogenic). These genes all have potential to act 
as genomic biomarkers for the onset and development of many respiratory 
diseases. Of these nine potential genomic biomarkers, three were of particular 
interests (CYP7A1, HMOX1 and PTGS1). Two genes were unique to a 
specific disease pathway, whilst the third was very highly up-regulated across 
three of the compounds. These genes have also been used previously in 
clinical research studies. CYP7A1 has been documented as an adult liver cell 
marker (Cai et al., 2007). HMOX1, the enzyme responsible for the synthesis 
of CO, is suppressed in lymphocytic bronchitis and airway luminal occlusion 
after transplantation (Minamoto et al., 2005). Inhibited PTGS1 (also known as 
COX1) has been known to increase side-effects of nonsteroidal anti­
inflammatory drugs (NSAIDs). Limited inhibition of COX1 increases the drug 
tolerability (Asero, 2007). This may support COX1 as a vital player in future 
drug development.
4 .6  C o n c lu s io n
The microarray analysis has provided transcriptional data on the exposure of 
the ETM to TSC. The technique has been shown to be highly-reproducible 
between replicates, confirmed by qPCR. This study has identified nine genes 
with the potential as genomic biomarkers of specific disease mechanisms 
associated with tobacco smoke. Another potential genomic biomarker has 
been identified which has not previously been related to tobacco smoke; 
PTGS1, the key enzyme in prostaglandin biosynthesis. This could result in a 
disruption of tissue homeostasis and the onset of disease. It represents a 
major genomic biomarker for TSC-related lung injury.
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C hapter  5:
P r o t e o m ic  A n a l y s is  In T h e  ETM  A fte r  
Ex p o s u r e  T o  T o b a c c o  S m o k e  C o m p o n e n ts
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5.1  In t r o d u c t io n
Transcription omics (Chapter 4) is widely-used to compare changes in gene- 
expression levels between a diseased and control state. Whilst this data is 
useful, differences in gene-expression do not necessarily correspond to 
differences in protein levels (Bye et al., 2008). There are also high-degrees of 
variability between mRNA and protein concentrations (Greenbaum et al., 
2003). Post-translational modifications, such as phosphorylation, can not be 
quantified or identified when examining the mRNA levels. In reality, the 
measurement of protein compared to nucleic acid expression could lead to a 
better understanding of disease processes and the identification of 
biomarkers (Hanash, 2003).
Functional proteomics, combined with mass spectrometry (MS), provides the 
tools required to study the response of cells to stimuli, i.e. xenobiotics, by 
identifying protein expression changes in the test and control scenarios 
(Conrads et al., 2001). Standard approaches to proteomics have been 1-/2 
dimensional electrophoresis followed by MS. In this gel-based system, 
proteins are separated by their isoelectric point (pi) and/or molecular weights, 
detected by staining, excised from the gel and digested prior to identification 
by MS. This approach requires extensive optimisation and is prone to 
experimental errors (Righetti et al., 2004). Although advances in differential- 
in-gel-electrophoresis (DIGE) technology have aided this technology, by 
allowing multiplexing for three separate protein mixtures (Wu etal., 2005).
In the following work, the proteomic change following TSC challenge was 
determined. The use of human tissue equivalent models of respiratory 
epithelium provided human protein data for identification of biomarkers that 
could be related to many respiratory diseases (Sexton et al., 2008). To 
measure differential protein expression, state-of-the-art tandem MS Time of 
Flight (TOF/TOF) Analyzer, Nano-LC (Dionex Ultimate 3000, Probot 
Microfraction Collector and Global Proteome Server (GPS) Explorer Software
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v3.6) and iTRAQ was utilised. The peptide analysis was carried out using 
MASCOT software.
5.2  Materials  and  S tock  Solutions
5 .2 .1  P r o t e in  Ex t r a c t io n , L a b e l l in g  a n d  Id e n t if ic a t io n
Materials: Supplier
Triethylammonium Bicarbonate (T7408) Sigma
Nonidet P40 (74385) Fluka
Phenylmethylsulfonyl Fluoride (93482) Fluka
Bovine Serum Albumin (B8667) Sigma
iTRAQ Reagents multiplex kit (4352135) Applied Biosystems
Trypsin (4352157) Applied Biosystems
Ethanol Fisher
Ultimate 3000 Nano-LC Dionex
Bio-SCX Dionex
PepMaplOO Dionex
PepMap75pm Dionex
Acetonitrile (43,913-4) Aldrich
Probot microfraction collector Dionex
CHCA (C2020) Sigma
4800 MALDI TOF/TOF Applied Biosystems
Trifluoroacetic acid (91709) Fluka
[Glu1] -  Fibrinopeptide B (F3261) Sigma
Table 5.1 Materials used and their suppliers. All suppliers are UK based unless 
stated
5 .2 .2  W e s t e r n  a n d  A n t ib o d y  D e t e c t io n
Materials: Supplier:
X-cell SureLockIM Mini-Cell SDS-PAGE Apparatus Invitrogen
140
P ro te o m ic  a n a ly s is  in t h e  ETM a f t e r  e x p o s u re  t o  to b a c c o  sm oke c o m p o n e n ts
Materials: Supplier:
X-cell II™ Blot Module Western Blot Apparatus Invitrogen
Hybond-P polyvinylidenedifluoride (PVDF) membrane Amersham
Chromatography Paper 3MM Whatman
P200 Gel Loading Tips Alpha Laboratories
Powerpac 300 Power Suppliers Biorad
X-OMATIM LS Kodak Film 18 x 24 cm Amersham
NuPAGE 4-12% Bis-Tris 1mm x 12 well (NP 0322 
BOX)
Invitrogen
Immobilon Western HRP Substrate (WBKLS0100) Millipore
Actin Primary Antibody (A-2066) Sigma
COX1 Primary Antibody (sc-19998) Santa Cruz, USA
Cystatin-A Primary Antibody (sc-32803) Santa Cruz, USA
Goat Anti-Rabbit IgG, HRP-linked Antibody (7074) Cell Signalling
Goat Anti-Mouse IgG, HRP-linked Antibody (7076) Cell Signalling
Table 5.2 Materials used and their suppliers. All suppliers are UK based unless 
stated
5.2.3 S t o c k  S o l u t io n s
MALDI matrix was prepared by making a CHCA (Sigma; C2020) 2mg/ml 
solution in 70% (v/v) acetonitrile in 0.1% (v/v) Trifluoroacetic acid (TFA) 
containing 10fmol/pl Glu-Fib); this solution was prepared as required.
Electrophoresis running buffers for pre-cast gels -  MOPS (Invitrogen; 
NP0001) were diluted appropriately to 1x for use and were stored at room 
temperature.
Transfer buffer was prepared as a 1x working solution containing 25mM Tris- 
HCI, 192mM glycine and 20% (v/v) analysis grade methanol (Fisher). This 1x 
working solution was stored at room temperature.
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Pre-stained SeeBlue Plus 2® molecular weight marker (Invitrogen; 
LC5925) was supplied as a ready-to-use protein marker and were stored in 
aliquots at 4°C.
PBS-Tween containing 0.1% Tween-20 detergent (v/v) in 1x PBS was 
prepared and stored at room temperature.
Blocking buffer was prepared as a 1x working solution containing 0.2% I- 
block (Tropix. Inc) and 0.02% (v/v) sodium azide (NaN3) supplemented in 
PBS-Tween. The blocking buffer was stored for up to 1 month at 4°C.
Immobilon Western HRP Substrate (Millipore) was supplied as two 
separate solutions stored at 4°C. Equal volumes of solution A and B (5ml 
total) were warmed to room temperature and mixed then allowed to stand for 
5 minutes prior to its application to the membrane (Section 5.3.7).
MESNA stripping buffer was prepared as a 1x working solution containing 
62.5mM Tris-HCI pH 6.8, 2% w/v SDS and 50mM 2-mercaptoethanosulfonate 
(MESNA; Sigma M-1511). MESNA stripping buffer was kept for no longer 
than two weeks and was stored at 4°C.
Trifluoroacetic acid (TFA) buffers: A = 2% acetonitrile in water with 0.05% 
(v/v) Trifluoroacetic acid (TFA) and B = 90% acetonitrile in water with 0.01% 
(v/v) TFA.
5.3 M e th o d s
5 .3 .1  P r o t e in  Ex t r a c t io n  a n d  p r e p a r t io n
The following techniques were all carried out at the Central Biotechnology 
Services, Cardiff University. The Protein from the TSC exposed and control 
ETM (NHBE cells) was isolated and labelled using the iTRAQ reagents 
(Applied Biosystems), as outlined in the Applied Biosystems (AB) iTRAQ
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Reagents Chemistry Reference Guide (2004). This labelling system consisted 
of isobaric tags with a charged reporter group that was unique to each of the 
four reagents (Figure 5.1). The four reagents had the same mass and upon 
fragmentation in MS/MS gave rise to four unique reporter ions (m/z = 114- 
117; Zieske, 2006). This technique was developed by Darryl Pappin at AB 
(Ross et al., 2004) and could be used for multiplexed profiling of up to four 
different samples.
r
Reporter
(Mass =114 thru 117)
Isobaric Tag
(Total mass = 145)
'P R G MS/MS fragmentation
Balance
(Mass = 31 thru 28)
Figure 5.1 iTRAQ™ Reagent Structure. iTRAQ reagents were non-polymeric, 
isobaric tagging reagents consisting of a reporter group, a balance group and a peptide 
reactive group (PRG; adapted from AB iTRAQ Reagents, 2008)
5.3.1 .1  P r o tein  Isolation  and  Q u a n tif ic a tio n
Frozen cell pellets were resuspended in 10mM triethylammonium bicarbonate 
with 1% (v/v) Nonidet P40 (NP®-40) and 10mM phenylmethylsulfonyl fluoride 
(PMSF) and incubated for 15 minutes on ice. Lysates were clarified by 
centrifugation (10,000 x g, 5 minutes) and quantified using the Bradford assay 
(Bradford, 1976). Briefly, sets of standards were made up using bovine serum 
albumin (BSA) (0 to 20pg/ml). Cell lysate was diluted 10-fold in 0.1% NP®-40 
and 200pl of sample was added to each well in a 96-well plate. Bradford
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reagent (50|jl) was added to each sample and the absorbance was read at 
590nm using a plate reader. Assays were performed in triplicate for each cell 
lysate and the mean value recorded.
5 .3 .1 .2  P r o t e in  La b ellin g
There were four main steps in the process of iTRAQ labelling (Figure 5.2). 
The first step required reducing and denaturing the sample, followed by 
blocking the cysteines. This was carried out by adding 1pl of denaturant to 
each 10pg of protein sample; this was then vortexed (10 seconds). A further 
2pl of reducing reagent was added to each sample tube and vortexed to mix 
followed by a centrifugation (12,000 x g, 1 minute). The sample tubes were 
then incubated at 60°C for 60 minutes. Post-incubation, the samples were 
centrifuged (12,000 x g, 1 minute) and 1pl of cysteine-blocking reagent was 
added. The sample was vortexed (10 seconds) and incubated at room 
temperature for a further 10 minutes. The second step required the protein 
sample to be digested with trypsin, which was carried out by adding 10pl of 
the trypsin solution to each sample tube. The sample tube was then vortexed 
(10 seconds) to mix and incubated at 37°C overnight. The sample tubes were 
then centrifuged (12,000 x g, 1 minute) and the third step was performed and 
involved the labelling of the protein digests with the iTRAQ reagents. The 
iTRAQ reagents needed to be at room temperature, and were reconstituted 
with 70pl of ethanol, vortexed for 1 minute followed by centrifugation (12,000 x 
g, 1 minute). The content of one iTRAQ reagent was transferred to one 
sample tube, the sample tubes were then vortexed (10 seconds) and 
centrifuged (12,000 x g, 1 minute) prior to an incubation at room temperature 
for 60 minutes. The final step in the labelling process was to combine the 
iTRAQ reagent-labelled sample tubes into one fresh tube, with a final vortex 
(10 seconds) and centrifugation (12,000 x g, 1 minute).
5 .3 .2  L C  S e p a r a t io n  o f  i TR A Q  R e a g e n t  La b e l l e d  P e p t id e s
Equal volumes of the digested peptides labelled with different iTRAQ reagents 
were mixed and peptides corresponding to 2pg of undigested protein were
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Parallel Denature 
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PRG+.
PRG +
MS/MS
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b
114
113
112
111
Peptide fragments 
Reporter ions different
Figure 5.2 Schematic overview of a multiplex iTRAQ reaction. General 
workflow for four samples (S1-S4), each sample is reduced, alkylated and ezymatically 
digested with trypsin, the peptides are then labelled and combined and analysed by LC- 
MS/MS. The resultant mixture provided a set of single precursor ions, for the identification of 
single proteins from a known sample (adapted from Zieske, 2006)
separated on a nano-LC system using a two-dimensional salt plug method. 
Peptides were applied to a SCX cartridge (BioX-SCX, 500pm, 15mm, 5pm) 
that was plumbed upstream of the RP desalting cartridge (PepMaplOO, 
300pm, 5mm, 100 A ). Samples were separated on the SCX cartridge using 
20pl step elutions with increasing concentrations of NaCI (100mM, 200mM, 
400mM, 800mM, and 1M). Each step elution was loaded onto the RP 
desalting column where the eluting peptides were desalted. Peptides were 
then separated using a C18 column (PepMap75pm id, 30cm, 3pm, 100 A ) at
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a flow rate of 300nl/min. Peptides were separated using a two-step gradient 
with the first step from 5 to 20% solvent B for 25 minutes and the second step 
from 20% to 50% solvent B for 21 minutes. A chromatogram was recorded at 
214 nm. Fractionation of the peptides into 8 second spots on a LC-matrix 
assisted laser desorption ionization (MALDI) sample plate was performed with 
a Probot Microfraction Collector (Dionex). MALDI matrix was continuously 
added to the column effluent via a p-tee mixing piece at a flow rate of 
1.4pl/min.
5 .3 .3  M a s s  S p e c t r o m e t r y  a n d  P r o t e in  Id e n t if ic a t io n
MS was performed using a MALDI TOF/TOF mass spectrometer (AB 4800 
MALDI TOF/TOF Analyzer) with a 200Hz solid-state laser operating at a 
wavelength of 355nm (AB; High Mass Linear Analysis of Intact Proteins on 
the 4800 MALDI TOF/TOF™ Analyzer: Technical Note) After screening of all 
LC-MALDI sample positions in MS positive reflector mode, using 800 laser 
shots (mass range 700-4000Da; focus mass 2000), the fragmentation of up to 
6 automatically selected precursors was performed (most intense ion signals 
per spot position with signal to noise ratio (S/N) above 50 and strongest 
analysed first). Internal calibration of each spot in MS was achieved against 
the Glu-Fib added to the matrix. Common trypsin autolysis peaks and matrix 
ion signals and precursors within 300 resolution of each other were excluded 
from the selection. In MS/MS positive ion mode 4000 spectra were averaged 
with 1kV collision energy (collision gas was air at a pressure of 1.6 x 10'6 Torr) 
and default calibration.
5 .3 .4  D a t a  a n d  S ta tist ic a l  A n a l y s is
MS/MS queries were performed using the MASCOT Database search engine 
v2.1 (Matrix Science Ltd), embedded into Global Proteome Server (GPS) 
Explorer software v3.6 on the Swiss-Prot database (O’Donovan et al., 2002). 
Searches were restricted to the human taxonomy with trypsin specificity (one 
missed cleavage allowed); the tolerances set for peptide identification 
searches was 0.3 Da for MS/MS. Cysteine modification by
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methylmethanethiosulfonate (MMTS) and iTRAQ modification of the N- 
terminus and lysines was employed as a fixed modification. Quantitation 
based on signature-ion peak areas was performed using GPS-Explorer 
software. Fold-changes (FC) between the treated samples and the reference 
control samples were calculated by the software for each of the quantified 
peptides of the same protein. Search results were evaluated by protein and 
peptide score confidence intervals (Cl) % calculated in the GPS-Explorer 
software and based on the MASCOT score (Gluckmann et al., 2007). In order 
to get average FC, all single peptide expression values with minimum Cl% 
above 50, were normalized for each protein on the median. Protein 
identification results with Cl% score above 95 were accepted, all the 
identifications in (Table 5.5) were additionally manually inspected for 
correctness. Data from three independent biological replicates were examined 
for consistent protein changes that were more than 2-fold altered.
The significance of differentially expressed proteins could only be resolved 
following statistical analyses (Gluckmann et al., 2007). The appropriate 
statistical analysis in this instance was a 2 Class Unpaired t-test (Tian et al., 
2008). The two-tailed Student’s t-test is a test used to examine a difference 
between mean values of two groups of data. A Null Hypothesis of no 
expression-level difference in individual proteins between control and nicotine, 
FA, urethane and cadmium ETM exposure was adopted. The resultant 
statistical value could then be used to determine which proteins were 
significantly differentially expressed. A p value of <0.05 was deemed 
significant. The statistically differentially expressed proteins identified, were 
processed using the Genecodis (Carmona-Saez et al., 2007), to determine 
the molecular function data of each protein.
5.3.51D SDS P a g e
Pre-cast gels (Invitrogen) were prepared by rinsing the gel cassette with its 
storage buffer and by carefully removing the tape covering the slot at the back 
of the gel cassette and the well comb. The exposed loading wells were then
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rinsed with 1x electrophoresis running buffer. The gel cassette was inserted 
into the lower buffer chamber assembled with the gel tension wedge, adjacent 
to the buffer core. Wells were filled with 1x electrophoresis running buffer. 
Protein samples to be loaded onto the gels were first prepared. Following the 
quantification of protein concentration, an equal volume of 2x GSB (100mM 
Tris-CI pH6.8, 20% Glycerol, 0.2M DTT, 4% SDS, 0.02% bromophenol blue) 
was added and the samples were heated at 100°C for 5 minutes on a dry 
heating block. These samples, along with a pre-stained molecular weight 
marker, were loaded onto the gels by pipetting under the running buffer using 
the P200 gel loading tips. Gels were run at 200V for 50 minutes to 1 hour.
5.3.6 W e s te rn s
Hybond-P polyvinylidenedifluoride (PVDF) membrane was soaked in analysis 
grade methanol before use and then equilibrated in transfer buffer. 
Polyacrylamide gels were placed onto the membranes between two pieces of 
Whatman 3MM filter paper soaked in transfer buffer in a blotting cassette. 
Western blotting was carried out using an X-cell II™ Blot module inserted into 
an X-cell SureLock™ Mini-Cell unit (Invitrogen) at 30V, 250mA for 60 minutes. 
The blots were then washed in PBS-Tween.
5.3.7 A n tib o d y  D e te c tio n
Western Blots were incubated in a sealed polyethylene bag with 
approximately 15ml-20ml of blocking buffer for 1 hour at room temperature on 
an orbital shaker (Stuart-Scientific). The blocking buffer was then replaced 
with 10-20ml of primary antibody diluted to the required concentration in 
blocking buffer (Table 5.3). To fully utilise each blot they were cut into three 
sections, this was permitted by the differences in MW of COX1, Actin and 
Cystatin-A (Figure 5.3). The blots were incubated with primary antibody 
overnight at 4°C. Post-incubation, blots were then washed three times for at 
least 10 minutes in PBS-Tween. Subsequently, the blots were incubated for 1 
hour with 10-20ml of appropriate horseradish peroxidise (HRP)-conjugated
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secondary antibody diluted to 1/10,000 with blocking buffer (see Table 5.3). 
Blots were then washed again three times for at least 10 minutes in PBS- 
Tween. Following this, the blots were incubated with Immobilon Western HRP 
Substrate for 5 minutes in a section of polyethylene film. Any excess reagent 
was removed and blots were exposed to autoradiograph film; through a new 
section of polyethylene film. Following exposure each section of the blot was 
stripped and placed incubated in a sealed polyethylene bag with 
approximately 15ml-20ml of MESNA stripping buffer for 30 minutes at 50°C.
MW Marker 
(kDa)
Samples
Cox1 (72kDa) 
Actin (45kDa)
Cystatin-A (11 kDa)
Figure 5.3 Schematic overview of a Western blot. The western blot was cut into 
three sections to allow simultaneous antibody detection of three different antibodies; the 
scissors indicate where the cuts were made
1° A ntib o d y D il u t io n MW 2° A n tib o d y D il u t io n
Cox1 1:200 7 2 k Da M o u s e 1:10000
A ctin 1:10000 4 5 k Da Ra b b it 1:10000
C y s t a t in -A 1:200 1 1k Da M o u s e 1:10000
Table 5.3 Primary and secondary antibodies for Westerns. Overview of the 
primary (7°) and secondary (2°) antibodies with their optimised dilution factor used in an 
antibody detection of a western technique for proteomic validation (Section 5.3.7)
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5.4 R esu lts
5.4.1 P ro te in  C o n c e n tra tio n
The protein from control and TSC exposed ETM cells (n=3; Table 5.4), 
indicated that the protein yield for each sample was sufficient for proteomic 
analysis.
Exposure of 
ETM
Abs A 
(590nm)
Abs B 
(590nm)
Abs Av 
(590nm)
pi for 100pg 
protein
Nicotine3 1.025 0.898 0.962 79.4
Nicotineb 0.93 0.935 0.933 84.7
Nicotine0 0.817 0.667 0.742 80.68*
Cadmium3 1.016 0.977 0.997 73.5
Cadmiumb 0.925 0.94 0.933 84.7
Cadmium0 0.829 0.687 0.758
*
77.7
Urethane3 1.006 0.837 0.922 86.2
Urethaneb 0.965 0.919 0.942 82.0
Urethane0 0.85 0.723 0.786 72.9*
Formaldehyde3 0.929 0.938 0.934 84.7
Formaldehyde13 0.963 0.875 0.919 87.7
Formaldehyde0 0.924 0.854 0.889 59.2*
Control3 0.934 0.832 0.883 96.2
Control13 0.865 0.841 0.853 104.2
Control0 0.954 0.962 0.958 79.4
Table 5.4 Bradford assay data and the volume required for a total protein 
concentration of 100pg. Absorbance (590nm) values of a Bradford assay to determine 
protein concentrations (n=3) isolated from control and TSC exposed ETM; * indicates values 
were taken from a secondary standard curve
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5 .4 .2  M a s s  S p e c tro m e try  an d  P ro te in  Id e n tific a tio n  A n a ly s is
Analysed MS data (n=7) from the exposed cell cultures was analysed to show 
differential protein expression for the four different TSC (Table 5.5). When 
comparing protein expression in cadmium, formaldehyde and urethane to 
PBS, 413 proteins were identified. This number was reduced to 250 protein 
identifications when the parameter of two or more peptides was imposed for 
an individual identification. The Gene Ontology information, prepared using 
Genecodis (Carmona-Saez et al., 2007), for molecular function was carried 
out on all proteins identified in each TSC (Figure 5.4).
When placing the final stringent parameters (Section 5.3.4), which included 
data from three independent biological replicates, consistent protein changes 
altered by more than 2-fold identified 10 proteins (Table 5.5). Some of the 
largest changes, as shown in Table 5.5, were defence proteins (cystatin-A, 
ubiquitin and protein plunc precursor), inflammatory proteins (complement-C3 
and protein plunc precursor) and structural/development proteins (cornifin-B 
and calmodulin).
When comparing the protein expression of the TSCs to PBS; two proteins 
(cystatin-A and ubiquitin) were consistently induced by 2 fold or more across 
all TSC. Cystatin-A and ubiquitin proteins also exhibited the greatest 
inductions (Table 5.5). Cadmium, formaldehyde and urethane had fewer 
numbers of proteins with a 2-fold expression, compared with nicotine, which 
had nine proteins altered by 2-fold or more.
Further analysis placed all the proteins identified into the following functional 
and molecular groups (annotated by Genecodis): (1) protein binding, (2) 
nucleotide binding, (3) oxidoreductase activity, (4) calcium ion binding, (5) 
ATP binding, (6) Nucleotide binding with ATP binding, (7) Structural molecule 
activity and (8) Nucleotide binding with protein binding. These groups were 
common for all compounds, with the protein binding being the functional 
group containing the greatest numbers of proteins (Figure 5.4).
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Figure 5.4 Molecular function grouping of all the proteins identified from TSC exposures. Genecodis was used to
obtain the gene oncology for all proteins that were identified by parameters set out in Section 5.3.4. All proteins, regardless of fold-change, were 
used in this analysis
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Nicotine Cadmium Urethane Formaldehyde
Protein ID Fold P-value Fold P-value Fold P-value Fold P-value Protein name
CYTA HUMAN 5.23 0.005 6.7 0.011 3.29 0.003 3.8 0.042 Cystatin-A
C 03 HUMAN 2.97 0.0072 - - 2.66 0.044 - - Complement C3 precursor
UBIQ HUMAN 3.27 0.014 3.86 0.00001 2.42 0.00001 3.45 0.021 Ubiquitin
CALM HUMAN 2.33 0.0007 3.56 0.018 - - - - Calmodulin
AL3A1 HUMAN - - 2.1 0.015 - - - - Aldehyde dehydrogenase
SPR1B HUMAN 2.37 0.041 - - - - 5.63 0.00001 Cornifin-B
CD9 HUMAN 3.09 0.003 - - - - - - CD9 antigen
PLUNC HUMAN 2.62 0.025 - - - - - - Protein Plunc precursor
MARCS HUMAN 2.36 0.026 - - - - - - Myristoylated alanine-rich C-kinase substrate
NGAL HUMAN 2.38 0.002 - - - - - - Neutrophil gelatinase-associated lipocalin precursor
Table 5.5 Overview of the proteomic expression data from exposed cell cultures. The proteins that were identified by parameters 
set out in section 5.3.4. Protein names and abbreviations in the NCBI database of the proteins are indicated. Coloured cells highlight protein homology 
between two or more TSC exposures
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5.4 .3  W e s t e r n  B l o t  A n a ly sis
The aim of Western blot analysis was to determine whether the changes in 
protein expression predicted by the nano-LC and MS were accurate. COX1, 
actin, and cystatin-A were selected for Western blotting analysis from the list 
of experimentally altered proteins (Figure 5.5). COX1 was selected due to the 
elevated gene expression data observed in cadmium, formaldehyde and 
urethane (Section 4.4.2), actin was used for normalisation of the blot. Western 
blots were then scanned and the densitometry of the bands quantified by 
using Genetools software (Table 5.6)
C F N P U
COX1
Actin
Cystatin-A
Figure 5.5 Analysis of four proteins by western blotting. Whole cells extracts 
were generated from TSC exposed of the MatTek EpiAirway tissue samples. They were 
resolved by 1D SDS-PAGE electrophoresis followed by Western blotting. Resolved proteins 
were analysed by immunoblotting using primary antibodies specific to COX1, actin and 
cystatin-A. Key: C-cadmium, F-formaldehyde, N-nicotine, P-PBS control and U-urethane
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TSC C y s ta t in -A  Induction COX1 In d u c t io n
C a d m iu m 4.2 0.9
F o r m a l d e h y d e 3.1 0.7
N ic o t in e 2.5 0.8
U r e t h a n e 4.0 1.0
Table 5.6 Quantification of protein induction by immunoblotting. Western 
blots were scanned and the bands quantified by densitometry using Genetools software 
(n=3). The cystatin-A induction result concurs with the data from the iTRAQ, experiment
5.5 D is c u s s io n
Traditional proteomic methods have utilised 2-dimensional gel 
electrophoresis, coupled with MS for the identification of changes in protein 
expression (Wattiez and Falmagne, 2005; Malard et al., 2005; Nicholas et a/., 
2006). This technique has several limitations, especially the fact that only the 
most abundant proteins will be detected, severely limiting the depth of 
coverage of the experiment (Tyers and Mann, 2003). With the advent of DIGE 
technology, gel-electrophoresis has evolved to permit two different proteins 
samples to be labelled with different fluorescent dyes. These are mixed and 
electrophoresed on the same gel but the throughput is relatively low (Wu et 
al., 2005).
However, recent advances in liquid chromatography (LC) now includes nano- 
LC which can be coupled with a strong cation exchange column (SCX) and 
reverse phase (RP) separation of complex cell lysates. The key advantage of 
this approach was that the peptides resolved from the SCX column could be 
directly placed into the MS/MS system (Wu et al., 2005). As proteomic 
techniques become more established, the need to move from the qualitative 
to the quantitative is ever increasing. The type of proteomic study utilised for 
this research project involved a differential expression analysis. This approach 
included comparative analysis of protein expression in the normal and
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exposed tissue, where these identified changes in protein expression may 
represent markers (Pan et al., 2008; Joo Lee et al., 2008). To perform this 
study we required multiplexing, broad-proteome coverage and absolute 
quantification and iTRAQ met these criteria.
Applied Biosystems iTRAQ reagents were a multiplexed set of four isobaric 
reagents (same mass) which are amine specific and yield labelled peptides 
that were identical in mass, and hence, also identical in single MS mode. 
However, they produced strong, diagnostic, low-mass MS/MS signature ions 
allowing for quantitation of up to four different samples simultaneously 
(Aggarwal etal., 2006).
A complementary approach was required to evaluate the biological responses 
post-genomics (Chapter 4), as means to compare protein function with the 
identified biomarkers of exposure and harm, for specific mechanisms of lung 
injury attributed to smoking. In this study, a subtoxic dose of nicotine, 
cadmium, urethane and formaldehyde had significant effects on lung epithelial 
protein expression.
As described in Chapter 4, the effect of nicotine in the animal and cell system 
has been comprehensively researched (Yildiz, 2004; Hukkanen et al., 2005). 
For the purpose of this study, only the thrombogenic and atherosclerotic 
mechanisms of nicotine were investigated. The majority of significantly altered 
proteins identified were involved in ‘binding’ and was consistent for all 
exposures carried-out (e.g. ANXA1; Skrahina et al., 2008). A total of nine 
proteins were identified (cystatin-A, complement C3, ubiquitin, calmodulin, 
cornifin-B, CD9 antigen, protein plunc, myristoylated alanine-rich protein 
kinase C substrate and neutrophil gelatinase-associated lipocalin) of which 
seven could be associated with atherosclerosis.
There were two proteins not directly related to atherosclerosis, one of which 
was a plunc protein. Plunc is classed as a defence protein believed to function 
in the innate immune response and involved in inflammatory responses to 
irritants in the upper airways (Bingle and Craven, 2002). This finding has also
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been observed by other researchers (e.g. Lindahl et al., 2001) for inhaled 
xenobiotics (i.e. exposed to epoxy). This protein may be used as marker of 
irritancy. The second protein with no associations to atherosclerosis was 
cornifin-B. Cornifin-B is expressed in squamous tissue and normally absent in 
normal mucociliary epithelium but increased levels were expressed when 
exposed to environmental toxicants (Tesfaigzi and Carlson, 1999). The same 
study also indicated that this protein could be induced under certain states of 
cell proliferation. No link to atherosclerosis has been published.
The remaining significantly altered proteins (cystatin-A, complement C3, 
ubiquitin, calmodulin, CD9 antigen, myristoylated alanine-rich protein kinase C 
substrate and neutrophil gelatinase-associated lipocalin) could be separated 
further into anti-atherosclerosis and pro-atherosclerosis associations.
The anti-atherosclerosis protein cystatin-A is another defence protein that was 
induced. Cystatin-A inhibits cysteine proteases, which play a central role in 
extracellular matrix (ECM) remodelling. ECM remodelling has been implicated 
in the progression of cardiovascular diseases (Bengtsson et al., 2008; 
Lutgens et al., 2007). Ubiquitin is a regulatory protein that labels proteins for 
proteasomal degradation; other functions equally important include stability 
and function of many proteins (Ventii and Wilkinson, 2008). Ubiquitin is also 
involved in a number of biological processes (e.g. inflammation and 
apoptosis), that contribute to atherosclerosis. The induction of ubiquitin 
proteins has also been related to the production of coronary plaques 
(Herrmann et al., 2002). Myristoylated alanine-rich protein kinase C substrate 
(MARCKS) is involved in the airway homeostatic process, since it is one of 
the molecules regulating the secretion of the mucin (Park et al., 2008). A 
recent study by Guo (2007), highlighted the rapid recruitment of MARCKS to 
membrane rafts that would mediate S1P stimulation, and enhanced 
endothelial barrier integrity; failure of this barrier could result in 
atherosclerosis. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein 
capable of binding small lipophilic substances (Flower, 1994). NGAL is also 
expressed by epithelial cells during inflammation or injury (Gwira etal., 2005). 
It is thought that NGAL can be induced by a number of xenobiotics but this
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induction would act as an anti-apoptotic effect (Tong, 2005). Recent studies 
have indicated NGAL as a marker of several diseases (Moniaux et al., 2008; 
Bennett et al., 2008) but this was not due to the detrimental effect of the 
protein on the disease. In the case of atherosclerosis, its induction has been 
associated with vascular repair (Bu et al., 2006).
The remaining proteins (complement C3, calmodulin and CD9) can be 
classed has having pro-atherosclerosis associations. Studies have shown that 
atherosclerosis is an inflammatory disease (Ross, 1999) and C3 is a mediator 
of the inflammatory process (Muller-Eberhard, 1988). Past studies have 
indicated the elevated concentration of C3 in patients with atherosclerosis 
(Geertinger and Sorensen, 1973). Recent investigations have corroborated 
these findings with the added information that induced C3 was involved in the 
progression of atherosclerosis (Szeplaki et al., 2004). Calmodulin plays a role 
in several biological processes such as inflammation, metabolism, apoptosis 
and muscle contraction. Calmodulin is vital for proteins unable to bind 
calcium, and as such, use calmodulin as a calcium sensor and signal 
transducer (Stevens, 1983). Calmodulin is thought to be constitutively- 
expressed in eukaryotic cells; however, expression can vary during the cell 
cycle (Koller and Strehler, 1993). Atherosclerosis can be characterised by the 
presence of lesions called atheromatous plaques (Gamble, 2006). It has been 
suggested that one of the processes of this disease is the calcium 
precipitation which binds the cholesterol with the plaque precursor matrix; one 
of the components of this matrix is calmodulin (Gamble, 2006). By inducing 
calmodulin, its increase triggers (up-regulate) plaque precursor matrix and 
initiates the atherosclerosis process (Chen et al., 2002). CD9, a cell surface 
protein that plays a role in cell development, regulation and growth, modulates 
cell adhesion and migration (Maecker et al., 1997; Berditchevski, 2001). It has 
also been implicated in platelet activation and aggregation events (Jennings 
et al., 1990). CD9 can be found expressed on macrophages and has been 
shown to enhance the juxtacrine mitogenic activity, which in turn, can lead to 
the development of atherosclerosis (Ouchi eta!., 1997).
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As previously described in Chapter 4, there are many biological effects 
exerted by cadmium on membranes. The majority of candidate proteins 
identified from the cadmium exposure study were involved in protein binding. 
This was consistent for all exposures, although the molecular function profiles 
were very similar for all compounds there was an increase in calcium ion 
binding. The four proteins (cystatin-A, ubiquitin, calmodulin and aldehyde 
dehydrogenase) significantly altered by cadmium exposure were investigated 
for potential associations to cytotoxicity. Of the four significantly altered 
proteins, three proteins (cystatin-A, ubiquitin, calmodulin) had also been 
induced by nicotine but all four had no associations with cytotoxicity. Cystatin- 
A is a protease inhibitor and studies have shown it to suppresses ultraviolet B- 
induced apoptosis (Takahashi et al., 2007), indicating the protective/anti- 
apoptosis mechanisms. Ubiquitin is in the centre of cellular proteolysis and 
using its degradative capacity has become integral to processes in the cell 
(i.e. DNA repair; McBride et al., 2003). Oxidative stress is initiated by 
cadmium in many cell types, as determined by decreased activity of 
antioxidants (Manca etal., 1994; Yang et al., 1997). The response of ubiquitin 
to oxidative stressors has been examined by Grunge (2005) and increased 
levels of oxidative stress induced the degradation rate of the oxidised proteins 
(Grune et al., 1995). As mentioned previously in this section, calmodulin plays 
a role in several biological processes such as inflammation and apoptosis 
(Stevens, 1983) but exposure to reactive oxygen intermediates (ROI) can 
activate signalling pathways that are considered to prevent cell death. The 
mechanism to prevent apoptosis is thought to be the ROI-induced 
phosphorylation of calmodulin, leading to the inhibition of calmodulin- 
dependent kinases (Franklin et al., 2006). The final protein significantly and 
uniquely altered by the cadmium exposure was aldehyde dehydrogenase 
(ALDH-2), which plays a major role in the detoxification of aldehydes. 
Research of ALDH-2 has concentrated on its deficiency in the oxidative 
stress-related diseases (Ren, 2007; Wenzel et al., 2008). The up-regulation of 
this protein would benefit the anti-oxidant defensive mechanism.
The biological effects and target tissues of urethane have been documented 
(Siemiatycki et al., 2004) and the proteins that have been significantly-altered,
159
P r o t e o m ic  a n a l y s is  in  t h e  E T M  a f t e r  e x p o s u r e  t o  t o b a c c o  s m o k e  c o m p o n e n t s
post-urethane exposure, have been investigated for potential associations to 
carcinogenicity. Two principle proteins can be classed as being anti- 
carcinogenic and include cystatin-A (also known as stefin-A) and ubiquitin. 
Cystatin-A functions as a cysteine protease inhibitor and has the potential to 
be a biomarker (Kehinde et al., 2008). Its up-regulation in lung tumour 
samples compared to normal lung tissue suggests it is able to counteract 
(suppress) harmful tumour-associated proteolytic activity (Parker et al., 2008; 
Werle et al., 2006). Ubiquitin’s ubiquitinous (and hence its name) functions of 
degradation, proliferation and apoptosis reveals the importance of its role in 
carcinogenesis (Voutsadakis, 2008; Wolf and Hilt, 2004). In this work, its 
regulation once again pointed to a role in defensive/protection for cell survival 
(Sun et al., 2004).
The remaining protein identified by exposure to urethane could be classified 
as being pro-carcinogenic. Complement C3 plays a vital role in the activation 
of the inflammatory process, especially in airway hyper-responsiveness 
(Walters et al., 2002). There is evidence that links inflammation to cancer 
development (e.g. Crohn’s disease; Weitzman and Gordon, 1990; Shacter 
and Weitzman, 2002). Also users of anti-inflammatory drugs have a reduced 
development of cancer (Williams et al., 1999; Meier et al., 2002). These 
observations may indicate therapeutic strategies. Nevertheless, a study by de 
Visser (2004) lends serious doubt regarding the actual function of C3, and it’s 
accumulation in inflammatory cells.
Formaldehyde has the potential to be mutagenic and genotoxic due to the 
ability to form cross-linkages between protein and single stranded DNA (Merk 
and Speit, 1998). The proteins significantly altered by FA exposure (cystatin- 
A, ubiquitin and cornifin-B) were investigated for potential associations to 
mutagenicity. Cystatin-A, ubiquitin and cornifin-B all have anti- 
mutagenic/protection properties (Parker et al., 2008; Tesfaigzi and Carlson, 
1999; Sun etal., 2004).
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One specific gene (PTGS1), highlighted in Chapter 4, was significantly 
induced in three out of the four compounds. PTGS1/COX1, is thought to be 
responsible for the production of prostaglandins, which in turn are responsible 
for a host of physiological responses (e.g. inflammation and platelet 
aggregation; Park et al., 2006). Western blot analysis indicated a decreased 
induction of protein expression, except for urethane, which induced no change 
in protein expression, despite the highly significant changes at the gene level. 
This result was also observed by Martey et al., (2004). This study examined 
the effect of cigarette smoke on lung fibroblasts, in particular, COX2 and 
prostaglandin E2 (PGE2). The conclusion of that investigation was COX2 and 
not COX1, was the key enzyme responsible to the induction of PGE2 after 
exposure of cigarette smoke.
5.6 C o nclusio n
The proteomic analysis utilising iTRAQ™, nano-LC and MALDI TOF/TOF MS 
has provided protein data on the exposure of the ETM to different TSC. The 
technique has been shown to be reproducible between replicates and this has 
been confirmed by using Western blotting and antibody detection. Two 
proteins were identified (cystatin-A and ubiquitin) to be significantly induced 
for all TSC exposures and could be described as ‘defence proteins’; due to 
their protective properties and mechanisms. Consequently, they represent 
potential biomarkers of general lung injury. This work also identified three 
proteins (complement C3, calmodulin and CD9) that could be used as 
biomarkers of specific disease mechanisms (e.g. platelet activation and 
aggregation associated with tobacco smoke, e.g. atherosclerosis). The protein 
COX1 was also analysed, using Western blotting with antibody detection, due 
to its significant induction at the genomic level. There was no significant 
change at the protein level to indicate that COX1 could not be used as a 
potential protein biomarker.
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6.1 O v e r v ie w
The overall objective of this research was to identify intelligent biomarkers in 
human respiratory epithelia following exposure to selected particle (e.g. 
cadmium and nicotine) and vapour phase (e.g. formaldehyde and urethane) 
tobacco smoke components (TSC). The key components were selected for 
their thrombogenic capacity (nicotine), cytotoxicity (cadmium) and production 
of reactive metabolites during xenobiotic metabolism (formaldehyde and 
urethane), to provide a holistic approach towards the identification of 
biomarkers in the pulmonary epithelium (i.e. cells derived from human primary 
explant tissue) in vitro.
Scientific reviews of the chronic inhalation studies of mainstream cigarette 
smoke in all five species of laboratory animals (e.g. rats, mice, hamster, dog, 
non-human primates) used to evaluate carcinogenic potential, revealed no 
statistically significant increase in the incidence of malignant lung tumours and 
atherosclerosis following exposure to smoke. Furthermore, these findings 
were not consistent with the epidemiological results observed in human 
smokers. The outcome of the comprehensive animal studies reviewed does 
support the idea that research should focus on the use of human tissue to 
corroborate the epidemiological findings. This obviously limits what can be 
achieved using acute/chronic exposure studies to cigarette smoke and/or 
various tobacco components. It is also difficult to study environmental 
contaminants such as tobacco smoke because of methodological problems in 
testing entire atmospheres. Most investigations are based on in vivo and in 
vitro experiments that use model substances and surrogate mixtures to 
simulate the real life situation. In this respect, in vitro systems, in particular, 
offer the use of human target cells and comparing the results with human 
data. This eliminates any difficulties in extrapolating animal data to humans, 
and reduces the need for animals in testing such atmospheres.
An important research objective was to carry out conventional toxicological 
analysis to establish the dose of the various TSC required to induce
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alterations in epithelial resistance, secreted surface proteins and release of 
inflammatory markers. It was imperative that the final working doses used 
were sub-toxic, since the aim was to identify the important biomarkers 
involved with toxicant stress and avoid studying dead or dying cells.
The first hypothesis for this study was concerned with the premise that the 
“use of human respiratory epithelia (normal tracheal-bronchial epithelia) 
was a viable in vitro alternative to the rodent (e.g. rat) lung model (in 
vivo)”. When compared to a standard, epithelial, mono-layer culture, this 
system more closely resembled human bronchioles, both morphologically and 
physiologically, and therefore, deemed a viable alternative to the rat lung 
model (in vivo) [e.g. Hermann et al., 2004; Grainger et al., 2006; BeruBe et 
al., 2009]. For the system to be judged as a viable alternative to a rat lung 
model for toxicological studies, it was important that the system originated 
from normal (non-immortalised) cells. It was equally important to choose a 
human-derived tissue model in order to avoid the inevitable species-related 
differences that could compromise experimental results. The cell-cell
interactions that occur in vivo (but not generally present in single-cell
cultures), can significantly alter the cellular effects of many toxins. The range 
of these effects can only be fully-investigated in a biological system capable of 
transcribing and translating genes in response to the action of toxins. The 
ETM (i.e. EpiAirway™ Tissue) consisted of cells derived from healthy, human, 
primary, explant tissue (i.e. normal human bronchial epithelium; NHBE), as 
opposed to lung tumour or diseased tissue. Consequently, the cells were
genotypically and phenotypically more representative of normal epithelia than
other commonly used models (e.g. A549 [Padar et al., 2005] and BEAS-2B 
[Penn et al., 2005]). The overriding advantage of this in vitro tissue model was 
that the epithelium was cultured to form a 3-dimensional, pseudo-stratified 
state which exhibited a functional mucocilliary phenotype with tight junctions, 
as observed in vivo.
The second hypothesis was based upon the supposition that “exposure of 
the human respiratory epithelia to tobacco smoke components (vapour 
and particle phases) caused harm”. This was indeed, the circumstance,
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whereby acute, sub-toxicological exposures of the ETM to the four different 
TSCs evoked analogous biochemical and physiological responses; as 
measured by conventional toxicology assays and complimentary 
histopathology and IHC). The responses induced cell proliferation, increased 
protein secretion, elevated cell viability, electrical resistance and cytokine 
expression. These communal response patterns could be likened to a 
protective response or potentially an over-correction to the damaged airway 
epithelium. This so-called, “protective response”, was typified by an 
immediate peak in all the measured toxicological parameters, followed by a 
subsequent decline, as the TSC concentrations were increased. This dose- 
response relationship can also be described as a hormetic response but 
toxicological thinking has so far been hesitant to accept the existence of this 
response (Calabrese, 2004). At high concentrations of the TSC, the elevated 
responses were over-whelmed and all the biomarkers of toxicity rapidly 
deteriorated, i.e. decreased cell numbers, cell viability, electrical resistance 
and cytokine expression. The only exception to this was the increased levels 
of protein released into the apical surface wash. Detailed morphological 
changes in the cellular and tissue architecture for each TSC concentration 
investigated revealed four key pathological modifications: (1) hyperplasia, (2) 
hypertrophy, (3) cytolysis and, (4) necrosis. In conjunction with these findings, 
targeted IHC assays also resolved three discrete zones of tissue injury and 
repair: (1) the apical region and its Goblet cells; (2) the suprabasal region 
reactive intermediate cells; (3) the basal zone.
The third hypothesis considered the postulation that “genomics and 
proteomics can be utilised to identify biomarkers of exposure and harm 
in the human respiratory epithelia to tobacco smoke components”. This 
hypothesis was resolved to be correct in that a complementary approach was 
required to evaluate the biological responses post-genomics. The proteomic 
analysis high-lighted post-translational modifications identifying potential 
biomarkers of harm for specific mechanisms of injury attributed to smoking. 
There were also high degrees of variability between mRNA and protein 
concentrations. Post-translational modifications, such as phosphorylation, can 
not be quantified or identified when examining the mRNA levels. The
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measurement of protein rather than nucleic acid expression lead to a better 
understanding of disease processes and the consequent identification of 
biomarkers. Recent advances in mass spectrometry and the development of 
tags permitting proteomic quantification (e.g. iTRAQ™) has moved proteomic 
analysis towards direct mass spectrometry. The methods utilised in this study 
were very successful, with the identification of over four hundred proteins. At 
the onset of this research project, it had been envisioned that a gel-based 
method which involved using two-dimensional gel-electrophoresis would be 
implemented. There were limitations with this technique, with regard to 
sensitivity, reproducibility and quantification but technology has progressed to 
ease these shortfalls, i.e. the development of DIGE. Also once the spot of 
interest had been selected; it was digested into peptides and identified by 
using mass spectrometry. Moreover, the cost of analysing each protein spot 
was expensive, and prohibitive, when large sample numbers were required to 
be analysed.
The move to nano-LC, coupled with strong, cation, exchange columns (SCX) 
and reverse phase (RP) separation to permit partitioning of complex cell 
lysates, was not without its problems. To work within the time limitations and 
financial constraints of this research project, membrane proteins were not 
isolated, i.e. proteins that were fundamental in biological processes such as 
cell signalling. However, the identification and quantification of membrane 
proteins may be regarded as a different branch of proteomics. The ability to 
analyse intact proteins, pin-point the region and orientation, along with 
integration into a membrane, represent enormous challenges that today’s 
researchers face.
6.2 C onclusio ns
In conclusion, the holistic experimental approach undertaken in this study 
identified a number of correlative biomarkers, at the biochemical, 
morphological, immunological and inter-omic levels, in the human respiratory
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epithelia following exposure to TSC. The many findings from this study 
included:
Key deductions from conventional toxicology:
• A biphasic response was observed when measuring TEER, with low 
concentrations of the TSC eliciting a large and significant increase in 
TEER above the control level, followed by a decrease in TEER as the 
concentration of the TSC increased
• All TSC elicited a similar dose response in cell viability that differed 
from the membrane resistance in a characteristic manner. In each 
case, the peak in cell viability occurred at a higher concentration than 
that required to induce the peak of TEER. After this distinctive peak, 
cell viability decreased with increasing concentration
• The four TSC induced similar pro-inflammatory cytokine expression 
profiles, where cadmium and nicotine induced IL-7 expression and 
formaldehyde and urethane induced IL-2 and IFN-g secretion
• Comparison of the ETM with other (academic and commercial) cell 
culture systems indicated that it was more impervious to toxicants than 
single-cell cultures
• A TD10 was established for all four TSC exposures to the ETM which 
disclosed the early protective mechanisms of toxicity
Key deductions from histopathology and IHC:
• H+E staining indicated tissue thickening that coincided with peaks in 
TEER
• Evidence of cell/tissue hypertrophy was resolved using H+E staining
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• The differentiation between secreted protein and cell debris could be 
elucidated by H+E staining
• The p63 expression profiles were TSC-specific and enabled the 
clarification of their different modes of action in disease and repair
• Protein 63 expression patterns at the supra-basal tissue region inferred 
a squamatous metaplastic disease status
• Cytokeratin 5/6 expression was consistently higher at the lowest TSC 
doses, with the exception of cadmium (versus control), which was 
suggestive of a protective mechanism
• Morphological analysis at the LM and TEM levels made evident four 
main pathological cell/tissue states; hyperplasia, hypertrophy, cytolysis, 
and necrosis
Key deductions from genomics:
• 42 mRNA transcripts were altered significantly by TSC exposure
• Functional group analysis demonstrated a notably high homology when 
compared to nicotine
• The DNA repair functional group was a prominent feature of the 
nicotine exposures
• Cadmium, formaldehyde and urethane exposures induced 18 genes by 
greater than 3-fold
• Nicotine exposures induced 5 genes by greater than 1.5-fold
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• Nine genes were identified as potential genomic markers for the early 
onset of pulmonary injury
• CYP7A1 and HMOX1 transcriptomic patterns were specific to nicotine 
and resolved to be a robust biomarker for tobacco smoke exposure 
and harm
• Cadmium, formaldehyde and urethane exposures up-regulated PTGS1 
(also known as COX1)
Key deductions from proteomics:
• Four hundred and thirteen proteins were verified that had one or more 
associated peptide identifications
• Two hundred and fifty proteins were resolved to have two or more 
associated peptide identifications
• Three main protein functionalities were recognised: (i) defence 
(cystatin-A, ubiquitin and protein plunc precursor), (ii) inflammatory 
(complement-C3 and protein plunc precursor) and, (iii) structural- 
development (cornifin-B and calmodulin)
• Nicotine exposure to the ETM induced the highest number of protein 
changes
• The defence proteins cystatin-A and ubiquitin were consistently 
induced and observed in all exposures
• Complement-C3, myristoylated alanine-rich protein kinase C substrate 
and neutrophil gelatinase-associated lipocalin correlated with the 
tobacco smoking-related disease, atherosclerosis
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• Western blotting and antibody detection of the highly-expressed gene, 
COX1, disclosed that its’ expression was not induced at the protein 
level
6.3 Ult im a te  O b je c tiv e
Inter-omic analysis unveiled unknown functional mechanisms of TSC-induced 
toxicity (Table 6.1). The dysregulation in responsive lung genes could be 
correlated with injury mechanisms for a number of pulmonary disorders. 
Furthermore, the related post-translational modifications in responsive 
proteins uncovered pathways leading to cardiac disease. It is self-evident that 
extrapolation of these results to exposures using whole cigarette smoke could 
induce parallel adverse transcriptional changes. Further classification of the 
intelligent biomarkers, revealed a preponderance of genes and proteins 
involved in ‘anti-disease’ mechanisms; a TD10 was employed to examine 
‘early protective mechanisms’ of TSC toxicity and not cell death.
There was no overlap of gene and protein biomarkers, which was 
understandable, when considering the study utilised a ‘stress and toxicology’ 
gene-array and not the full-human genome. Furthermore, the limitations in 
current proteomic technology, which is still in its infancy of development, 
should not detract from the utility of searching for protein biomarkers. In these 
studies, identification of responsive proteins provided complimentary 
information (‘anti-disease’ mechanisms) and supplementary information 
(biomarkers for cardiovascular disease).
6.4 F u tu r e  W o rk
6.4 .1  E p iA ir w a y ™ Tis s u e  M o d el
The EpiAirway™ Tissue Model utilised had a ‘limited shelf-life’, i.e. 72 hours 
post-conditioning. Regardless of a researcher’s country of shipping
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Disease Pro-disease Anti-disease
Atherosclerosis
Gene Protein Gene Protein
CYP7A1
HMOX-1
Complement C3
Calmodulin
CD9
CYP2E1
ELK-1
HIF1A
Cystatin-A
Ubiquitin
MARCKS
NGAL
Cytotoxicity CCND-1
MVT
XDH
ABCC1
ABCC2
BAX
CYP1A1
MT3
MVP
Cystatin-A
Ubiquitin
Calmodulin
ALDH-2
Carcinogenicity PPARD Complement C3 BAX
CASP10
CCND-1
CHEK-2
CXCL10
CYP1A1
EGFR
MET
HGFR
Cystatin-A
Ubiquitin
Mutagenicity CDKN2A
CYP1A1
BAX
CCND-1
CYP4B1
E2F1
Cystatin-A
Ubiquitin
Cornifin-B
Table 6.1 Overview of biomarkers identified using inter-omic analysis. A
summary of the combined responsive gene and protein biomarkers related to functional 
mechanisms for the on-set of cardio-pulmonary injury and disease; Sexton et al., (2008)
destination, the model would be posted on a Monday from the USA and arrive 
48 hours later via special courier delivery (e.g. arrived in the UK on 
Wednesdays). The model would need to be used within four days of delivery 
for optimised viability; this also included a 24 hour pre-conditioning step.
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When searching for a suitable dose range, the small experimental window 
prevented cost-effective searches. The concentration of TSC required to 
obtain a TD10 (in 24 hours) was particularly high, as well as being comparable 
to a lifetime exposure for certain components. In retrospection, the 
assessment of membrane integrity and cell viability would have been best 
evaluated by a gene-specific approach. This approach would utilise a gene 
previously deemed specific to a particular TSC, as determined by peer- 
reviewed literature searches. This gene expression would then be monitored 
via Q-PCR across the dose range. Subsequently, the dose which generated 
significant TSC-specific gene activity would be employed in impending 
experiments. This could prove to be a more robust (sensitive) tactic and 
ascertain practical (i.e. lower) responsive doses when compared to the MTT 
benchmark.
6.4 .2  Ex p e r im e n t a l  D e v e l o p e m e n t
The tracheo-bronchial mucin assay was not as sensitive/specific as required 
and it is recommended that further optimisation must be undertaken and/or an 
alternative method sourced. One particular alternative option for the mucin 
assay could be the lectin-based mucin assay. The lectin-based assay used a 
modified standard ‘sandwich’ immuno-assay and the sensitivity would allow 
for increased detection and quantification (using a standard 
spectrophotometer; Jackson et al., 2002).
One of the major functions of epithelial cells is secretion. This critical 
defensive mechanism is carried out by the release of pro-inflammatory 
mediators (Gabay and Kushner, 1999; Parsanejad et al., 2008). The Oligo 
GEArray® Human Toxicology & Drug Resistance Microarray was restrictive in 
the number of early-response, inflammatory genes such as IL-8 and 
Osteopontin which it could measure. If there were unlimited funds, it would 
have been beneficial to of used one of the full-spectrum, human genome, 
microarray systems for a comprehensive transcriptomic screen.
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6.4 .3  To b a c c o  S m o k e
In a continuation of this work, the human lung tissue model would be re­
utilised to examine early genetic responses following exposure to whole 
tobacco smoke (TS). The objectives would be three-fold: (i) discovery of 
unknown TS biomarkers, (ii) corroboration of existing biomarkers from this 
study for further validation of their role in exposure and harm and, (iii) 
determine whether epigenetic modifications regulated the gene changes 
accounting for specific biomarker expression. The term ‘epigenetics’ refers to 
heritable changes in gene expression without accompanying alterations in 
DNA sequence. Their misdirection by toxin exposure leads to disease and 
cancer by distinct mechanisms that appear intricately related in initiating and 
sustaining epigenetic modifications: micro-RNA mediated silencing, DNA 
methylation and histone modification. TS induced epigenetic signals would be 
characterised to dissect-out the precise biological pathway(s) of TS action 
within the lung environment. The added value of this research workflow would 
be the unique endpoint data, which lend themselves to dictating clinical and 
therapeutic directions. This would not be limited to the tobacco sciences and 
health research but would also impact other forms of ambient aerosol 
pollutants and health research (e.g. solid and vapour phase components of 
anthropogenic combustion processes).
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Abstract
One of the first lines of defence to inhaled toxins is the barrier formed by the tracheobronchial epithelium, making this the ideal 
region for studying the toxicity of inhaled substances. This study utilises a highly differentiated, three-dimensional, in vitro model 
of human upper respiratory tract epithelium (EpiAirway-100) to measure the acute toxicological responses to well-characterised 
tobacco smoke components.
To determine the suitability of this model for screening inhaled toxicants, the EpiAirway tissue model (ETM) was treated apically 
with tobacco smoke components (nicotine, formaldehyde, cadmium, urethane) which are known to induce a variety of toxic effects 
(e.g. cytotoxic, thrombogenic, carcinogenic). A range of concentrations were used to model different mechanisms and severity of 
toxicity which were then compared to known in vivo responses.
Similar trends in stress response occurred, with distinct alterations to the tissue in response to all four toxins. Athigh concentrations, 
cell viability decreased and tight junctions were degraded, but at sub-toxic concentrations epithelial resistance (indicating tissue 
integrity) increased 20-60% from control. This peak in resistance coincided with an increase in secreted protein levels, elevated 
cytokine release and goblet cell hyperplasia and hypertrophy.
In conclusion, acute exposure to tobacco smoke components induces measurable toxic responses within human respiratory 
epithelium. Sub-toxic concentrations appear to illicit a protective response by increasing mucus secretion and mediating immune 
responses via cytokine release. These responses are comparable to human in vivo responses, indicating potential for the ETM as a 
tool for screening the toxicity of inhaled compounds.
© 2007 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The respiratory tract is constantly exposed to an array 
of gases, solids and liquids suspended in the air. Exposure
* Corresponding author. Tel.: +44 29 20874125; 
fax :+44 29 20875211.
E-mail address: balharry@cardiff.ac.uk (D. Balharry).
to any number o f these substances has the potential to 
damage the pulmonary epithelium. For example, long­
term inhalation o f ambient airborne particulate matter 
is an important factor in the development o f cardiopul­
monary disease and lung cancer (Pope et al., 2002). 
One o f the greatest challenges when studying respiratory 
toxicology is the complex nature of inhaled air which 
consists o f a wide mixture o f substances with varying 
chemical, physical and biological characteristics.
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Traditionally, in vivo studies are used to investigate 
toxicant effects in the lung, however, public opinion and 
government legislation is leading to a decrease in the 
popularity of animal testing. A growing number of sci­
entists are now working towards the Three R’s principles 
of Russell and Burch (1959); the “reduction, refinement 
and replacement” of animal experiments. Consequently, 
viable alternatives need to be developed which can repro­
duce in vitro, toxic events that may occur in the human 
lung.
The tissue initially affected by toxic gases and parti­
cles in the ambient air is the epithelial lining of the upper 
airways. As such, the biological activity of airborne 
substances is usually studied using bronchial epithelial 
cells or macrophages (Steimer et al., 2005). There are a 
number of well-known cell models which all have dif­
ferent advantages, and selection of the most appropriate 
model to address a specific question in a study can pro­
vide extremely valuable information, but there are also 
some perceived disadvantages to this approach. It is dif­
ficult to isolate and culture functional cells from human 
pulmonary tissue (Schwarze et al., 1996), and despite 
attempts to immortalise human pulmonary cells they can 
have a limited lifespan. In contrast, transformed cell lines 
have an unlimited lifespan allowing prolonged studies, 
but may not accurately represent the in vivo situation, as 
the phenotype of transformed cells differs from that of 
normal cells (Foster et al., 2000). In addition, individual 
cell types may respond quite differently to a complex 
mixture like tobacco smoke (Andreoli et al., 2003), as 
they may lack the requisite biotransformation enzymes 
(e.g. P450s) (Castell et al., 2005). Similarly, cell lines 
may show altered expression of a range of secretory 
and signalling molecules (Forbes and Ehrhardt, 2005). 
Overall, there are in built biases when using these kinds 
of experimental systems. The advent of mixed popula­
tion cultures and multi-differentiated cultures generates 
in vivo-like characteristics by enabling further cell-cell 
interactions. A highly differentiated, three-dimensional 
system is desirable because it models not only the dif­
ferent effects of toxins on specific cell types, but also 
the interaction between the cells. Moreover, epithelium 
cultured at the air—liquid interface would facilitate in 
vivo-like chemical exposures. These requirements are 
met by a human derived, primary, upper airway, culture 
known as the EpiAirway tissue model (MatTek Corpo­
ration). The EpiAirway tissue model (ETM) consists of 
normal, tracheobronchial epithelial cells derived from 
human primary explant tissue. It is cultured to form 
a pseudostratified, highly differentiated tissue with a 
mucociliary phenotype that closely resembles the epithe- 
lia of the human respiratory tract (Fig. 1).
Ciliated 
apical surface
Collagen matrix
Ciliated 
apical surface
Connective tissue
Fig. 1. H&E stained sections at lOx magnification, showing the pseu­
dostratified phenotype common to both (A) EpiAirway tissue and (B) 
normal human bronchiole. Images reproduced with kind permission 
from MatTek.
This study is designed to investigate the potential of 
the ETM to screen the toxicity of inhaled compounds. 
This can range from airborne particulate matter (e.g. 
diesel, pollen) to prescription medication (e.g. asthma 
inhaled medication). Among various inhaled toxins, one 
of the most common is tobacco smoke, which affects 
not only smokers, but also anyone coming into con­
tact with environmental tobacco smoke (ETS). ETS 
is implicated in the exacerbation of many respiratory 
diseases including asthma and chronic obstructive pul­
monary disease, as well as the development of lung 
cancer (Ambrose and Barua, 2004; Dhala et al., 2006). 
It has even been indicated that ETS is more toxic than 
mainstream smoke inhaled by the smoker (Schick and 
Glantz, 2005). Children are particularly at risk due to 
their higher respiratory rate which results in increased 
ETS inhalation. This can result in numerous respira­
tory tract infections and impaired pulmonary function 
(Li et al., 1999), behavioural and cognitive problems 
(DiFranza et al., 2004), and has been linked to sud­
den infant death syndrome (Anderson and Cook, 1997). 
Despite the large number of compounds found in tobacco 
smoke (at least 4000 bioactive compounds) (Andreoli 
et al., 2003) the toxicological effects of a number of 
the compounds have been well characterised. Four of 
these were investigated in this study: nicotine is known 
mainly for its addictive nature; however it is also thought 
to have thrombogenic capacity (Hioki et al., 2001); 
cadmium is a human carcinogen (Smith et al., 1997) 
and also exerts cytotoxic effects by inducing oxidative 
stress (Pinot et al., 2000); formaldehyde is also classi­
fied as a human carcinogen by the International Agency 
for Research on Cancer (IARC) and is both muta­
genic and genotoxic (de Serres and Brockman. 1999); 
urethane (also known as ethyl carbamate) generates 
reactive metabolites (e.g. vinyl carbamate, vinyl car­
bamate epoxide) during xenobiotic metabolism which
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are genotoxic and carcinogenic (Zimmerli and Schlatter, 
1991).
The ETM , representing human tracheobronchial tis­
sue, was used to determine the acute toxicological 
responses to these well-characterised tobacco smoke 
components (TSC). Epithelial integrity (trans-epithelial 
electrical resistance; TEER), cell viability (mitochon­
drial activity; M TT assay), protein (Bradford assay) and 
cytokine (Proteoplex Array Merck) expression were con­
sidered as measures of toxicity. Histological analysis was 
also carried out to assess structural modifications to the 
tissue model. A number of morphological and physio­
logical changes were identified and compared to known 
toxicity mechanisms which occur in humans in vivo. The 
consistencies/inconsistencies between the in vivo and in 
vitro studies help identify the potential of this model for 
screening of inhaled toxicants.
2. Methods
2.1. Cells, culture and exposure conditions
The EpiAirway cell cultures were transported from MatTek 
in the US in a 24-well plate. Each well contains a 12 mm M il- 
lipore insert on which the E TM  is cultured at the air—liquid 
interface for approximately 25 days prior to dispatch. This 
allows for differentiation o f the model into a pseudostrati­
fied structure, containing basal, ciliated and goblet cells, which 
closely resembles the human tracheobronchial region (Fig. 1). 
On arrival, the cells were handled according to the manufac­
turer’s specifications as follows. Briefly, each insert was placed 
into 0.9 ml pie-warmed culture medium (serum free DM EM  
enriched with various growth factors and hormones, provided 
by MatTek) in six-well culture plates. The cells were equi­
librated at 37 °C with 4.5%  CO 2 for 24 h. After this time, 
initial TEER values were recorded (see below) to confirm tissue 
integrity. Following this culture preconditioning, acute expo­
sure (24 h) o f ETM  cells to TSC solutions was carried out at the 
air-liquid interface. TSC solutions were made up in sterile PBS 
(supplemented with magnesium and calcium) and warmed to 
37 °C before 100 p. 1 was applied to the apical surface of the 
insert. A series o f concentrations were selected for each TSC 
to determine sub-toxic and toxic effects. The concentrations 
were as follows: nicotine: 0, 25, 50, 75, 100, 125 mM; cad­
mium (cadmium chloride): 0, 0.08, 0.16, 0.24, 0.32, 0.4 mM; 
urethane: 0, 100, 250, 500, 2000,4000 mM; formaldehyde: 0, 
1, 5, 7.5, 10, 15 mM. Each concentration was carried out in 
triplicate. After 24 h the toxin (TSC) was removed from the 
surface and TEER, M TT, cytokine and protein assays were 
carried out (see below).
2.2. Trans-epithelial electrical resistance
TEER measurements were taken using an Endohm tis­
sue resistance chamber (World Precision Instruments) which
is linked to a resistance meter (Evom; World Precision 
Instruments). The electrodes of the Endohm chamber were 
equilibrated 24 h before use by filling the chamber with 
PBS and connecting the electrodes to the base unit with the 
power off. Immediately before use (and subsequently every 12 
measurements) the calibration was checked and zeroed. The 
cultures (n = 3) were washed basally in 2 ml PBS prior to an 
additional 0.3 ml PBS wash of the apical surface. The apical 
wash was aspirated and retained to determine the total acellu- 
lar surface protein content. A further 0.25 ml of PBS was then 
added to the apical surface for TEER measurement. An empty 
culture insert (containing 0.25 ml PBS) was used as a “blank” 
and subtracted from each subsequent sample reading (Duff et 
al., 2002). TEER measurements were taken at time zero and 
24 h after exposure and are presented as resistance values (in 
ohms, 12).
2.3. MTT
M TT reagent (3-[4,5-dimethylthiazol-2-yll-2,5-diphenyl 
tetrazolium bromide) was warmed to 37 °C and 300 jxl added to 
each well o f a 24-well plate (Mosmann, 198 3). After measuring 
TEER the ETM  inserts were placed in the M TT  solution (n = 3). 
These were protected from light and incubated at 37 °C in 4.5% 
CO2 for 3 h. After this, the cultures were immersed in 2 ml M TT  
extracting solution (containing acidified isopropanol) and incu­
bated in the dark for a further 24 h. Triplicate 100 jjlI aliquots 
o f M TT  extractant from each culture were assayed on a plate- 
reader at a wavelength o f 590 nm.
2.4. Protein assay
The aspirated material from the first apical surface wash was 
stored at 1—4 °C until use within 48 h. The total amount of pro­
tein (p,g) contained in each sample (« = 3) was then identified 
using the Bradford (1976) assay for protein.
2.5. Cytokine assay
The production and release of endogenous cytokines into 
the basal medium of the ETM  was measured using the Pro­
teoplex Human Cytokine Array (Merck Biosciences). The 
Proteoplex Array consists of 16 wells each of which contain 
an identical microarray o f 12 anti-cytokine capture antibod­
ies, spotted in quadruplicate (Barchet et al., 2006). Detection 
is based on a standard ‘sandwich’ immunoassay and relies on 
biotinylated detection antibodies and streptavidin-conjugated 
fluorophores.
The samples (n = 3) were processed as described in the user 
protocol, briefly outlined below. The Proteoplex wells were 
washed with PBST (provided) prior to adding aliquots of the 
basal media. These were incubated for 1 h at room tempera­
ture with gentle agitation before washing again with PBST. A  
detection antibody cocktail (provided) was added to each well 
and incubated for an hour, then washed with PBST. A solution 
containing the fluoiophore (SensiLight; provided) was incu­
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bated with the samples for 90 min. A fter a final wash in PBST 
the array was washed in rinse solution (provided) and then 
dried. The Proteoplex Array was then shipped to the ‘Proteo- 
Plex Slide Analysis Service’ (Nottingham, U K ) for scanning 
and analysis.
2.6. Histology
The ETM  from concurrent experiments were fixed in 10% 
neutral-buffered formalin for a minimum o f 24 h prior to paraf­
fin embedding and sectioning. The embedded E TM  were cut 
into 5 |xm sections using a microtome and stained with haema- 
toxylin and eosin (H & E ). The sections were finally analysed by 
light microscopy. Random areas o f each section were selected 
and the number o f nuclei (cell number) along a 40 |xm length 
of the ETM  were counted (n = 6).
2.7. Statistical analysis
A ll data are represented with error bars illustrating the 
standard deviation. Significance has been calculated using a 
Student’s /-test, with p  <  0.05 deemed significant and p  <  0.01 
being highly significant.
3. Results
3.1. TEER
Prior to treatment with TSC the ETM  samples consis­
tently generated a TEER of over 700 fT This indicated 
that the integrity of the epithelial membrane was good, 
and that the cells were healthy. Post-exposure, the 
TEER measurements were dramatically altered, with 
all TSC exhibiting similar trends in response to treat­
ment (Fig. 2). A biphasic response was observed with 
the low concentrations eliciting a large and signifi­
cant (nicotine: p = 0.009, cadmium: p = 0.005, urethane: 
p — 0.048, formaldehyde: p = 0.014) increase above the 
control level (Table 1), followed by a steady decrease in 
TEER as the concentration increased.
3.2. MTT
The M TT assay, which measures mitochondrial activ­
ity in viable cells, was carried out on all the samples 
24 h after treatment with the toxins. A ll TSC elicited
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Fig. 2. The response of ETM to a range o f TSC concentrations. TEER (black) is measured as resistance (ohms, £2). Significant (*P < 0.05) and 
h ig h ly  significant (**p <  0.01). Cell viability (white) is determined by MTT uptake and measured using absorbance (590 nm). Significant (*p < 0.05) 
and h ig h ly  s ig n i f i c a n t  (**p < 0.01). (A) Nicotine; (B) cadmium; (C) urethane; (D) formaldehyde. Standard deviation is indicated by error bars.
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Table 1
Summary of toxicology data for ETM dosed with nicotine, cadmium, urethane and formaldehyde
TEER peak (mM) MTT rise (mM) Protein plateau (mM) TD10/TD50 (mM)
Nicotine 50 75 75 75/125
Cadmium 0.16 0.32 0.16 0.35/-
Urethane 250 5(X) 250 2100/3000
Formaldehyde 5 5 15 5/18
The dose at which each event (e.g. TEER peak) is given. TD10 and TD50 are determined by MTT assay.
a similar dose response that differed from the TEER 
response in one distinct way (Fig. 2). In each case, the 
peak in cell viability occurred at a higher concentration 
than that required to induce the peak of TEER (Table 1). 
After this peak, cell viability decreased with increasing 
concentration. The MTT values were used to calculate 
TD10 and TD50 values (concentration required to kill 
10 and 50% of cells, respectively) for each of the TSC 
(Table 1).
3.3. Protein assay
A Bradford assay was carried out on the apical sur­
face wash of all the samples. This wash contained all 
proteins secreted onto the apical surface, as well as any 
cellular debris. All the toxins induced similar patterns 
of change in protein levels, with two slightly differ­
ent profiles observed (Fig. 3). Protein levels reached a 
maximum of 45 |xg (induced by nicotine and formalde-
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Fig. 3. Amount of total protein present in the initial 0.3 ml apical surface wash in response to a range of TSC concentrations. Protein detected using 
Bradford assay. (A) Nicotine (grey diamond); (B) cadmium (black square); (C) urethane (white circle); (D) formaldehyde (grey triangle). Significant 
(*p <  0.05) and highly significant (**/? < 0.01). Standard deviation is indicated by error bars. TEER is shown for comparison (dashed line).
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Table 2
List of cytokines that are significantly altered from control levels in 
response to TSC
Cadmium Nicotine Formaldehyde Urethane
IL -la IE  la IL -la IL -la
I L IP 1E1P IL-ip I E ip
- - IL-2 IL-2
IL-6 IL-6 IL-6 IL-6
- IL-7 - -
IL-10 - IL-10 -
GM-CSF GM-CSF GM-CSF GM-CSF
- - IFN-y IFN-y
hyde) or 27 p,g (induced by cadmium and urethane) in 
the apical wash. A “plateau effect” occurred closely after 
(nicotine, formaldehyde) or coinciding with (cadmium, 
urethane) the concentration range where TEER was at 
its peak.
3.4. Cytokine assay
The level of endogenous cytokines found in the basal 
medium of all the samples was measured. Several of 
the cytokines (Table 2) showed concentration dependant 
changes in expression induced by the TSC. In all cases 
the greatest levels of expression occurred for interleukin 
(EL) la ,  IL-6 and granulocyte-macrophage colony-
stimulating factor (GM-CSF); ranging from ~20 pg/ml 
to a concentration dependant peak of ~70 pg/ml. A trend 
was noted, with maximum cytokine expression corre­
sponding with the peak of TEER for over 70% of the 
cytokines. The remaining cytokines were found in con­
centrations of between 1 and 5 pg/ml depending on TSC 
concentration.
3.5. H istology
All the TSC seemed to illicit similar changes to the 
morphology of the ETM (Fig. 4). Even the lowest con­
centration of each TSC appeared to induce thickening 
of the tissue in comparison to the control. The tissue 
reached it’s maximum thickness at the second concentra­
tion (Fig. 4B-D[ii]), coincident with the peak of TEER. 
At this point, the cells within the tissue appeared to 
increase in volume, as well as multiplying in number 
(Fig. 5). Subsequent increases in concentration led to a 
break down of the cellular structure, thinning of the tis­
sue due to reduced cell swelling and cell numbers, and 
eventual sloughing off of the cells.
4. Discussion
The objective of this study was to determine the acute 
toxicological responses of human derived bronchial
C<Hi)
Fig. 4. H&E stained sections of ETM treated with increasing concentrations of (A) PBS; (B) cadmium: (i) 0.08, (ii) 0.16, (iii) 0.24, (iv) 0.32, (v) 
0.4 mM; (C) nicotine: (i) 25, (ii) 50, (iii) 75, (iv) 100, (v) 125 mM; (D) formaldehyde: (i) 1, (ii) 5, (iii) 75 ,  (iv) 10, (v) 15 mM; (E) urethane: (i) 100, 
(ii) 250, (iii) 500, (iv) 2000, (v) 4000 mM.
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Fig. 5. Total number of cells counted along a 40 length of the ETM. (A) Nicotine (grey diamond); (B) cadmium (black square); (C) urethane 
(white circle); (D) formaldehyde (grey triangle). Standard deviation is indicated by error bars. TEER is shown for comparison (dashed line).
epithelium to well-characterised tobacco smoke com­
ponents in comparison to known in vivo effects. This 
human tissue equivalent of respiratory epithelia is a com­
mercially engineered in vitro model used by researchers 
in industry and academia for inhalation toxicology (Agu 
et al., 2006; BeruBe et al., 2006; Chen et al., 2006). 
This model circumvents any potential species-related 
differences that could compromise the interpretation 
of experimental results (Coggins, 2002), by utilising 
normal (non-immortalised) human tissue to derive the 
model. The range of toxic effects can only be fully inves­
tigated in a biological system capable of transcribing 
and translating genes in response to the action of toxins, 
as cell-cell interactions that occur in vivo can signifi­
cantly alter the cellular effects of many toxins (Ekwall 
et al., 1990). The ETM consists of cells derived from 
healthy human primary explant tissue (normal human 
bronchial epithelium (NHBE) as opposed to lung tumour 
or diseased tissue). Consequently, the cells are genotyp­
ically and phenotypically more representative of normal 
epithelia than other commonly used models (e.g. Calu-3: 
carcinoma derived, BEAS-2B: transformed). The over­
riding advantage of this system is that the epithelium
is cultured to form a three-dimensional, pseudostratified 
state which exhibits a functional mucocilliary pheno­
type with tight junctions. These characteristics are vital 
in the normal functioning of the human epithelium in 
vivo (Chilvers and O’Callaghan, 2000; Godfrey, 1997). 
The ETM contains columnar, ciliated cells interspersed 
with goblet cells, in addition to undifferentiated basal 
cells which have the potential to act as progenitor cells 
for damaged epithelium (Inayama et al., 1988). When 
compared to standard epithelial monolayer culture, this 
system more closely resembles human bronchial tissue, 
both morphologically and physiologically (Pampaloni et 
al., 2007).
The concentrations of TSC used in this study were 
intended to achieve a full range of responses from the 
ETM, from sub-toxic concentrations to widespread cell 
death. The methods used to study the response of the 
ETM are well established conventional toxicology tech­
niques used in numerous cell culture studies. TEER 
was used as the primary indicator of tissue stress by 
measuring the integrity of cellular tight junctions, and 
hence epithelial permeability. Breakdown of tight junc­
tions is an early indication of cellular degradation and
D. Balharry et al. /  Toxicology 244 (2008) 66-76 73
is known to interfere with the inflammatory process 
which can lead to loss of tissue function (Fink and 
Delude, 2005). The TSC all induced a biphasic response 
with low-concentration stimulation followed by high- 
concentration reduction in TEER.
This reduction in TEER indicates increased epithe­
lial permeability which is known to occur in response 
to tobacco smoke exposure, leading to inflammatory 
responses (Morrison et al., 1999). The appearance of a 
peak in TEER prior to tissue degradation was an unex­
pected consequence of TSC exposure. It is not known 
whether this effect occurs in vivo, as a thorough litera­
ture search unveiled no previous studies on this subject. 
However, it can perhaps be explained by the further tox- 
icological and histological measurements taken during 
this study, outlined below, which are consistent with in 
vivo findings.
The MTT assay for cellular growth and survival was 
used as an indicator o f tissue viability, and to corroborate 
the TEER results. The MTT data profile was fairly con­
sistent across the four TSC with a measurable decrease in 
cell viability in response to treatment. It is not surprising 
that higher concentrations of the TSC led to cytotoxicity, 
as this occurrence has been observed in vivo (Gelbman 
et al., 2007), however, a small increase in viability was 
noted shortly after the TEER peak. This may infer that 
a loss of tight junctions (indicated by increased TEER) 
leads to an acute increase in cellular activity (and there­
fore increased MTT metabolism). Alternatively, it could 
be that increased cell numbers (known to occur in vivo) 
(Innes et al., 2006) leads to increased MTT conversion 
generating a false impression of increased viability. A 
comparison of the TEER and MTT data (and other toxi- 
cological measurements detailed below) implies that the 
peak in TEER readings may act an early indicator for 
toxicity and deterioration of the tissue model.
The epithelium of the upper respiratory tract secretes 
a large number of proteins involved in protecting and 
stabilising the ciliated surface (Ali and Pearson, 2007). 
These mucin-rich proteins (mucus) scavenge, immo­
bilise or kill pathogens that come into contact with the 
apical surface of the tissue (Sheehan et al., 2006). The 
total amount of protein accumulated on the surface of the 
ETM was measured to monitor the occurrence of protein 
secretion. The protein levels appeared to increase with 
TSC concentration, but the Bradford assay measures 
total protein concentration, and as such, no distinction 
was made between secreted protein and cellular debris. 
However, there was visual confirmation of a viscous sub­
stance on the apical surface of the cells. This material 
had the characteristics of mucin, i.e. clear and viscous, 
as reported in by other investigators (Chemuturi et al.,
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Fig. 6. Proposed rationale for the shape of the protein dose response 
to all TSC (data for cadmium shown). The outline of the total pro­
tein (solid black line), secreted proteins thought to be mucins (dashed 
black/white line) and cellular debris (dotted grey line) are represented.
2004; Greenwell et al., 2005). This would be consistent 
with previous in vivo studies which have identified gob­
let cell hypertrophy and hyperplasia in human smokers, 
leading to increased stores of epithelial mucin (Innes et 
al., 2006). This is largely due to increased expression of 
MUC5AC, the predominant gel forming mucin of the 
bronchial epithelium (O’Donnell et al., 2004). A plateau 
in protein levels occurs shortly after the peak in TEER 
which may suggest a change in cellular activity, from 
protein (possibly mucus) secretion to accumulation of 
cell debris (Fig. 6). If this is the case, this could partially 
explain the TEER peak, as mucus on the cell surface 
could increase the electrical resistance of the tissue.
H&E staining was carried out on ETM sections 
to monitor morphological changes to the tissue. This 
confirmed that thickening of the tissue was induced, 
concurrent with the elevated TEER. Image analysis of 
the sections showed that the low concentrations bring 
about an increase in the number of cells, as well as the 
observed increase in the size of many of the cells. These 
findings appear consistent with previous studies which 
have identified goblet cell hypertrophy and hyperplasia 
in human smokers (Innes et al., 2006). This could fur­
ther account for the changes in TEER as increasing cell 
volume can lead to a rise in TEER due to the obliteration 
of the intercellular space (Madara, 1998). It would be 
interesting to note whether repeated exposure to these 
toxins may disrupt the normal progression of hyperpla­
sia (and hence epithelial recovery), which could result 
in the development of diseases such as asthma, chronic 
bronchitis and cancer (Tesfaigzi, 2003) as observed with 
tobacco smoking. The histology also verified the high- 
concentration tissue degradation (and break down of
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tight junctions) indicated by decreases in the TEER and 
M TT assays. Taken in overview, the histological analysis 
seems to confirm the postulated differentiation between 
secreted proteins (possibly mucins) and cell debris; with 
hyper secretion of protein at low concentrations, and cell 
breakdown leading to further protein release at high con­
centrations (Fig. 6), but further studies involving mucin 
assays would be required to substantiate these observa­
tions.
The levels of cytokines expressed by the ETM  were 
determined as a further measure of cellular activity and 
cell-cell interactions. There were a number of similari­
ties between the four TSC, with the pro-inflammatory 
cytokines IL -la , IL -lp , IL -6  and GM-CSF induced 
by all the compounds. The main difference between 
the TSC was that cadmium and nicotine induced IL-7  
expression, while formaldehyde and urethane induced 
IL -2 and IFN-y secretion. Interleukin-2 and -7 are both 
thought to be involved in T-cell homeostasis (Boy man 
et al., 2007), so this difference could be due to alter­
nate mechanisms for achieving the same goal. IFN -y is 
also thought to be indirectly involved in T-cell home­
ostasis and has been demonstrated to enhance T-cell 
mediated immune responses (Boyman et al., 2007). The 
apparent link between elevated cytokine secretion and 
TEER could be related to the increase in cell numbers 
within the ETM. Simply; the higher the cell numbers, 
the greater concentrations of cytokines are expressed. 
The elevated expression of cytokines suggest that the 
ETM  was functioning in an in vivo-like manner, with 
the induction of signalling cascades and various immune 
responses (Chung, 2001). This permits further investiga­
tion into whether xenobiotics, such as the TSC, play a 
role in inducing respiratory defence mechanisms as well 
as biotransformation events.
The four TSC all appear to illic it a similar response 
from the ETM . The low concentrations seem to be 
sub-toxic, inducing cell proliferation, increased protein 
secretion, cell viability and electrical resistance as well 
as elevated cytokine expression. This reaction could be 
linked to a protective response or potentially an overcor­
rection to the damage caused to the airway epithelium. 
This response peaks then declines as the concentrations 
increase. At high concentrations of the TSC the ele­
vated responses are overwhelmed, and all the markers 
of toxicity rapidly decline, with a drop in cell viability 
and TEER, limited cytokine expression and reduced cell 
numbers. The only exception to this is the increasing 
levels of protein released into the apical surface wash. 
This is believed to be due to the degradation of the tissue 
and discharge of the protein contents of the cells as they 
disintegrate.
Comparison of the ETM  with established cell cul­
ture models (Forbes and Ehrhardt, 2005) showed that 
in general, the ETM  appears to be more toxicologically 
resistant to these toxicants than single-cell cultures. For 
example, the TD10 (10% reduction in cell viability deter­
mined by M TT metabolism) for cadmium chloride is 
ten times greater in the ETM  than in a monolayer of 
mammalian pulmonary cells (i.e. A549) (Watjen et al., 
2002). Both nicotine and urethane show TD50 (50% 
reduction in cell viability) values that are approximately 
100 times higher than in mammalian monolayer cul­
tures (ICCVAM and NICEATM, 2001). This is probably 
due to the interactions between the different cell types 
within the model (increased protein secretion result­
ing from hyperplasia and hypertrophy, and cytokine 
mediated immune responses). However, the protective 
response to formaldehyde is induced by only two-fold 
compared to a monolayer of A549 cells (Lestari et al.,
2005). This difference in response may be partially due 
to the bioavailability of the TSC, or possibly the lack 
of activation of specific metabolism mechanisms. A  fur­
ther benefit of the ETM  is the ease of use. The model 
is fully differentiated, and screened for metabolic activ­
ity and tissue integrity (P450 activity, mucin dot blot, 
TEER >  270) prior to dispatch (MatTek, 2007) and can 
provide viable tissue for up to 27 days (Hayden et al.,
2006). The multi-well (24-well/96-well) format is ideal 
for multiple exposure experiments and screening, with 
easy access to both the apical and basal surfaces of the 
cells. This model has the added advantage of deriva­
tion from normal human tissue, circumventing the need 
for extrapolation of data from in vivo studies in differ­
ent species. As such, the ETM  could provide a tool to 
assess respiratory tract toxicity while avoiding species 
extrapolation and the use of laboratory animals.
In conclusion, acute exposure to TSC induces toxic 
responses within the ETM  causing loss of cell via­
bility, tight junction degradation and stimulation of 
secretory processes. These changes are preceded by 
a rapid increase in TEER which has consequently 
been identified as a potential early marker of tox­
icity. The toxins induce increased protein secretion, 
resulting from cell hyperplasia and hypertrophy, and ini­
tiate immune responses via altered cytokine expression. 
These changes closely mimic documented changes in the 
human bronchial epithelium indicating that, after valida­
tion, this model could prove useful for screening inhaled 
toxins and for further respiratory toxicology studies.
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Genomic biomarkers of pulmonary exposure 
to tobacco smoke components
Keith Sexton, Dominique Balharry and Kelly A. BeruBe
Background Associations between smoking and the 
development of tobacco-related diseases in humans have 
historically been assessed by epidemiological studies. 
These studies are further complicated by the number of 
chemicals used in tobacco and individual smoking habits. 
An alternative approach is required to assess the biological 
responses.
Objective Toxicogenomics was earned out to identify early 
molecular markers for events in pulmonary injury resulting 
from tobacco smoke components (TSC) exposure.
M aterials and methods EpiAirway-100 cells were 
exposed at the air/liquid interface to representative particle 
(nicotine; cadmium) and vapour phase [formaldehyde (FA) 
and ethyl carbamate] components of cigarette smoke. 
Microarray technology was used to compare expression 
profiles of human genes associated with toxicity and drug 
resistance, from control and TSC-treated respiratory 
epithelium (n= 5/dose).
Results Using the GEArray ‘toxicology and drug 
resistance’ microarray followed by significance analysis of 
microarray analysis, 42 mRNA transcripts were found to be 
significantly altered by the TSC exposure. The vapour [ethyl 
carbamate, FA and particle (nicotine, cadmium)] phase TSC 
exhibited differential transcriptional responses that could
Introduction
The respiratory tract of humans is constantly exposed to 
an array of gases, solids and liquids suspended in the 
air. Exposure to any number of these substances has the 
potential to damage the pulmonary epithelium. For 
example, long-term inhalation of airborne particulate is 
an important factor in the development of cardiopulmon­
ary disease and lung cancer [1—4]. Most of the early 
studies performed on tobacco smoke [5] were compli­
cated by the vast number o f the tobacco chemical 
components; approximately 1015 reactive species in the 
gas phase [6] w ith varying chemical, physical and 
biological characteristics [7 ].
Traditionally, in vivo studies are used to investigate 
toxicant effects in the lung, however, public opinion 
and government legislation [8,9] is leading to a decrease 
in the popularity o f animal testing. A growing number 
of scientists are now working towards the three R’s
1744-6872 ©  2008 Wo  Hers Kluwer Health | Lippincott Williams & Wilkins
not be attributed to their chemical phase The 
transcriptional changes could be classified according to a 
functional family, where ethyl carbamate, FA and cadmium 
classified as carcinogens, demonstrated the highest gene 
homology when compared with the noncarcinogen, 
nicotine
Discussion Analysis of the microarray data and further 
confirmation (reverse transcriptase-PCR) identified three 
potential biomarkers for TSC-induced injury. These three 
genes (CYP7A1, HMOX1 and PTGS1) are highly 
upregulated and have been linked with mechanistic 
pathways of disease Pharmacogenetics and Genomics 
18:853-860 © 2008 Woiters Kluwer Health | Lippincott 
Williams & Wilkins.
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principles of [10] ‘Reduction, Refinement and Replace­
ment’ of animal experiments. Consequently, viable 
alternatives need to be developed which can reproduce 
in vitro, toxic events that may occur in the human lung.
The EpiAirway tissue model (E T M , M atTek Corp., 
Ashland, Massachusetts, USA) is a commercially available 
in vitro model used by researchers in industry and 
academia for lung toxicology [11-13]. This model 
eliminates any potential species-related differences that 
could compromise the interpretation of experimental 
results [5], by utilizing normal (nonimmortalized) human 
tissue to derive the model. The range of toxic effects can 
only be fully investigated in a biological system capable 
of transcribing and translating genes in response to the 
action of toxins, as cell-cell interactions that occur in vivo 
can significantly alter the cellular effects of many toxins 
[14]. The E T M  consists of cells derived from healthy 
human primary explant tissue (normal human bronchial
DOI: 10.1097/FPC.0b013e328307bddf
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epithelium as opposed to lung tumour or diseased tissue). 
Consequently, the cells are genotypically and phenotypi- 
cally more representative o f normal epithelia than other 
commonly used models (e.g. Calu-3: carcinoma derived, 
BEAS-2B: transformed). Th e  primary advantage o f this 
system is that the epithelium  is cultured to form a three- 
dimensional, pseudostratified state, which exhibits a 
functional mucocilliary phenotype w ith tight junctions. 
These characteristics are vital in the normal functioning 
of the human epithelium  in vivo [15,16]. When compared 
with standard epithelial monolayer culture, this system 
more closely resembles human bronchial tissue, both 
morphologically and physiologically [17].
The development o f successful biomarkers requires the 
combination of a number o f disciplines and skills, such 
as models of different types of toxicity to generate 
regiospecific biomarkers, analytical/bioinformatic capabil­
ity to identify and characterize them , and ability to 
develop and validate appropriate assays to confirm ‘fit 
for purpose’. Validated biomarkers are needed to replace 
insensitive functional and labour intensive pathological 
methods, which only reflects advanced toxicity.
The objective of this study was to utilize the Oligo 
GEArray Human Toxicology and Drug Resistance (Super- 
Array, Bethesda, Maryland, USA) Microarray to compare 
the patterns of m RNA expression of human genes 
associated with toxicity and drug resistance, from control 
and treated respiratory epithelia. To achieve this objec­
tive, the E T M  must maintain certain levels of function­
ality, w ith cellular interactions and relatively low levels 
of cell death [toxic dose 20% (dose required to kill 
20% of cells)]. T h e  compounds were selected from the 
particle phase (e.g. cadmium and nicotine) and vapour 
phase [e.g. formaldehyde (FA) and ethyl carbamate] o f 
tobacco smoke and exhibit a variety of known mechan­
isms of toxicity (e.g. thrombogenic, carcinogenic, muta­
genic and cytotoxic). T h e  combination of human tissue 
equivalent models o f respiratory epithelia and microarray 
technology provides human m RNA transcript data allow­
ing identification of biomarkers that could be related to 
many respiratory diseases.
Methods
Cells, culture and exposure conditions
The EpiAirway cell cultures were transported from 
M atTek in the USA in a 24-well plate format. Each 
insert was basally attached to an agarose/media preserva­
tion matrix, the inserts were then covered w ith a wetted 
gauze and sealed before transport. Transport took 24 h 
at 4CC. Each well contains a 12 mm millipore insert on 
which the E T M  is grown. On arrival, the cells were 
handled according to the manufacturer’s specifications as 
follows: briefly, the basal surface o f the E T M  was rinsed 
with prewarmed [phosphate buffered saline (PBS)
supplemented with magnesium and calcium, 37CC )] 
and each insert was placed into 0.9 ml prewarmed culture 
medium (37°G) in six-well culture plates. The cells were 
equilibrated at 37°G with 4.5% CO2 for 24 h. Following 
this culture preconditioning, acute exposure (24 h) of 
E T M  cells to tobacco smoke component (TSG) solutions 
was carried out at the air-liquid interface. TSC solutions 
were made up in sterile PBS ( +  Mg and Ga) and warmed 
to 37°G before dosing. Each insert was apically dosed 
w ith 100 pi warm TSG solution. A  dose for each TSC was 
determined from earlier studies described in Ref. [18]. 
The doses were as follows: nicotine: 30 mmol/1; cadmium 
(cadmium chloride): 0.1 mmol/1; ethyl carbamate:
70 mmol/1; FA: 7 mmol/1. Each dose was replicated 
(i» =  5 ). After 24h the toxin (TSG) was removed from 
the surface and the tissue was stored in RNA later 
(Qiagen, Crawley, UK) before processing for genomics 
(see below).
Microarray of EpiAirway tissue model
The Oligo GEArray Human Toxicology and Drug 
Resistance Microarray profiles the expression of 263 
genes related to the metabolic processes of cell stress, 
cell toxicity, drug resistance and drug metabolism. Genes 
critical in drug metabolism and resistance such as those 
encoding enzymes important for drug transport and phase 
I  metabolism (specifically P450-mediated oxidation) are 
included.
The nylon membrane array matrix is a permeable support 
w ith a high D N A  binding capacity. Carefully designed 
60-mer oligonucleotide probes printed on each microarray 
minimizes any cross-hybridization between spots on the 
same array despite the representation of closely related 
members of the same gene families.
The microarray procedure was performed on control 
(PBS), nicotine, FA, ethyl carbamate and cadmium- 
treated E T M  (n =  5) in accordance with the GEArray 
Human Toxicology and Drug Resistance Microarray 
manual (GA-034). In  brief, total RNA was isolated from 
the exposed E T M  (Q IA ZO L, Qiagen). This was then 
enzymatically converted into a biotinylated cRNA target 
using the TrueLabeling-AMP 2.0 k it (SuperArray). The 
resultant-labelled target was hybridized to individual 
GEArray microarrays in HybTubes (GEArray OHS-401) 
in a standard hybridization oven. The detection of the 
microarray was carried out w ith chemiluminescent 
detection k it reagents and a chemi-doc imaging system 
(C C D  camera).
Micvoarray data analysis
In itia l acquisition of the array data was carried out using 
GEArray Expression Analysis Suite Software. The result­
ing raw data was found to be normally distributed 
according to the Anderson-Darling statistical test. The
Copyright ©  Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Table 1 Overview of microerrey data from exposed cell cultures to show differential gene expression for the various TSC
Nicotine Cadmium Urethane Formaldehyde
Gene ID Fold P value Fold P  value Fold P value Fold P  value Gene name
ABCC1 t 5.31 0.010 4.44 0.0002 3.90 0.001 ATP-binding cassette, subfamily C (CFTR/MRP), member 1
ABCC2 • 8.37 0.001 7.83 0.00001 8.60 0.000004 ATP-binding cassette, subfamily C (CFTR/MRP), member 2
BAX ■ -3 .29 0.008 -3 .27 0.009 -4 .30 0.006 BCL2*aseociated X protein
CASP10 • a 3.82 0.0001 3.80 0.00005 Caspase 10, apoptosis-related cysteine protease
CCND1 • -6 .27 0.002 -3 .68 0.003 -3.91 0.003 Cyclin D1 (PRAD1: parathyroid adenomatosis 1)
CDKN2A t a a -3 .04 0.00002 Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
CDKN2D a -3 .12 0.0001 a -3 .00 0.0002 Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)
CHEK2 a 18.66 0.015 18.23 0.00001 14.96 0.00002 CHK2 checkpoint homolog
CRYAB a 3.29 0.002 a a Crystallin, a B
CSF2 a 4.34 0.000004 4.18 0.000002 3.87 0.0001 Colony stimulating factor 2 (granulocyte-macrophage)
CTPS a 9.31 0.006 8.10 0.00000002 6.19 0.00000003 CTP synthase
CXCL10 a 23.82 0.003 18.84 0.00002 15.46 0.00002 Chemokine (C-X-C motif) ligand 10
CYP1A1 a 4.21 0.008 4.31 0.00002 4.28 0.001 Cytochrome P450, family 1, subfamily A, polypeptide 1
CYP1B1 a 3.08 0.002 a a Cytochrome P450, family 1, subfamily B, polypeptide 1
CYP2E1 -1 .99 0.032 a a a Cytochrome P450, family 2, subfamily E, polypeptide 1
CYP20A1 a 11.03 0.0005 9.0 0.000001 7.36 0.00004 Cytochrome P450, family 20, subfamily A, polypeptide 1
CYP4B1 a a a -3 .14 0.004 Cytochrome P450, family 4, subfamily B, polypeptide 1
CYP4F3 -2 .87 0.037 a a a Cytochrome P450, family 4, subfamily F, polypeptide 3
CYP7A1 -3 .73 0.008 a a a Cytochrome P450, family 7, subfamily A, polypeptide 1
E2F1 a a a -4 .18 0.00003 E2F transcription factor 1
EGFR a a -3 .32 0.00003 -4 .30 0.00002 Epidermal growth factor receptor (erythroblastic leukemia viral (verbb) 
oncogene homolog)
ELK1 -1 .85 0.001 3.15 0.007 a a ELK1, member of ETS oncogene family
ERCC3 -1 .63 0.014 8 a a Excision repair cross-complementing, complementation group 3
HIF1A -2 .16 0.044 a a a Hypoxia-inducible factor 1, a subunit (basic helix-loop-helix 
transcription factor)
HMOX1 -1 .80 0.006 a a a Heme oxygenase (decycling) 1
HMOX2 -1 .87 0 .0 0 0 a a a Heme oxygenase (decycling) 2
MET a -4 .53 0.000002 -3 .17 0.000002 a Met protooncogene (hepatocyte growth factor receptor)
MT3 a 3.15 0.021 a a Metallothionein 3 (growth inhibitory factor (neurotrophic))
MVP a 3.65 0.035 a a Major vault protein
MYC a 3.14 0.042 a a V-myc myelocytomatosis viral oncogene homolog
NNMT -2 .8 0.047 a a a Nicotinamide A/-methyltransferase
PPARD a a 3.49 0.00001 3.95 0.001 Peroxisome proliferative activated reoeptor, 8
PPARGC1A a 6.80 0.015 5.83 0.001 6.03 0.007 Peroxisome proliferative activated receptor, y, coactivator 1
PTGS1 a 11.14 0.013 6.91 0.001 6.15 0.007 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase
RARA
and cyclooxygenase)
1.79 0.023 a a a Retinoic acid receptor, alpha
SULT1A1 1.78 0.022 a a a Sulfotransferase family, cytosolic, 1 A, phenol-preferring, member 1
SULT2A1 2.23 0.038 a a a Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)
SULT2B1
preferring, member 1
1.70 0.017 a a a Sulfotransferase family, cytosolic, 2B, member 1
TBXAS1 -1.74 0.005 a a a Thromboxane A synthase 1 (platelet, cytochrome P450, family 5,
TOP1
subfamily A)
1.84 0.038 a a a Topoisomerase (DNA) I
TPMT -2 .99 0.018 a a a Thiopurine S-methyltransferase
XDH a 3.53 0.001 a a Xanthine dehydrogenase
Three cultures for each TSC and oontrol were analysed. Only genes analysed by SAM and found to be significant were listed. 
TSC, tobacco smoke components.
“No significant change.
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array data were normalized using global normalization. 
As a final assessment, the data were analysed using 
significance analysis of microarrays (SAM; Stanford 
University) analysis. SAM correlates gene expression data 
to a wide variety of parameters and uses data permuta­
tions to provide an estim ate of false discovery rates for 
multiple testing. Changes in gene expression were 
expressed as a ratio (fold change). T he lower cut-off 
point for identifying relevant genes was set at a ratio of 
1.5 [18-20].
Quantitative reverse transcriptase-polymerase 
chain reaction
RNA (n =  4) prepared from PBS, nicotine, FA, ethyl 
carbamate and cadmium-treated ETM was converted to 
complementary DNA using QuantiTect reverse transcrip­
tion kit (Qiagen). A small sample of genes (» =  12) 
highlighted by the SAM analysis were sampled to validate 
microarray results. Real-time PCR was performed on 
an MJ Research Opticon (BioRad, Hercules, California, 
USA) using the QuantiTect SYBR green PCR kit 
(Qiagen) under the following conditions: 1 cycle:
15 min 95CC; 40 cycles: 15 s 94CC, 30 s 55CC, 30 s 72CC. 
Ct values for the genes of interest were compared with 
the control samples to calculate fold change.
compounds. Moreover, nicotine also contained the DNA 
repair functional group (Fig. 1) and cadmium, ethyl 
carbamate and FA had genes in the apoptosis and cell 
cycle functional grouping (Figs 2-4).
Fig. 1
Functional classification of the significant genes from nicotine exposure 
of the EpiAirway tissue model. TF, transcription factors.
Fig. 2
Results
When comparing gene expression in cadmium, FA and 
ethyl carbamate to PBS, 18 genes were upregulated by 
more than three-fold (Table 1). T he greatest changes as 
noted were responses to DNA damage stimulus (CHK2 
checkpoint homolog), cell stress (CTP synthase), chemo- 
kines [chemokine (C-X-G motif) ligand 10] and oxido- 
reductases [cytochrome P450, family 20, subfamily 
A, polypeptide 1, prostaglandin-endoperoxide synthase 
(PTGS)]. Nine genes were downregulated by more than 
three-fold (Table 1), with the most notable change 
observed in a gene involved in cell cycle [cyclin D1 
(CCND1)]. In contrast, when comparing the gene 
expression of nicotine to PBS, fewer changes in mRNA 
expression were induced. Five genes were upregulated 
by more than 1.5-fold, with the largest change observed 
in sulphotransferases. Eleven genes were downregulated 
by more than 1.5-fold, with the greatest change in the 
oxidoreductases [cytochrome P450, family 7, subfamily A, 
polypeptide 1(CYP7A1)] and drug metabolism (TPMT; 
Table 1). Reverse transcriptase-PGR was carried out to 
validate the accuracy of the gene expression changes 
predicted by the microarray. RT-PCR confirmed 80% 
microarray gene expression changes (data not shown).
Further analysis placed the genes of interest into 
functional groups annotated by SuperArray. The func­
tional groups of drug metabolism, transcription factors/ 
regulators, stress response, cell growth/proliferation and 
differentiation and transporters were common for all
Functional classification of the significant genes from cadmium 
exposure of the EpiAirway tissue model. TF, transcription factors.
Fig. 3
Functional classification of the significant genes from ethyl carbamate 
exposure of the EpiAirway tissue model. TF, transcription factors.
Fig. 4
Cell cycle 21%
Apoptosis 16%
Transporters 11%
Drug metabolism 
20%
TF and regulators 5%
Stress response 
11%
Cell growth, proliferation 
and differentiation 16%
Functional classification of the significant genes from formaldehyde 
exposure of the EpiAirway tissue model. TF, transcription factors.
DNA repair 6%
Cell growth, proliferation and 
differentiation 13%
Stress response 
TF and regulators 6%
Drug metabolism
Cell cycle 19%  
Apoptosis 5%  
Transporters
Cell growth, proliferation 
and differentiation 24%
metabolism
23%
TF and regulators 5%
Stress response 
14%
Cell cycle 13%  
Apoptosis 13%
Transporters
Drug metabolism 18%
TF and regulators 6%
Stress response 13%
Cell growth, proliferation 
and differentiation 24%
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Discussion
A number o f lung-related diseases associated with 
tobacco smoke [21] are observed. Studies in this field 
are complicated by the number of chemicals (about 4500; 
[22]) used in tobacco and individual smoking habits. An 
alternative approach is required to assess the biological 
responses and highlight potential biomarkers of harm for 
specific mechanisms of injury attributed to smoking. In  
this study, a subtoxic dose of nicotine, cadmium, ethyl 
carbamate and FA had significant effects on epithelial 
gene expression.
The effect of nicotine in the animal and cell system 
has been comprehensively researched [23,24]. Nicotine 
has been shown to elicit a variety of physiological effects 
(i.e. cardiac contractility, mobilization of blood sugars and 
increased free fatty acids), but for the purpose of this 
study only the thrombogenic and atherosclerotic mechan­
isms of nicotine were investigated. Th e  majority of 
significantly altered genes from the nicotine exposure 
study were involved in drug metabolism. An additional 
functional group of D N A  repair not present in other 
exposure studies was also identified. Further examination 
of the nicotine gene list found five of the 16 genes might 
be involved in atherosclerosis; these can be separated 
further into antiatherosclerosis and proatherosclerosis. 
The antiatherosclerosis genes cytochrome P450fam ily 2, 
subfamily E, polypeptide 1, ELK I -  member of ETS 
oncogene family and Hypoxia-inducible factor /, a subunit 
have different mechanisms o f action; downregulation of 
cytochrome P450, family 2, subfamily E, polypeptide 1 reduces 
reactive oxygen species (ROS) stabilizing the initiation 
of inflammation [25]. Decreased expression of ELK1 -  
member of ETS oncogene family in smooth muscle cells 
leads to an increase in the expression of proteins required 
for the differentiated function of smooth muscle cells. 
A number of disease states are associated with a decrease 
of these muscle cell proteins [26]. Downregulation of 
Hypoxia-inducible factor 1, a subunit inhibits foam cell 
formation, and hence, atherosclerosis [27]. The proather­
osclerosis genes are CYP7A1 and haem oxygenase 
(HMOX1). CYP7A1 encodes for a protein with a rate 
lim iting enzyme activity for bile acid synthesis [28]. 
Downregulation o f CYP1A1 could result in a decrease 
of cholesterol absorption, and be classed as hyperchole- 
sterolemic with significant increases in the low-density 
lipoprotein fraction [29,30]. This is likely to result in an 
individual susceptibility to the development of athero­
sclerosis [30], HMOX1 is a cytoprotective gene that when 
induced, is one of the major defence mechanisms against 
oxidative stress [31]. This could indicate that reduced 
HMOX1 may be involved in the mechanism of athero­
sclerosis because of the overproduction of ROS and 
increased inflammatory responses [32].
Many biological effects exerted by cadmium on mem­
branes, mitochondrial structure and function, D N A  and
gene expression are present [33]. Oxidative stress is 
initiated by cadmium in many cell types; this has been 
determined by decreased activity of antioxidants [34,35]. 
The genes significantly altered by cadmium exposure 
were investigated for potential associations to cytotoxi­
city. N ine of a possible 20 genes were found to be related 
to cytotoxicity; this was further separated into pro- 
cytotoxic and anticytotoxic. An anticytotoxic, that is, 
protective, mechanism was observed with [ATP-binding 
cassette, sub-family G (C FTR /M R P), member 1 and 
ATP-binding cassette, sub-family G (CFTR/M RP), 
member 2 (ABCC2)]. Elevated levels of these genes in 
tumour cells can lead to resistance to cytotoxic drugs 
[36]. Another anticytotoxic mechanistic gene is B-cell 
leukemia/lymphoma 2-associated X  protein (BAX), down­
regulation of this gene could inhibit the initiation of 
mitochondrial dysfunction [37]. Mitochondrial dysfunc­
tion would lead to the release of cytochrome c, which 
activates D N A  damaged initiated apoptotic pathways 
[38]. The xenobiotic-metabolizing enzymes play a crucial 
role in the detoxification processes and bioactivation 
of several xenobiotic compounds [39]. Cytochrome P450, 
family 1, subfamily A, polypeptide 1 (CYP1A1) was 
elevated in this study, which suggests a cytoprotective 
role. Metallothioneins play a vital role in defending cells 
against heavy metals and oxidative stress [40]. In  this 
study metallothionein 3 was elevated by three-fold, 
similar to the results observed in a study with metal­
lothionein 2A with a cadmium exposure to lens epithelial 
cells which resulted in a 20% protection against 
cadmium-induced oxidative stress [41]. Major vault 
protein is also known as lung resistance protein [42] 
and has a proposed role in drug resistance [43]; 
upregulation would suggest a protective role. Procytotoxic 
genes, such as CCND1 are consistently inhibited in 
chemotherapy drug tests when investigating develop­
ment o f resistance to chemotherapy treatment [44], MVP 
is also known as human growth factor receptor, which 
protects cells from apoptosis [45], but in this study MVP 
was downregulated indicating a decrease in protection 
against apoptosis. XDH is associated with the reductive 
activation of chemotherapeutic agents and elevation of 
this gene as observed in this study, would lead to a greater 
rate o f formation of oxygen radicals and significantly 
increased cytotoxicity [46].
Extensive research has been prompted into the potential 
biological effects of ethyl carbamate, which has given its 
tumourigenesis in humans [47,48]. The principle targets 
are the liver and lung [49] in animals, which has led to 
increased research into ethyl carbamate’s mechanisms 
of action. The genes significantly altered by ethyl 
carbamate exposure were investigated for potential 
associations to carcinogenicity. The ethyl carbamate 
exposure study found 10 of a possible 16 significantly 
altered genes associated with carcinogenicity. Further 
analysis differentiated genes into procarcinogenicity
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and anticarcinogenicity. Anticarcinogenicity genes make 
up 90% of the significantly altered genes; this is 
demonstrated by BAX, also known as B-cell leukemia/ 
lymphoma 2-associated X  protein, that suppresses D N A  
repair [50]. This study found the genes to be down­
regulated, increasing genetic stability and inhibiting 
D NA damage. Inhibition of caspase 10, apoptosis-related 
cysteine peptidase is associated w ith the pathogenesis 
of trophoblast tumourigenesis; [51] this study found an 
elevated level, which again demonstrates anti carcinogeni­
city. The CCND1 gene is elevated in human breast 
cancers [52], which is opposed to the observations in this 
study that found CCND1 to be inhibited. CHK2 
checkpoint homolog has been reported as an important 
signal transducer o f cellular responses to D N A  damage 
and a candidate tumour surppressor [53]. Significantly 
elevated levels of this gene would suggest increased 
anticarcinogenicity. As observed in this study elevated 
expression of Chemokine (C-X-C motif) ligand 10 has been 
shown to lim it the cancerous process [54,55]. In  addition, 
associations w ith increased epidermal growth factor 
receptor and pulmonary adenocarcinomas have been 
reported [56]. Downregulation was observed in this 
study, which could indicate an anticarcinogenicity me­
chanistic action. This downregulation was also observed 
with met proto-oncogene, also known as hepatocyte 
growth factor, w ith similar consequences of an antic­
arcinogenicity mechanistic role [57]. Only two procarci­
nogenicity genes that were significantly altered in this 
study are peroxisome proliferator-activated receptor 8 
(PPARD) and CYP1A1. PPARD is a nuclear receptor 
implicated in tumourigenesis by the activation of PTGS2, 
a rate lim iting enzyme for prostaglandin synthesis and 
tumour growth [58]. Procarcinogens are substrates for 
CYP1A1 and increased regulation observed in this study is 
thought to be associated to procarcinogenicity [59]. The  
low number of procarcinogenicity genes could be because 
of the bioavailability of the TSG , or possibly the lack of 
activation of specific metabolism mechanisms [60].
FA is mutagenic and genotoxic [2]. The mutagenic and 
genotoxic potential o f FA is consistent w ith its ability to 
form cross linkages between protein and single stranded 
D N A  (DNA-protein cross-links [61]). The genes signi­
ficantly altered by FA exposure were investigated for 
potential associations to mutagenicity. The FA exposure 
study found six o f a possible 19 significantly altered genes 
associated w ith mutagenicity. Further analysis differen­
tiated genes into pro and antimutagenicity. As mentioned 
earlier BAX suppresses D N A  repair [50], this study found 
this gene to be downregulated increasing genetic stability 
and inhibiting D N A  damage and hence is antimutagenic. 
Investigation of cell cycle regulatory protein, CCND1 
suggested that it is found at elevated levels in tumour 
progression; the downregulation of this gene in this study 
implies an antimutagenic role. Cytochrome P450, family 4, 
subfamily B, polypeptide 1 activates amines that can be
carcinogenic [62]; downregulation of this gene would 
indicate an inhibition of amine activity. Elevated E2F 
transcription factor 1 has been associated with increased 
sensitivity to apoptosis [63] indicating that downregula­
tion of this gene would have an antimutagenic role. Two 
genes of significant change have been associated promu­
tagenicity: cyclin -dependent kinase inhibitor 2A (CDKN2A) 
and CYP1A1. Inhibition of CDKN2A has been linked to 
specific activities that allow cells to evade differentiation 
processes, these properties are linked to malignancy [64]. 
In  comparison with literature searches on ethyl carbamate 
and carcinogenicity, CYP1A1 has been associated with the 
mediation of ROS, which in turn creates an environment 
favourable to D N A  damage [65].
One gene [ {prostaglandin-endoperoxide synthase 1 (PTGS1)] 
was not associated to any of the specific mechanisms of 
toxicity investigated in this study, but was significantly 
induced in three out of the four compounds. PTGS1 is 
thought to be responsible for the production of prosta­
glandins, which in turn are responsible for a host of 
physiological responses for example, inflammation and 
platelet aggregation [66].
This study has identified nine genes, which can be linked 
directly to the specific mechanisms of toxicity identified 
in this study (carcinogenic, cytotoxicity, mutagenic and 
thrombogenic). These genes (CCND1, CDKN2A, CYP1A1, 
CYPIA1, HM0X1, MVP, PPARD, PTGS1 and XDH) all 
have potential to act as genomic biomarkers for the onset 
and development of many respiratory diseases. O f these 
nine potential genomic biomarkers, three are of particular 
interests (CYF7A1, HM0X1 and PTGS1). Two genes are 
unique to a specific disease pathway whereas, the third is 
very highly upregulated across three of the compounds. 
These genes have also been used earlier in clinical 
research studies. CYP1A1 has been documented as an 
adult liver cell marker [67] whereas HM0X1, the enzyme 
responsible for the synthesis of GO, is suppressed in 
lymphocytic bronchitis and airway luminal occlusion after 
transplantation [68]. Inhibition of PTGS1 [also known as 
cyclooxygenase-1 (COX/)] is known to increase side 
effects of nonsteroidal anti-inflammatory drugs. Limited 
inhibition of COX1 increases the drug tolerability [69], 
which indicates that COX1 could play a vital role in future 
drug development.
Conclusion
The microarray analysis has provided transcriptional data 
on the exposure of human respiratory epithelium to TSG. 
The technique has been shown to be highly reproducible 
between replicates and this has been confirmed by 
RT-PCR. This study has identified nine genes with the 
potential as genomic biomarkers of specific disease 
mechanisms known to be associated with tobacco smoke, 
for example, cytotoxic. Another potential genomic
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biomarker has been identified which has not been related 
earlier to tobacco smoke; PTGS1 is the key enzyme in 
prostaglandin biosynthesis and is inhibited by nonster­
oidal anti-inflammatory drugs such as aspirin. This could 
result in a disruption o f tissue homeostasis, which may 
lead to the onset o f a number o f diseases. As such this 
gene represents the most significant biomarker for TS C - 
related injury to the lung.
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